Epidemiological study of young and later onset Parkinson's disease by Wickremaratchi, Mirdhu
An Epidemiological Study of 
Young and Later Onset 
Parkinson’s Disease
Dr Mirdhu Wickremaratchi
i
UMI Number: U585357
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U585357
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Dedication
/  would like to dedicate this thesis to my late father, 
who died unexpectedly and suddenly during my time 
in research.
He and my mother provided the love, support, 
inspiration and encouragement needed to enable 
me to follow my dreams.
2
Table of Contents
TABLES........................................................................................................................................................................6
FIGURES......................................................................................................................................................................7
ACKNOWLEDGEMENTS......................................................................................................................................8
ETHICAL STATEMENT....................................................................................................................................... 10
THESIS SUMMARY...............................................................................................................................................11
CHAPTER 1 EPIDEMIOLOGICAL STUDIES OF PARKINSON’S DISEASE IN THE U K  12
1.1 C h a p t e r  S u m m a r y .......................................................................................................................................................12
1.2 In t r o d u c t i o n ............................................................................................................................................................12
1.3 P a r k i n s o n ’s d i s e a s e ...................................................................................................................................................12
1.3.1 Aetiology.............................................................................................................................................  13
1.3.2 Age at Onset............................................................................................................................................  13
1.3.3 Difficulties in studying PD ...................................................................................................................  13
1.4 In c i d e n c e  a n d  P r e v a l e n c e ................................................................................................................................... 14
1.5 St u d y i n g  E p i d e m i o l o g y  o f  D is e a s e  in t h e  U K ....................................................................................... 15
1.6 In c i d e n c e  S t u d i e s  in P D ..........................................................................................................................................16
1.7 S u m m a r y  o f  P u b l i s h e d  P D  P r e v a l e n c e  St u d i e s  in t h e  U K ...............................................................17
1.7.1 Carlisle 1966 .........................................................................................................................................  18
1.7.2 Northampton 1985 .................................................................................................................................  19
1.7.3 Aberdeen 1986 ........................................................................................................................................  19
1.7.4 Northampton 1995 .................................................................................................................................  20
1.7.5 London 2000 ...........................................................................................................................................  21
1.7.6 Rural North Wales 2005 ....................................................................................................................... 22
1.7.7 North Tyneside 2006 .............................................................................................................................. 23
1.7.8 Discussion o f  methodological differences in UK published prevalence studies ........................23
1.8 In c id e n c e  vs  P r e v a l e n c e  in St u d y i n g  Y O P D ............................................................................................24
CHAPTER 2 CLINICAL ASPECTS OF YOUNG ONSET PARKINSON’S DISEASE................... 26
2.1 C h a p t e r  S u m m a r y ......................................................................................................................................................26
2.2 In t r o d u c t i o n ..................................................................................................................................................................26
2.3 S e a r c h  St r a t e g y .........................................................................................................................................................28
2 .4  D e f i n i t i o n ........................................................................................................................................................................ 28
2.5 D is e a s e  P r o g r e s s i o n ................................................................................................................................................. 29
2 .6  P a r k i n s o n i a n  S y m p t o m s  a t  P r e s e n t a t i o n  a n d  D o m i n a n t  M o t o r  P h e n o t y p e ...................... 34
2.7 D y s t o n i a ...........................................................................................................................................................................37
2.8 S l e e p  B e n e f i t ..................................................................................................................................................................38
2 .9  D e m e n t ia  a n d  N e u r o p s y c h i a t r i c  F e a t u r e s ................................................................................................39
2 .10  T r e a t m e n t  R e s p o n s e  a n d  R e l a t e d  C o m p l i c a t i o n s ...............................................................................40
2.11 F a m i l i a l  A g g r e g a t i o n .............................................................................................................................................42
2 .12 D if f ic u l t ie s  in c o m p a r i n g  c u r r e n t  e v i d e n c e ............................................................................................43
2 .13 C o n c l u s i o n s ...................................................................................................................................................................4 4
CHAPTER 3 METHODS.................................................................................................................................. 46
3.1 O v e r a l l  S t u d y  D e s i g n .............................................................................................................................................46
3.2 S a m p l e  S i/ e a n d  Po w e r  C a l c u l a t i o n .............................................................................................................46
3.3 U n iq u e  S t u d y  N u m b e r .............................................................................................................................................47
3.3.1 GP Study Codes....................................................................................................................................... 47
3.4 P r e v a l e n c e  St u d y ......................................................................................................................................................48
3.4.1 Pilot GP searches ....................................................................................................................................48
3.4.2 Refinement o f  Search Strategy Following Pilot Visits.................................................................... 51
3.4.3 GP contact.................................................................................................................................................53
3
3.4.4 GP visit protocol.......................................................................................................................................................53
3.4.5 Data extraction proform a .....................................................................................................................................55
3.4.6 Age at Onset Data .................................................................................................................................................... 55
3.4.7 Cross check w ith secondary' care sources .....................................................................................................56
3.4.8 Prevalent C ases ........................................................................................................................................................56
3.4.9 Statistical m ethod .................................................................................................................................................... 57
3.5 C l in ic a l  F e a t u r e s  by  A g e  a t  O n s e t  St u d y ................................................................................................ 57
3.5.1 Recruitment o f  Non Prevalent C ases ...............................................................................................................57
3.5.2 First contact with the study group .................................................................................................................... 57
3.5.3 Postal Pack 2 ............................................................................................................................................................. 58
3.5.4 Clinical Assessm ent.................................................................................................................................................58
3.5.5 Postal Questionnaires follow ing C linic ..........................................................................................................60
3.5.6 Drug Information ......................................................................................................................................................60
3.5.7 Data E ntry ...................................................................................................................................................................60
3.5.8 Data analysis ..............................................................................................................................................................60
3.6 D a t a b a s e  D e s i g n ........................................................................................................................................................ 61
3.6.1 Preadmin D atabase .................................................................................................................................................61
3.6.2 Main Admin D atabase ............................................................................................................................................62
3.7 S p e c if ic  Et h ic a l  c o n s i d e r a t i o n s .......................................................................................................................62
CHAPTER 4 PREVALENCE STUDY OF PARKINSON’S DISEASE IN CARDIFF BY AGE AT 
ONSET  65
4.1 C h a p t e r  S u m m a r y ......................................................................................................................................................65
4 .2  In t r o d u c t i o n ................................................................................................................................................................. 65
4 .3  R e s u l t s ............................................................................................................................................................................. 66
4.3.1 Practice participation ............................................................................................................................................. 66
4.3.2 Electronic database searches and notes review in prim ary c a re ........................................................66
4.3.3 Additional Cases recruited via secondary care sources ..........................................................................<57
4.3.4 Exclusion as not P D ................................................................................................................................................<57
4.3.5 Crude and age and sex standardised preva lence .......................................................................................69
4.3.6 Diagnostic Certainty.............................................................................................................................................  69
4.3.7 Age at o n se t ..............................................................................................................................................................  70
4.3.8 Diagnosing and Follow up Care p ro v ision ................................................................................................  72
4.3.9 Misdiagnosis rates amongst those seen in research clin ic ..................................................................  72
4.3.10 Comparison with other UK PD Prevalence S tudies .......................................................................  73
4 .4  D i s c u s s i o n .......................................................................................................................................................................74
4.4.1 Limitations .................................................................................................................................................................  78
4.4.2 Impact o f  Prevalence study on Furthering Knowledge o f  YOPD ....................................................... 82
4.4.3 Conclusion ................................................................................................................................................................... 82
CHAPTER 5 NON MOTOR FEATURES OF YOUNG VERSUS LATE ONSET PARKINSON’S 
DISEASE  84
5.1 C h a p t e r  S u m m a r y ......................................................................................................................................................84
5.2 In t r o d u c t i o n ..................................................................................................................................................................84
5.3 R e s u l t s ............................................................................................................................................................................. 85
5.3.1 Study Cohort...............................................................................................................................................................85
5.3.2 Prodromal Non Motor Features........................................................................................................................ 88
5.3.3 Current Non Motor Features at time o f  assessm ent................................................................................. 89
5.3.4 Neuropsychiatric fea tures ...................................................................................................................................  90
5.3.5 Sleep Disturbance ................................................................................................................................................... 93
5.3.6 C 'ardi ff Community based  v.v Non C ardiff Supplementary secondary care referred cases ...9 4
5.3. 7 YOPD (onset <45) Cardiff vs N on-C ardiff cases .....................................................................................  95
5.3.8 YOPD (onset <55) C ardiff vs. N on-Cardiff cases ...................................................................................  96
5.4 D i s c u s s i o n .......................................................................................................................................................................97
5.4.1 Prodromal non motor sym ptom s .....................................................................................................................  97
5.4.2 Non motor symptoms in established disease ............................................................................................... 99
5.4.3 Limitations..............................................................................................................................................................  101
5.4.4 Strengths ..................................................................................................................................................................  103
5.4.5 Pathophysiology ................................................................................................................................................... 103
4
5.4.6 Further work.........................................................................................................................................  104
5.5 C o n c l u s i o n s ................................................................................................................................................................105
CHAPTER 6 MOTOR FEATURES OF YOUNG VERSUS LATER ONSET PARKINSON’S 
DISEASE  106
6.1 C h a p t e r  S u m m a r y ................................................................................................................................................... 106
6.2 In t r o d u c t i o n ............................................................................................................................................................... 106
6.3 R e s u l t s ...........................................................................................................................................................................107
6.3.1 Study-Cohort........................................................................................................................................ 107
6.3.2 Onset Sym ptom ....................................................................................................................................  107
6.3.3 Asymmetry o f  Parkinsonian signs....................................................................................................  109
6.3.4 Dystonia ................................................................................................................................................. 110
6.3.5 Dyskinesia.............................................................................................................................................  I l l
6.3.6 C ardiff Community- based vs Non C ardiff Supplementary- secondary- care referred cases. 115
6.3.7 YOPD (onset <45) C ardiff vs N on-C ardiff ca ses .........................................................................  115
6.3.8 YOPD (onset <55) Cardiff vs N on-C ardiff cases .........................................................................  117
6.4  D i s c u s s i o n .................................................................................................................................................................... 118
6.4.1 Clinical fe a tu re s ..................................................................................................................................  118
6.4.2 Response to treatment.........................................................................................................................  120
6.4.3 Lim itations............................................................................................................................................  121
6.4.4 Strengths ................................................................................................................................................  122
6.5 C o n c l u s i o n s .................................................................................................................................................................122
CHAPTER 7 CONCLUSION........................................................................................................................124
7.1 M a j o r  F i n d i n g s .......................................................................................................................................................... 124
7.2 A l t e r n a t i v e  A p p r o a c h e s .....................................................................................................................................125
7.2.1 Prevalence Study-.................................................................................................................................  125
7.2.2 YOPD vs. LOPD study ......................................................................................................................... 128
7.3 Im p a c t  o f  S t u d y  F i n d in g s  o n  t h e  m a n a g e m e n t  o f  Y O P D ................................................................ 130
7 .4  F u t u r e  D i r e c t i o n s .................................................................................................................................................... 132
REFERENCES........................................................................................................................................................134
APPENDICES.........................................................................................................................................................144
A d d i t i o n a l  T a b l e s ................................................................................................................................................................. 144
P u b l i c a t i o n s ................................................................................................................................................................................. 147
P u b l i s h e d  A b s t r a c t s ..............................................................................................................................................................148
P r o j e c t  P a p e r w o r k ..................................................................................................................................................................149
5
Tables
TABLE 2-1 : DISEASE PROGRESSION YOPD VS L O PD .................................................................................30
TABLE 2-2 : DISEASE PROGRESSION -  OTHER ANALYSIS M ETH O D S................................................32
TABLE 2-3 : TREMOR AT O N SE T ........................................................................................................................... 35
TABLE 2-4 : GAIT DISTURBANCE AT O N S E T .................................................................................................. 36
TABLE 2-5 : D Y STO N IA ..............................................................................................................................................38
TABLE 2-6 : DYSKINESIA AND MOTOR FLUCTUATIONS..........................................................................41
TABLE 3-1 : RESULTS FROM PILOT SEARCH STRATEGIES FROM THREE CARDIFF GP
PRACTICES............................................................................................................................................................50
TABLE 4-1 : AGE, SEX SPECIFIC AND STANDARDISED PREVALENCE RATES OF PD ..................69
TABLE 4-2 : AGE AT ONSET FREQUENCY OF ALL PREVALENT CASES WHERE DATA
AVAILABLE FROM GP AND HOSPITAL R EC O R D S............................................................................ 71
TABLE 4-3 : MEAN AGE, AGE AT ONSET AND DISEASE DURATION BY GENDER AND
W HETHER OR NOT PATIENTS WERE SEEN IN RESEARCH CLINIC............................................71
TABLE 4-4 : DISTRIBUTION OF DIAGNOSING AND FOLLOW -UP SPECIALTY BY AGE OF
DISEASE O N SE T ................................................................................................................................................. 73
TABLE 5-1 : CLINICAL CHARACTERISTICS OF STUDY C O H O R T ..........................................................86
TABLE 5-2 : FREQUENCY OF PRODROMAL N M S .......................................................................................... 88
TABLE 5-3 : CURRENT NMS BY AGE AT O N SET............................................................................................ 89
TABLE 5-4 : MEAN MMSE SCORES IN ONSET GROUPS SPLIT AT ONSET BEFORE AND AT OR
ABOVE 45 YEARS...............................................................................................................................................90
TABLE 5-5 : MULTIPLE REGRESSION ANALYSIS SHOWING EFFECT OF ONSET GROUP ON
MMSE AFTER ADJUSTING FOR DISEASE DURATION...................................................................... 91
TABLE 5-6 : MEAN BDI SCORES IN ONSET GROUPS SPLIT AT ONSET BEFORE AND AT OR
ABOVE 45 YEARS............................................................................................................................................... 91
TABLE 5-7 : DEPRESSION BY BDI SC O R E ......................................................................................................... 92
TABLE 5-8 : MULTIPLE REGRESSION ANALYSIS SHOWING EFFECT OF ONSET GROUP ON
BDI SCORE AFTER ADJUSTING FOR DISEASE DURATION............................................................ 92
TABLE 5-9 : MEAN EPWORTH SLEEPINESS SCALES SCORES IN ONSET GROUPS SPLIT AT
ONSET BEFORE AND AT OR ABOVE 45 Y E A R S ..................................................................................93
TABLE 5-10 : SLEEPINESS SCORES FROM EPWORTH SLEEPINESS SCALE SC O R ES....................93
TABLE 5-11 : MULTIPLE REGRESSION ANALYSIS SHOWING EFFECT OF ONSET GROUP ON
EPWORTH SCORE AFTER ADJUSTING FOR DISEASE D U RA TIO N ............................................. 93
TABLE 5-12 : BASELINE CHARACTERISTICS OF CARDIFF VS NON-CARDIFF C A S E S .................94
TABLE 5-13 : NMS IN CARDIFF AND NON-CARDIFF CASES WITH ONSET < 4 5 ............................... 95
TABLE 5-14 : NMS IN CARDIFF VS. NON-CARDIFF CASES WITH ONSET <55...................................96
TABLE 6-1 : BASELINE CHARACTERISTICS OF STUDY POPULATION ............................................ 107
TABLE 6-2 : FREQUENCY OF ONSET SYMPTOM BY AGE AT O NSET...............................................  108
TABLE 6-3 : FREQUENCY OF TREMOR VS AKINETIC RIGID ONSET BY AGE OF O N SE T....... 108
TABLE 6-4 : ASYMMETRY AT ASSESSMENT BY AGE AT ONSET STRATIFIED BY DISEASE
DURATION.........................................................................................................................................................  109
TABLE 6-5 : FREQUENCY OF DYSTONIA BY AGE AT O N SET..............................................................  110
TABLE 6-6 : PROPORTION OF WAKING DAY REPORTED TO BE AFFECTED BY DYSKINESIA
................................................................................................................................................................................  I l l
TABLE 6-7 : MEAN L DOPA TREATMENT DURATION AND DOSE IN YOPD AND LOPD IN
THOSE WITH D Y SK IN ESIA ........................................................................................................................ 113
TABLE 6-8 : RISK FACTORS FOR DEVELOPING DYSKINESIAS........................................................... 114
TABLE 6-9 : BASELINE CHARACTERISTICS OF CARDIFF VS. NON-CARDIFF C A S E S..............  115
TABLE 6-10 : MOTOR FEATURES IN CARDIFF VS NON CARDIFF CASES WITH ONSET <45 ..116  
TABLE 6-11 : MOTOR FEATURES IN CARDIFF VS NON CARDIFF CASES WITH ONSET <55 . 1 1 7
6
Figures
FIGURE 1 : SUMMARY OF NUMBER OF CASES PREVALENT DURING JANUARY -  DECEMBER 
2006 IDENTIFIED VIA SEARCH GP DATABASE STRATEGY 68
FIGURE 2 : FOREST PLOT OF AGE-STANDARDIZED PD PREVALENCE RATES IN THE UNITED 
KINGDOM (1966-2008) 74
7
Acknowledgements
Firstly, I would like to thank my two main supervisors, Dr Huw Morris and Professor 
Yoav Ben-Shlomo, for the opportunity of working on this project. They have both been 
extremely supportive throughout my time on this project and have helped to drive the 
project forward, using their extensive expertise and enthusiasm.
The study was funded from research grants from the Ipsen Fund and the Parkinson’s 
Disease Society.
I would particularly like to acknowledge Professor Ben-Shlomo’s input in helping with 
the statistical analysis, providing guidance on the comparative tests namely the t-tests and 
chi squared analysis and performing the more detailed logistic regression analysis used in 
the manuscripts submitted on non motor and motor features, as well as the meta analysis 
o f all UK prevalence papers published over the past 40 years and producing the forest 
plot.
I would like to acknowledge Pete Shiarly for designing and updating the project database, 
without whom this vast amount of data collected would not have been stored in an 
efficient methodological way for adequate analysis.
I am ever grateful for the hard work o f the project administrators who have assisted with 
the running o f the project, namely Dee Perera and Clare O ’Loglen.
Also I’d like to acknowledge the help of the Cardiff based General Practitioners and 
Practice managers who participated in the prevalence study, for allowing us to visit their 
practices and search their electronic databases to identify cases and their help in sending 
letters out to appropriate patients. I am extremely grateful to all the neurologists and 
geriatricians who helped to identify further cases throughout South Wales, particularly 
Dick Weiser, Dwarak Sastry and Sandip Raha plus all the PD nurse specialists especially 
Maralyn Moran, Liz Morgan, Annie Jones and Louise Ebenezer who allowed me access 
to clinic space and offices to conduct assessments as well as referring cases to the study. 
Most importantly, I’d like to acknowledge all the patients and their carers who took the 
time and effort to participate in the study.
I’m ever indebted to my friends and family for providing me with emotional support and 
encouragement throughout this time, in particular Chari, Huw, Dee, Ann, Lucy, Mai,
Gill, Jaisi, Az, Haze, my sister and mum, and o f course Joe.
Declaration
This work has not previously been accepted in substance for any degree and is not 
concurrently submitted in candidature for any degree
Signed (candidate) Date 28.07.09
Statement 1
This thesis is being submitted in partial fulfilment of the requirement for the degree of 
PhD.
Signed '— (candidate) Date 28.07.09
Statement 2
This thesis is a result o f my own independent work/investigation, except where otherwise 
stated.
Other sources are acknowledged by explicit references.
Signed (candidate) Date 28.07.09
Statement 3
I hereby give consent for my thesis, if accepted, to be available for photocopying and for 
inter-library loan, and for the title and summary to be made available to outside 
organisations.
Signed (candidate) Date 28.07.09
9
Ethical Statement
Ethical approval was obtained by the Multi-Centre Research Ethical Committee for 
Wales (05/MRE09/58). All patients with Parkinson’s disease and healthy general 
population controls provided written informed consent to participate in this study.
10
Thesis Summary
Parkinson’s disease (PD) is a common neurodegenerative condition and the risk o f 
developing it is age dependent, the prevalence increasing with advancing age. There are 
relatively little published data on frequency and clinical features of Young Onset 
Parkinson’s disease (YOPD) and it is uncertain whether this subgroup of PD is a different 
disease entity to later onset Lewy body PD. Investigation of this question is the main 
focus o f this research thesis.
This work has two components -  the first provides an estimate of the prevalence of PD in 
Cardiff and describes age at onset, the second is a community based case control study of 
YOPD and later onset PD (LOPD) using the prevalence cohort as the main source of 
cases.
The prevalence o f PD in Cardiff is similar to the weighted average o f previous PD 
prevalence studies in the UK over the past 42 years. Our crude prevalence estimate was 
130 per lCf (95% Cl 117,144) and the age standardised prevalence 142 per 105 (95% Cl 
128,156) using 1997 England and Wales population figures as a standard population. 
Significant clinical differences were identified in YOPD as compared to LOPD.
YOPD patients reported less hyposmia, constipation and sleep disturbance in the pre- 
motor stage, but more depression, paraesthesiae and sleep disturbance and less dementia 
in established disease than LOPD. YOPD presented more commonly with akinetic rigid 
symptoms and had a lower frequency of tremor. YOPD was much more likely to involve 
dystonia and treatment related dyskinesia than LOPD.
These results support the hypothesis that PD is a clinically heterogeneous condition and 
that significant differences are seen according to age at onset.
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Chapter 1 Epidemiological Studies of Parkinson’s disease in 
the UK
1.1 C hapter Sum m ary
Methodological differences can in part explain variation in published incidence and 
prevalence figures. A recent systematic review o f incidence studies of PD has identified 
areas o f improvement when conducting epidemiological studies and makes suggestions 
as to how future studies should be conducted. We look here at the previously published 
prevalence studies o f PD in the UK and identify similar areas o f difficulty when 
comparing data. We analyse in detail the methodological differences which could explain 
heterogeneity in previous PD prevalence estimates and suggest how improvements in 
study design could benefit future studies. This forms the basis o f our own prevalence 
study o f PD in Cardiff.
1.2 Introduction
Epidemiological studies are important both for investigating possible aetiologies of 
disease and for planning health care provision. Data on the incidence and prevalence of 
Parkinson’s disease, the second most common neurodegenerative condition worldwide 
(de Lau and Breteler 2006), are essential to plan health care services for an ageing 
population. In addition, temporal and geographic variation may provide clues to possible 
aetiological factors, and follow up o f an incident cohort gives invaluable information on 
the natural history o f the disease.
1.3 P arkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disorder characterised by slowness of 
movement (bradykinesia), increased muscle tone (rigidity), impaired postural reflexes 
and involuntary shaking (tremor).
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1.3.1 Aetiology
The aetiology o f PD is unknown. However, recent interest in the genetic aspects of PD 
has grown due to the discovery of several causative monogenic mutations, although these 
are likely to explain only a small proportion o f all PD (de Lau and Breteler 2006). The 
exact pathogenic mechanisms underlying selective dopaminergic cell loss in PD are not 
understood. Possibilities include mitochondrial dysfunction, oxidative stress and protein 
mishandling (Greenamyre and Hastings 2004). The likely aetiology of non genetic PD, 
which seemingly accounts for the vast majority o f disease, is complex and may involve 
multiple risk factors. Large, well designed, population based cohort studies are needed to 
examine the effects of multiple potential risk factors and their interactions as well as 
effects that develop over time (de Lau and Breteler 2006).
1.3.2 Age at Onset
One risk factor that increases the chance o f developing PD is advancing age. 
Epidemiological studies have reproducibly identified an increasing incidence and 
prevalence o f PD with age, rising after the age o f 60 years, although many prevalence 
studies show a decline in the oldest age groups which is probably artefactual due to 
under-ascertainment in these groups (Twelves, Perkins et al. 2003). Despite this fact, 
some patients develop the condition at an earlier than expected age. These patients are 
described as having Young Onset PD (YOPD). Traditionally the exact age definition of 
YOPD has been variable and arbitrary in the published literature, ranging from less than 
40 to less than 55 years. Patients with YOPD must have some exceptional aetiological 
factor which causes the disease to occur earlier than usual. This may be an unusual 
environmental exposure or genetic influence, or possibly an interaction o f both, or a 
greater dose o f a more common exposure. Studying YOPD in detail and comparing 
features with “ordinary” late onset PD (LOPD) may provide an insight into the 
underlying aetiology.
1.3.3 Difficulties in studying PD
The diagnosis of PD can sometimes be difficult and is based on a detailed history and 
examination. In the early stages o f the disease, the diagnosis may be unclear. Diagnostic 
accuracy is improved with follow up when information on disease course and 
progression, appearance of additional symptoms and treatment response become
13
available. There is no definitive diagnostic test in life, and pathological confirmation is 
required for definite diagnosis after death, a practice which is not common in the UK.
The publication of the Queen Square Brain Bank Diagnostic Criteria for PD helped to 
standardise clinical diagnosis of PD in 1988 (Gibb and Lees 1988). Before the 
publication o f these operational diagnostic criteria the accuracy of physicians’ diagnosis 
during life as compared with pathological confirmation was only 76% in one pivotal 
study (Hughes, Daniel et al. 1992). A more recent study has reported much improved 
diagnostic accuracy (98.6%) in specialist movement disorder services (Hughes, Daniel et 
al. 2002) However, the diagnostic accuracy may be lower outside specialist clinics. A 
community based study using GP electronic records revealed that 15% of patients with a 
diagnosis o f PD did not fulfil strict diagnostic criteria, and in approximately 20% of 
patients with PD, who had already come to medical attention the diagnosis had been 
missed (Schrag, Ben-Shlomo et al. 2002)
The risk of developing PD is much higher with advancing age. However, symptoms of 
PD may often be confused with “normal” ageing, both by patients and by medical staff, 
leading to delayed or missed diagnosis. This will obviously affect prevalence estimates, 
and lead to underestimation of disease burden in the elderly.
Many reports have described clinical differences between young onset and late onset PD. 
However, most published studies on YOPD are based on small numbers of cases usually 
from specialist clinics which will be biased towards atypical cases and so may not be 
representative o f YOPD on a population basis. Differences between YOPD and LOPD 
may be due to differences in pathological processes depending on age at onset, or the 
effect o f age at onset on the same process and other co-morbid conditions which are more 
common in the elderly. In any case, younger patients with PD are likely to have particular 
health care and social requirements that need to be acknowledged and addressed.
1.4 Incidence and Prevalence
Incidence o f a disease is the rate at which new cases occur in a population during a 
specified period, usually expressed as an annual incidence. Incidence rates are not 
affected by differences in survival o f patients and so are a direct measure o f risk of
14
disease unlike prevalence estimates (Van Den Eeden, Tanner et al. 2003). However, 
incidence studies require large cohorts and long follow up periods to generate significant 
numbers o f cases, especially in rare conditions. Also, if follow up of a cohort is 
incomplete, substantial misclassification may occur, leading to significant 
underestimation of disease risk (de Lau and Breteler 2006).
Prevalence studies look at the number o f existing cases o f a disease at a given point in 
time, given a population at risk. Prevalence estimates are influenced by incidence, 
survival and migration, but may be more appropriate in studying rarer conditions, as the 
number o f cases will be greater. Also, in diseases where diagnostic accuracy is improved 
with disease progression, such as Parkinson’s disease, there may be less diagnostic 
uncertainty than in incidence studies.
1.5 Studying E pidem iology o f D isease in the UK
The most accurate epidemiological method is a door-to-door survey. However, this is 
very costly and time consuming as a complete population is screened for disease and 
potential cases require expert validation. Most UK prevalence studies use the case- 
finding method looking only at medically diagnosed cases with or without potential 
missed cases, which is more efficient but will lead to an under-estimation o f true 
prevalence due to the effect of pre-clinical disease.
The UK health care system has particular advantages for medical epidemiology. Health 
care is available free o f cost to all people resident in the UK. Every patient is entitled to 
register with a primary care general practitioner (GP) who is then responsible for acting 
as a gate keeper to secondary specialist care in hospitals. It is therefore reasonable to 
expect that health care in the community is accurately represented in GP records 
assuming that individuals seek medical advice. By law GPs are required to record clinical 
problems reported to them by their patients. However, the problem of misdiagnosis 
remains.
The advent o f computerised records in general practice has made identification of 
prevalent cases of disease more efficient, but inaccuracies still arise when estimating
15
prevalence relying solely on GP records due to the pitfalls inherent in the electronic 
coding systems. Therefore more accurate estimates o f prevalence use multiple case 
ascertainment in primary and secondary care.
1.6 Incidence Studies in PD
A systematic review of incidence studies in PD compared previously published data 
(Twelves, Perkins et al. 2003). They found none o f the studies used identical methods 
and this review highlighted significant flaws in the methodologies o f these studies 
including using hospital based case finding strategies, retrospective design and non­
standardised inclusion criteria. This may account for some o f the variation in reported 
incidence figures worldwide and makes comparison o f studies difficult. Only five studies 
were directly comparable giving incidence estimates from 8.4 to 19 per 105 per year.
Most o f the studies used both primary care and hospital records but used different 
methods to identify incident cases. Inclusion criteria varied from defining parkinsonism 
by the presence o f the four cardinal features in older studies to the more strict UK Brian 
Bank Criteria in more recent ones, as did exclusion criteria and the definition of incident 
cases. Few studies were prospective (about a quarter) and even fewer (less than ten 
percent) involved follow up of cases. In just over half the studies were attempts made to 
confirm the diagnosis by examination of patients by a specialist as part of the study. The 
systematic review reported the peak incidence o f PD was between 70 -79 years o f age, 
although some studies have reported a continued increase in incidence after the age of 80 
years. A fifth of the studies reviewed found the incidence o f PD was significantly 
increased in men. In an attempt to overcome problems in the future the authors suggested 
eight methodological points to which studies should adhere to in an attempt to 
standardising future epidemiological studies. These are 1) the base population should 
neither be too small nor too large e.g. between 250,000 to 500,000 is suggested by the 
authors, 2) the studies should be prospective to maximise case ascertainment and data 
accuracy, 3) multiple sources should be used to identify possible cases, 4) as many of the 
potential cases as possible should be seen by an expert in movement disorders, 5) an 
incident case should be defined by a specific symptom onset rather than date of 
diagnosis, 6) clear and consistent inclusion and exclusion criteria should be applied, 7) 
ideally there should be some follow up to give information to support the diagnosis of PD
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as per Queen Square Brain Bank Criteria and to assess for symptoms suggestive of a 
Parkinsonian plus syndrome and 8) incidence rates should be reported by standard age 
strata to enable comparisons between studies, and confidence intervals should be given. 
An incidence study was designed in Aberdeen addressing some of the points raised by 
Twelves and colleagues (Taylor, Counsell et al. 2006). This was a large community 
based incidence study of PD with long term follow up. They utilised multiple sources in 
primary and secondary care for ascertainment of cases, including a screening 
questionnaire in all patients over the age o f 75 in the participating GP practices. The 
authors particularly emphasise the importance o f long term clinical follow up of the 
inception cohort in improving the accuracy o f incidence figures by improving diagnostic 
accuracy and to provide unbiased information on prognosis in a representative cohort of 
patients. Their pilot study found a crude incidence o f PD of 22 per 105 per year (which is 
higher than previously published comparable studies), a mean age at diagnosis of 76 
years and a higher incidence in men. The authors suggest the higher incidence estimate 
may be due to better ascertainment o f cases in the elderly age group, as previous studies 
did not screen for disease in this way. This was supported by the older mean age at 
diagnosis. Eighty percent of this incident cohort had follow up for at least one year, and 
the diagnosis was changed in 33%, the majority o f which occurred in the first year from 
presentation (Caslake, Moore et al. 2008).
Good quality incidence studies, although giving accurate data on disease rates, require 
large populations and long follow periods to yield reasonable numbers of patients with a 
degree o f diagnostic accuracy. This is a particular problem in studying YOPD. An 
analysis o f incidence trends in PD suggested no variation in incidence rates over a 15 
year period (Rocca, Bower et al. 2001) however this study was based on the medical 
record linkage system of Rochester, Minnesota and may have been biased by the 
differential access to health care which operates in the US.
1.7 Sum m ary o f Published PD Prevalence Studies in the UK
We undertook a systemic review o f prevalence studies o f PD in the UK. Ovid Medline 
databases spanning the time period 1950 -  2007 was searched using the search terms 
“Epidemiology” and “Parkinson’s Disease” and confined to human and English
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language. Abstracts were screened and only original research articles describing 
prevalence studies of Parkinson’s disease carried out in the UK were included. Particular 
attention was paid to detailed epidemiological methodology, results given as crude and 
age adjusted rates. To date, there have been seven published studies looking at prevalence 
o f PD in the United Kingdom, spanning the past 42 years, reporting crude PD prevalence 
ranging from 108-164/100,000.
1.7.1 Carlisle 1966
Brewis et al (Brewis, Poskanzer et al. 1966) published the first prevalence study of 
neurological diseases, including PD, in the UK. This study was based on reviewing 
information gathered from GPs (18 practices), hospital notes from 4 main hospitals, the 
Ministry of Health medical officer, private consultations from consultant physicians and 
death certificates. A random sample o f the population were subjected to their head of 
house undergoing interview by standardised questionnaire asking if members o f the 
household had tremor. The diagnosis of the hospital physician was accepted. There are no 
further details o f inclusion or exclusion criteria mentioned in the publication.
Only patients resident in Carlisle were included in the prevalence estimates. The 
population denominator was taken as the 1961 Census population of Carlisle (71,101). 
Eighty cases were identified giving a crude prevalence o f 112.5 per 105, and the age 
specific prevalence was shown to rise rapidly with advancing age, but fell in patients over 
80. The age adjusted rates to the England and Wales population at that time were 114.5 
per 105.
The authors compared their findings to those o f a study performed in Rochester 
(Kurland) in 1958. Higher rates were found in the Rochester study and continued to rise 
in the very elderly age groups. The discrepancy in rates is possibly explained by different 
diagnostic definitions, especially in the elderly age groups, in some studies features of 
ageing such as slow shuffling gait and stooped posture may have been classed as 
Parkinsonian syndromes even if they lack tremor or rigidity, which were regarded as 
important diagnostic features as clinical definitions o f PD evolved with time. The authors 
also note the great variability in GP case note detail suggesting that some diagnostic 
information may have been missing, therefore highlighting the importance of a composite 
picture from primary and secondary care.
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1.7.2 Northampton 1985
Sutcliffe et al (Sutcliffe, Prior et al. 1985) used both primary and secondary care records 
to estimate the prevalence of PD in Northampton. They used the total list size o f the 
participating GP practices as the population denominator and only used secondary care 
patients who were registered with those practices. Information was gathered by the GPs 
and physicians using standardised questionnaires. Diagnosis of PD was made based on 
the essential presence o f bradykinesia and rigidity plus or minus rest tremor without 
cognitive deficit in the first two years o f onset. Other forms of parkinsonism were classed 
as drug induced, post-encephalitic, multi-system atrophy and cerebrovascular.
A pilot study was conducted to establish the validity of GPs filling out these 
questionnaires by asking a consultant physician to see patients o f 4 GPs whilst blinded to 
the information they had collected on the questionnaires over a period o f 4 weeks. The 
physician had identified more features o f PD than the GPs and there was a 66% 
agreement in identifying tremor, bradykinesia and rigidity between the consultant 
physician and the 4 GPs.
For the main study, the participating GPs were asked to fill questionnaires for all patients 
they knew or encountered with PD over a three month period, and the hospital physicians 
passed names of their known patients to the physician investigator who completed the 
questionnaires from the case notes and occasionally an assessment if  the notes were 
inadequate.
Seventy two percent o f the GPs approached participated, giving a denominator of 
208,499 which accounted for 75% of the Northampton district. Only 74 o f the 259 
parkinsonian patients were examined for validation. Two hundred and twenty six PD 
patients were identified giving a crude prevalence o f 108 per 105 (95% Cl 95.2, 123.5). 
The authors report no gender difference but describe an increase in prevalence with 
advancing age and compared their results to studies performed in Carlisle, Rochester, 
Finland and Iceland. Again, methodological differences were suggested to account for 
variation in differences seen, for example, the high prevalence in Iceland is explained by 
the greater intensity and duration of surveying patients before the prevalence day.
1.7.3 Aberdeen 1986
Mutch et al (Mutch, Dingwall-Fordyce et al. 1986) used a multisource ascertainment 
method to estimate the prevalence o f PD in Aberdeen. They asked all hospital doctors
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and GPs in Aberdeen to refer any known or new cases of PD to them, then used 
computerised records for inpatients from the Grampian Health Board files, attendance at 
the department o f therapeutics at Aberdeen University, GP medication prescriptions and 
by examining records from all neurology and medical clinics and visiting all private and 
local authority homes for the elderly. Information from these sources was used to compile 
lists which were given to general practices to ask if further cases were known to GPs, 
district nurses or health visitors. Practice receptionists were given a list of PD medication 
and asked to notify the team if any patient was prescribed these.
All patients were interviewed and examined by the authors. Information was 
supplemented by a relative or carer and by medical case notes. In addition, disability was 
graded using the Hoehn and Yahr scale and a ten point cognitive screen was performed. 
The diagnosis was based on the presence o f two or more o f tremor, rigidity, bradykinesia 
and postural instability. Those with arteriosclerotic, drug induced or post-encephalitic 
parkinsonism were excluded. If the diagnosis was unclear, the patient was seen by a 
neurologist.
In total 249 patients were identified as having PD in a population o f 151,616 giving a 
crude prevalence of 164 per 105 (no 95% Cl given). It was found that about 25% of 
patients were diagnosed by their GPs, 25% by a neurologist and 15% by a geriatrician. 
The modal age at onset in men was the 7th decade, in women the 8th. The authors state 
they used strict diagnostic criteria and examined 98% of cases. Fifteen percent of the 
referred cases were found not to have PD. O f these, 20% were drug induced 
parkinsonism. The authors report an increase in prevalence with increasing age, 
continuing to increase above the 8th decade, with a higher prevalence of PD in the very 
old, especially in women. This may be explained by the detailed intensive ascertainment 
methods used in this study (by visiting all elderly care homes). The age at onset median is 
reported as 60-69 years which had not changed over the previous 25 years.
Approximately 35% of cases were felt to have dementia based on the cognitive screen. 
The authors conclude by stating that PD is increasingly more common in the older 
population, many of whom are not under any regular review.
1.7.4 Northampton 1995
Sutcliffe et al (Sutcliffe and Meara 1995) repeated their study using similar methods to 
1985. GPs and hospital consultants were asked to refer any patient known to them with
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parkinsonism, on medication used for PD and those with familial tremor. Those referred 
were seen, questioned and examined in their home, hospital or residential or nursing 
homes. The diagnosis was based on the Queen Square Brain Bank Diagnostic Criteria for 
PD.
Three hundred and eighty three PD cases were identified from a population o f 302,000, 
92.5% of whom were assessed giving a crude prevalence of 121 per 105 (no 95% Cl 
given, but when calculated is 114.9-140.3, thus showing no significant change from 
1985). Patients were asked to estimate their disease duration and this was used to define 
cohorts with onset over each of the previous ten years to calculate a yearly incidence.
This was estimated as 12 per 105 person years.
The authors suggest an increase o f PD prevalence over a ten year period but the rates 
were very similar and presented without confidence intervals (crude 108 vs. 121, and 
standardised 134 vs. 140). It is noted when the data are reanalysed for age adjusted rates 
and confidence intervals calculated (see forest plot p71) there is no statistical difference 
between the rates. The authors comment on an increase in awareness o f PD and they were 
aided by the fact that more GPs had held a disease register. It was suggested that patients 
were also being diagnosed earlier as the disability profile of cases was different to that o f 
1985. The authors point out that as the case finding method is dependant on GP and 
hospital records, prescriptions and referrals, it is likely this prevalence figure is an under 
estimate as undiagnosed cases are not included. It was noted that prevalence rose sharply 
after the age of 50 years and that there was a male predominance.
1.7.5 London 2000
Schrag et al (Schrag, Ben-Shlomo et al. 2000) approached 15 GP practices in London 
whose total practice size gave a denominator o f 121,608. Records were screened for a 
diagnosis o f PD or parkinsonism, antiparkinsonian drugs or a mention o f tremor after the 
age o f 50 years. Diagnosis was based on the Queen Square Brain Bank Diagnostic 
Criteria for PD. Each patient was assessed and if the diagnosis was in doubt a video 
recording was made and reviewed for secondary confirmation by a movement disorder 
neurologist. Any case with an isolated classical rest tremor was classed as possible PD 
and was included in the prevalence estimate. Drug induced and vascular parkinsonism 
were classified as were Progressive Supranuclear Palsy (PSP) and Multiple System 
Atrophy (MSA), two neurodegenerative Parkinsonian plus syndromes.
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Crude prevalence o f PD was estimated as 128 per 105 (95% Cl 109, 150) and adjusted to 
the 1997 UK population this rose to 168 per 105 (95% Cl 142, 195).
The authors report that the prevalence o f PD in Southern England is similar to that of 
North England and Scotland, suggesting no marked geographical variation. The 
prevalence had remained stable over the previous 30 years despite a reduction in 
mortality for patients under 75 years. The authors report a misdiagnosis of 15% of those 
labelled with PD and found that 10-20% of cases had come to medical attention but had 
not been diagnosed, suggesting that the true prevalence may be as high as 200 per 105.
1.7.6 Rural North Wales 2005
Hobson et al (Hobson and Meara 2004) used primary care prescribing records for 
antiparkinsonian drugs and interviewed 11 GPs to identify all known cases of PD who 
were not actively being treated. They also looked at attendance at the local district 
general hospital, general outpatients and specialist movement disorder clinics as well as 
the local PD register. They excluded any case with serious mental illness given 
neuroleptic and anticholinergic medication implying these were drug induced 
parkinsonism cases. All cases were interviewed and examined.
A total o f 112 PD cases were identified giving a crude prevalence o f 144 per 105 (95% Cl 
120, 173), and when adjusted to the 1998 UK population this fell to 105 per 105 (95% Cl 
85, 124). No gender heterogeneity was demonstrated.
The authors stated that crude rates were similar to previously reported but the adjusted 
rate was lower than the London study. There may be a number of possible explanations. 
One possibility is the selection bias occurring in the London study as the London GPs 
were linked to neurology specialty clinics therefore leading to higher recruitment rates in 
the younger population. Other possibilities include that rural mortality is higher in the 
elderly, or that the frail elderly have limited health care access so there may be a 
significant proportion o f undiagnosed PD in elderly care homes. In addition the 
prevalence estimates in the North Wales study was diagnosis based rather than symptom 
onset based as in the London study, so may have lead to an underestimate of true 
prevalence. The London study also screened patients with isolated tremor which 
increases the prevalence o f previously undiagnosed PD. The authors comment that their 
estimate is dependant on medically known cases and strict inclusion criteria and so may
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have lead to an underestimation of true prevalence. Lastly, the lower rates may also be 
explained by less effective ascertainment methods or differential rural mortality.
1.7.7 North Tyneside 2006
Porter et al (Porter, Macfarlane et al. 2006) asked GPs, consultant neurologists, 
physicians and geriatricians to provide lists o f their patients with possible PD. Pharmacy 
records and case notes from the local PD clinic were also scrutinised. Patients were 
visited at home and the diagnosis was based on the Queen Square Brain Bank Criteria. If 
the case notes showed adequate information to fulfil the Brain Bank criteria these cases 
were also included. Those patients who declined assessment were only included in the 
prevalence estimate if they had been seen by secondary care. Drug induced and vascular 
parkinsonism were classified, as well as essential tremor, PSP, MSA and dementia with 
Lewy bodies (DLB).
O f the 144 potential cases of PD, 14% were found not to fulfil criteria, giving a crude 
prevalence o f 148 per 105 (95% Cl 124, 174) and when adjusted to the 2001 UK 
population, 139 per 105(95% CI 116, 162).
It was noted the Aberdeen study had higher prevalence estimates as care homes were 
visited and screened. The age adjusted rates had not changed over the previous 30 years. 
The prevalence of cases increases sharply with age, peaking in the over 90 age group. 
Men had a higher prevalence in the 75-79 age group, females in the over 90 age group. 
GP records alone gave an incomplete ascertainment picture and there was some level of 
misdiagnosis, again highlighting the need for a multisource approach.
1.7.8 Discussion of methodological differences in UK published prevalence 
studies
A review of UK prevalence studies revealed similar problems and inconsistencies to 
those identified in the systematic review o f incidence studies (Twelves, Perkins et al. 
2003). The earlier studies were based on case referral from physicians and GPs as 
electronic database systems were not in place. This relies on the physician and GPs’ own 
knowledge o f their patients and does not actively search out known cases. These studies 
also relied on the diagnostic accuracy o f the diagnosing physician without scrutiny. 
Clearly studies including active ascertainment in primary care are likely to be more 
accurate.
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In the early studies there is lack o f standardisation of diagnosis. The Queen Square Brain 
Bank Criteria for the diagnosis o f PD were first mentioned in 1992 as diagnostic 
inclusion criteria for prevalence estimates. Before this inclusion seems to be less 
standardised and may well have included some non PD cases. Certainly the Parkinsonian 
plus syndromes such as MSA, PSP and DLB now have published operational diagnostic 
criteria whereas during the earlier prevalence studies these entities may not have been 
widely recognised or diagnosed accurately, being misdiagnosed as PD.
Using computerised hospital records was first mentioned in the 1986 study, but 
systematic searching for diagnostic codes was not used until 2000. The later studies have 
used electronic search strategies to screen practice databases for potential cases and then 
used stringent methods to verify diagnosis by examining as many cases as possible or, if 
failing that, reviewing the case notes in detail.
Some, but not all studies report 95% confidence intervals for their prevalence estimates, 
others have calculated age adjusted prevalence estimates, but there is no consistency 
across the studies as to which standard population has been used and how these figures 
have been reported.
This variation in methodology o f case ascertainment and inclusion criteria is probably 
responsible for some o f the regional and temporal differences in reported PD prevalence. 
No meta-analysis of the published studies has been reported before. This would be useful 
to determine if there is true heterogeneity within the studies published to date.
No study has been performed estimating the prevalence o f PD in urban South Wales. 
None o f the previous studies has reported age at onset and so there are no data in which 
to base an estimate of the prevalence o f Young Onset PD.
1.8 Incidence vs Prevalence in Studying YO PD
In conditions such as PD where diagnostic accuracy improves with disease duration, 
prevalent cases can be examined with the advantage of time, thus increasing diagnostic
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accuracy. When studying rare conditions, such as YOPD, community based prevalence 
studies can establish a reasonably sized cohort o f diagnosed cases in a short period of 
time as compared with incidence studies where longer ascertainment periods are required 
to establish adequate numbers o f incident cases and an adequate follow up period must 
have elapsed to ensure a reasonable degree of diagnostic certainty. However, it should be 
noted that prevalence studies may be biased as patients with more rapidly progressive 
disease will be under-reported, known as “length bias” in screening studies.
We selected a prevalence study as the best way to investigate YOPD and attempted to 
follow best practice based on the recommendations o f the Twelves analysis and our own 
review o f previous UK prevalence studies.
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Chapter 2 Clinical Aspects of Young Onset Parkinson’s Disease
2.1 C hapter Sum m ary
Many clinicians view Young Onset Parkinson's Disease (YOPD) as a different condition 
to Late Onset Parkinson's disease and this has been reinforced by the identification of 
Mendelian genes that account for some cases o f YOPD. A systematic review of OVID 
Medline for articles relevant to the clinical features of YOPD published in English 
between 1950 and 2007 was performed. There are very few prospective community 
based studies which focus on the features of YOPD and a variety o f case definitions are 
used in the literature. Most studies of YOPD are based on specialist clinic referral series. 
The available evidence suggests that patients with YOPD have: i.) a slower disease 
progression, ii) an increased rate of dystonia at onset and during treatment, iii) a lower 
rate o f dementia, and iv) an increased rate o f dyskinesias in response to L-DOPA 
treatment. The majority o f the available studies do not report patient genotype data, but it 
is likely that the clinical heterogeneity o f PD will be further refined with detailed clinico- 
genetic studies.
2.2 Introduction
Parkinson’s disease (PD) is defined by the clinical features of pathologically diagnosed 
Lewy body disease with loss of nigro-striatal neurones and the presence of alpha- 
synuclein containing Lewy bodies(Litvan, Bhatia et al. 2003). The disease is 
progressive, the aetiology is unclear and there are no disease modifying treatments. The 
risk o f developing PD is age dependant, and the incidence increases rapidly over the age 
o f 60 affecting 1-2% of the population over 65 years o f age (de Rijk MC 1997; Van Den 
Eeden, Tanner et al. 2003). The relationship between PD and age suggests that 
cumulative exposure to an environmental factor, and/or an age dependant biological 
factor, determines its development. The incidence rate o f PD at an earlier than usual age 
(termed Young Onset Parkinson’s disease (YOPD)) is small; data from the Kaiser 
Permanente scheme in Northern California suggested that this was around 1.5 per 
100,000 person years for subjects aged less than 50 (Van Den Eeden, Tanner et al. 2003). 
However, previous incidence studies estimate that five to ten percent o f all patients with
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PD develop symptoms before the age of 50 and 4-7% before the age o f 40 (Teravainen, 
Forgach et al. 1986; Roller and Lang 1987; Gershanik 1988; Tanner and Langston 1990; 
Van Den Eeden, Tanner et al. 2003). The identification of Mendelian genes which can 
cause typical parkinsonism with young onset (three autosomal recessive genes namely 
parkin, DJ-1 and PINK-1, and two autosomal dominant genes a- synuclein and LRRK2 
which may also present in earlier life but are very much rarer), and reports of 
pathological heterogeneity raise the possibility that YOPD may be different to late onset 
PD (LOPD) (Morris 2005; Hardy, Cai et al. 2006; Klein, Lohmann-Hedrich et al. 2007). 
If this is the case then the advice and treatment given to patients, in particular future 
disease modifying therapies may need to be tailored according to the age of onset and 
related parkinsonism/PD sub-type. It is important not to overestimate the clinical 
relevance o f these genetic forms of parkinsonism however appreciating the gene 
frequencies in the whole population o f PD patients. Currently we understand that 
mutations in the parkin, PINK1 and LRRK2 genes together account for at least 3% of all 
patients with parkinsonism, parkin mutations accounting for 10-20% of young onset 
cases, PINK1 between 1-8% and LRRK2 having a usual onset between 50-70 years. In 
addition, there is ethnic variation in gene frequency in some of these genetic forms o f PD 
such as the commonest LRRK2 mutation accounting for 40% of PD in those patients with 
Arab descent and 20% in Ashkenazi Jews. (Klein, Lohmann-Hedrich et al. 2007). 
However in a large incidence study looking at variation by age, gender and ethnicity of 
newly diagnosed PD patients in Northern California, the incidence o f YOPD did not 
significantly vary by ethnic group but the rates for men were higher than for women (Van 
Den Eeden, Tanner et al. 2003).
Several clinical differences have been described which distinguish YOPD from LOPD.
If these differences are robust then there are several possible explanations: i) varying 
manifestations of the same disease at different stages of neurological development, ii) 
disease heterogeneity with variation in cellular and regional pathology or iii) an age 
dependant effect of co-morbidity. Here, we look at the evidence for separation of PD and 
parkinsonism based on age at onset and the problems in comparing and interpreting the 
available data.
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2.3 Search Strategy
This review is based on a literature search o f the Ovid Medline databases spanning the 
time period 1950 -  2007 using the following search terms: “Parkison’s Disease”, 
“parkinsonian syndrome”, “parkinsonism”, “paralysis agitans”, and “akinetic- rigid 
syndrome”. These were individually combined with each o f these search terms: “young 
onset”, “early onset”, “age at onset”, “juvenile onset”. Articles were limited to the 
English language. Abstracts were screened and articles containing original data from case 
series and case control studies as well as review articles were included. We have also 
used the authors’ personal knowledge and hand searching of references. A very small 
number o f original research articles describing clinical features o f YOPD were found and 
so any available literature about YOPD was surveyed even where the primary focus of 
the study was not a comparison of YOPD and LOPD or a clinical case series of YOPD.
2.4 Definition
One o f the principal difficulties in studies of YOPD is the terminology and case 
definition. Various terms have been used to describe PD developing in younger people. 
Historically, the term juvenile onset has been used to describe what is now termed young 
or early onset PD and there is considerable overlap in the age definition of these groups 
amongst different studies (Yokochi M 1981; Yokochi, Narabayashi et al. 1984;
Gershanik and Leist 1987; Gershanik and Nygaard 1990; Giovannini, Piccolo et al. 1991; 
Yokochi 1997). In 1987 Quinn and colleagues suggested that “juvenile onset 
parkinsonism” should be reserved for cases with onset before the age of 21 years, and 
“young onset” for patients with onset between 21 and 40 years (Quinn, Critchley et al. 
1987; Jankovic 1993). This division was supported by differences in familial aggregation 
in the two groups. More recent papers, including those reviewing genetic factors, have 
used the term early onset to describe PD occurring before the age of 45. There is still 
variation in the upper age limit which defines YOPD, leading to difficulty in comparison 
between studies. A further issue is whether young onset patients should be described as 
having parkinsonism, Parkinson’s syndrome or Parkinson’s disease. In this review we 
use the term Young Onset PD (YOPD) to describe all patients with younger onset 
parkinsonism or define the age at onset. The disease entity o f PD has been defined by the
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presence o f Lewy bodies, but only a minority o f patients have post-mortem analysis. It is 
worth emphasizing that many different pathological processes can cause a disease which 
meets the Queen Square Brain Bank clinical diagnostic criteria for PD (Jellinger 1987; 
Ward C 1990; Hughes, Daniel et al. 1992; Hughes, Daniel et al. 2001; Hughes, Daniel et 
al. 2002). Most pathological reports of PD with onset below the age o f 21 do not report 
Lewy body pathology, and recently this has been related to the presence of mutations in 
parkin (Paviour, Surtees et al. 2004). Only 3 PD cases with onset before age 21 years 
have been described with Lewy body pathology at autopsy (Gershanik and Nygaard 
1990). However, a brain bank series of 12 YOPD patients (onset before 40 years) and 24 
LOPD patients (onset after 70 years) showed no difference in the occurrence of Lewy 
body pathology although the younger onset cases had greater nigral cell loss and longer 
disease duration (Gibb and Lees 1988). It seems clear that some, but not all patients with 
YOPD have Lewy body disease. Very few cases o f parkin disease with early onset 
parkinsonism have come to autopsy, and only two of six have shown evidence of Lewy 
Bodies (Mori, Kondo et al. 1998; Hayashi, Wakabayashi et al. 2000; Farrer, Chan et al. 
2001; van de Warrenburg, Lammens et al. 2001; Sasaki, Shirata et al. 2004; Pramstaller, 
Schlossmacher et al. 2005). The limited pathological data suggest that Lewy body 
pathology is extremely rare with disease onset below the age of 21, but becomes 
increasingly common with advancing age at onset. This could relate to differences in the 
underlying diseases or to a greater likelihood o f developing Lewy bodies as a 
pathological response to neurodegeneration with increasing age.
2.5 D isease Progression
A number o f studies indicate that YOPD progresses more slowly than LOPD. Variations 
in measures of disease progression make direct comparison between these studies 
difficult (Tables 2-1 and 2-2). The majority o f studies are retrospective, estimating the 
rate o f progression using a measure of disability at case ascertainment and estimated age 
at onset to calculate disease duration (Marttila and Rinne 1977; Birkmayer, Riederer et 
al. 1979; Goetz, Tanner et al. 1988; Jankovic, McDermott et al. 1990; Lee, Schulzer et 
al. 1994; Hely, Morris et al. 1995). There are few prospective studies (Diamond, 
Markham et al. 1989; Hely, Morris et al. 1995) using change in disability scores during 
assessments over regular time intervals. Two main methods of relating age at onset to
29
progression are described. The first compares progression in two groups of patients 
defined by age at onset (Jankovic, McDermott et al. 1990; Lee, Schulzer et al. 1994; 
Hely, Morris et al. 1995); the other compares mean age at onset in groups defined by rate 
o f progression (Marttila and Rinne 1977; Birkmayer, Riederer et al. 1979; Goetz, Tanner 
et al. 1988; Jankovic, McDermott et al. 1990; Hely, Morris et al. 1995). By assessing 
progression both retrospectively and prospectively using both of these methods, the 
Sydney Multi-Centre Study group concluded that age at symptom onset was the best 
predictor of marked deterioration in PD symptoms and signs over 5 years (younger onset, 
slower progression) and this was followed by a second prospective confirmatory study 
(Diamond, Markham et al. 1989; Hely, Morris et al. 1995). In the DATATOP (deprenlyl 
and tocopherol antioxidative therapy of parkinsonism) study of 800 de novo PD patients, 
a retrospective estimate o f progression suggested more rapid progression in LOPD (onset 
at or above age 70) than YOPD (onset at or before age 40) (Jankovic, McDermott et al. 
1990).
Table 2-1 : Disease Progression YOPD vs LOPD
Study Author YOPD/
LOPD
(n)
AAO
YOPD
(yrs)
Disability
measures
Study details Conclusion
Hely (Hely, 
Morris et al. 
1995)
90 / 33 < 70 H+Y,
Modified
Columbia
Modified
NWUDS
Sydney Multi- 
Centre Trial
Prospective YOPD 
progresses 
more slowly
Diamond 
(Diamond, 
Markham et 
al. 1989)
1 3 /2 6 <50 UCLA score Prospective YOPD
progresses 
more slowly
Jankovic 
(Jankovic, 
McDermott et 
al. 1990)
33 / 85 <40 H+Y DATATOP
cohort
Retrospective Benign 
group has 
earlier mean 
age at onset
Abbreviations: AAO ^ age at onset, YOPD -  young onset Parkinson’s disease, LOPD = later onset 
Parkinson’s disease, H+Y = Hoehn and Yahr Scale, NWUDS ^Northwest university disability score, 
DATATOP = deprenyl and tocopherol antioxidative therapy o f parkinsonism
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Comparing “benign” and “malignant” subsets o f 118 untreated PD patients entering the 
same study, the benign group had a younger mean age at onset. Three further studies 
have confirmed that YOPD has a slower disease progression (Tables 2-1 and 2-2) 
(Birkmayer, Riederer et al. 1979; Goetz, Tanner et al. 1988; Lee, Schulzer et al. 1994).
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Table 2-2 : Disease progression -  Other analysis methods
Study A uthor n Methods Disability
measures
Patient group Study details Conclusion
Birkmayer 
(Birkmayer, 
Riederer et al. 
1979)
69 Rapid vs. 
Slow
Disability 
score 1-10 in 
10 parameters
Retrospective Younger age at 
onset
correlates with
slower
progression
Lee (Lee, 
Schulzer et al. 
1994)
238 Age at
onset
categories
UPDRS 
bradykinesia, 
practically 
defined off
Clinic Retrospective Younger age at 
onset
correlates with
slower
progression
Goetz (Goetz, 
Tanner et al. 
1988)
62 Rapid vs. 
Slow
H+Y Historical
cohort
Younger age at 
onset
correlates with
slower
progression
Martilla 
(Marttila and 
Rinne 1977)
442 Rapid vs. 
Slow
H+Y Community
based
Rapid 
progressors 
were older at 
onset
Abbreviations: UPDRS = Unified Parkinson’s disease Rating scale, H+Y = Hoehn and Yahr scale
However, conflicting views have been reported. This may be due to differences in 
defining disease progression. In a study of 60 YOPD (onset range between 24-39) and 60 
LOPD (onset range between 42-68) patients estimating disease progression as the interval 
from first symptom onset to the development of a bilateral clinical picture (Hoehn and 
Yahr stage over 2), 60% of the YOPD group developed bilateral involvement within 12 
months o f onset (termed rapid progressors) compared to 5% of the LOPD group 
(Giovannini, Piccolo et al. 1991). This may reflect earlier bilateral involvement in young 
onset disease but the relatively short follow-up period in this study means that it is 
difficult to generalise this finding. Some reports of patients with parkin mutations 
suggest that there is more symmetry in the disruption of striatal dopamine uptake, and 
neuropathology, than patients with typical LOPD (Portman, Giladi et al. 2001; Antonini, 
Moresco et al. 2002; Scherfler, Khan et al. 2004). The majority o f studies of YOPD are
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based on specialist clinic case ascertainment, therefore a further confounding factor is 
case referral bias. Elderly patients with indolent disease may be more likely to be treated 
by their non-specialist family practitioners, rather than being referred to specialist clinics, 
although clearly this will vary in different health care systems. This can only be 
addressed with community based studies looking at the prevalence of PD classified by 
age at onset. One study from the 1970’s suggests there is no significant correlation 
between age at onset and disease progression, although there was a trend for older onset 
patients to progress more rapidly (Marttila and Rinne 1977). O f interest is the higher 
prevalence o f vascular risk factors in LOPD patients, suggesting that the rate of 
progression in PD patients may be differentially influenced by disease co-morbidity. 
Concurrent degenerative joint disease or cerebrovascular disease in the older patient may 
cause an “apparent” more rapid progression to major impairment of gait and balance. 
Comparing the available evidence is difficult because of the variability in study design 
and this emphasizes the need for standardised population based studies. The difficulty of 
measuring progression in PD clinically also applies to studies o f disease modifying 
agents, and a standard methodology would help in defining both phenotypic 
heterogeneity and the effects of neuroprotection. The majority o f the evidence from 
retrospective clinic based series supports a slower disease progression in YOPD as 
compared to LOPD.
Whilst this may be a source of some reassurance for younger onset patients, the relative 
effect o f PD on mortality and absolute effect on life expectancy is, if anything, more 
marked for young onset cases. A previous population-based cohort study o f patients with 
parkinsonism noted that the standardised mortality ratio (SMR) for cases aged 40-50 
years at onset was 3.9 (almost four times that o f the general population compared to 2.0 
for cases aged between 75 to 84 years (Ben-Shlomo and Marmot 1995). The 
interpretation o f this figure requires some caution however as it may consist of patients 
with multiple system atrophy and progressive supranuclear palsy that have a worse 
prognosis (Nath, Thomson et al. 2005). A recent literature review (Ishihara,
Cheesbrough et al. 2007) estimated that the life expectancy o f patients with onset 
between 25 to 39 years was 38 years compared to 49 years in the general population 
resulting in a loss of 11 years life expectancy. The equivalent figures for cases with onset
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older than 64 was 5 years compared to 9 years in the general population and hence only a 
four year loss o f life expectancy.
Imaging studies suggest there is lower dopaminergic binding densities in patients with 
YOPD than LOPD when matched for disease duration, implying that there is greater 
dopaminergic neuronal loss in YOPD at the point of assessment (Antonini, Moresco et al. 
2002; Shih, Franco de Andrade et al. 2007). Although the majority of these imaging 
studies are based on patients with parkin mutations, one study systematically compared 
parkin positive and parkin negative patients and concluded that the pattern of 
dopaminergic depletion was not dependant on the presence or absence of the mutation 
(Thobois, Ribeiro et al. 2003).
2.6 Parkinsonian Sym ptom s at Presentation and D om inant M otor  
Phenotype
Distinctions are made between motor symptoms at presentation and symptom dominance 
with advancing disease. PD can be classified on the basis o f dominant motor phenotype- 
either tremor-dominant or postural instability with gait disorder (PIGD) dominant 
(Jankovic, McDermott et al. 1990). A proportion o f patients with tremor dominant 
disease at presentation will become predominantly bradykinetic as the disease course 
advances (Hershey, Feldman et al. 1991; Paulus and Jellinger 1991). The importance of 
recognizing phenotypic patterns in YOPD relates to early diagnosis and prognosis.
Several studies have associated motor phenotype with rate of progression. Tremor 
dominance both at presentation and after 2-7 years from onset are reported to be 
associated with slower progression (Schwab, England et al. 1959; Hoehn and Yahr 1967; 
Zetusky, Jankovic et al. 1985; Huber, Paulson et al. 1988; Jankovic, McDermott et al. 
1990; Hershey, Feldman et al. 1991; Biggins, Boyd et al. 1992). There is some 
suggestion that benign tremulous parkinsonism may in fact be a separate clinical entity 
with prominent tremor not responding well to L-dopa, minimal progression of other 
aspects of parkinsonism and often a family history of tremor or PD (Josephs, Matsumoto 
et al. 2006). There is no consensus on tremor frequency in YOPD having been reported 
less, more and equally as frequently as LOPD (Table 2-3) (Zetusky, Jankovic et al. 1985; 
Gibb and Lees 1988; Giovannini, Piccolo et al. 1991; Kostic, Przedborski et al. 1991;
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Pantelatos and Fomadi 1993; Friedman 1994; Hely, Morris et al. 1995; Gomez Arevalo, 
Jorge et al. 1997).
Table 2-3 : Tremor at onset
Study
Author
YOPD/
LOPD
AAO
YOPD
Source o f  
patients
Tremor at onset 
YOPD vs LOPD
Difference (%), 
(95% Cl) p-value
Conclusions
Gibb (Gibb 
and Lees 
1988)
4 6 /5 2 <45 Clinic 41% vs. 63% -22, (-41,-3) 
p=0.03
Tremor at 
onset 
commoner in 
LOPD
Hely 
(Hely, 
Morris et 
al. 1995)
9 0 /3 3 <70 Sydney
RCT
42% vs. 64% -22, (-41,-3) 
p=0.03
Tremor at 
onset 
commoner in 
LOPD
Freidman
(Friedman
1994)
44 / 46 <47 Clinic 34% vs. 59% -25 (-45, -5)
p=0.02
Tremor at 
onset 
commoner in 
LOPD
Kostic 
(Kostic, 
Przedborsk 
i et al. 
1991)
25 / 25 < 4 0 Clinic 32% vs. 36% -4, (-30, 22) 
p=0.76
Marginal
difference
Quinn 
(Quinn, 
Critchley 
e ta l. 1987)
5 6 / - <40 Clinic 52% 52% of 
YOPD had 
tremor at 
onset
Gomez 
(Gomez 
Arevalo, 
Jorge et al. 
1997)
3 4 /3 4 <40 Clinic 44% vs. 46.4% -2 (-26,21) 
p=0.84
Marginal
difference
Giovannini 
(Giovannin 
i, Piccolo 
e ta l. 1991)
6 0 /6 0 <40 Clinic 35% vs. 21.7% 13 (-3, 29)
p=0.11
Tremor at 
onset 
commoner in 
YOPD but 
could be 
chance
Pantelatos
(Pantelatos
and
Fomadi
1993)
221 / 
1511
<40 Hospital No difference 
(no figures 
given)
No
difference
Abbreviations: AAO = age at onset, YOPD = young onset Parkinson’s disease, LOPD = later onset 
Parkinson’s disease, RCT = randomised control trial
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It has also been reported that YOPD patients are less likely to have gait difficulty as an 
early symptom than LOPD (Table 2-4) (Gibb and Lees 1988; Kostic, Przedborski et al. 
1991; Gomez Arevalo, Jorge et al. 1997).
Table 2-4 : Gait Disturbance at Onset
Study
Author
YOPD/
LOPD
AAO
YOPD
Source o f  
patients
Gait difficulty 
at onset YOPD 
vs LOPD
Difference (%), 
(95% Cl) p-value
Conclusions
Gibb
(Gibb and
Lees
1988)
4 6 /5 2 <45 Clinic 4% vs. 63% - 59 (-73, -45)
p<0.0001
Gait difficulty at 
onset less 
common in 
YOPD
Gomez 
(Gomez 
Arevalo, 
Jorge et 
al. 1997)
3 4 /3 4 <40 Clinic 2.7% vs. 
38.8%
-36 (-53,-19) 
P=0.0002
Gait difficulty at 
onset less 
common in 
YOPD
Kostic(Ko
stic,
Przedbors 
ki et al. 
1991)
2 5 /2 5 < 4 0 Clinic 4% vs. 16% -12 (-28,4)
p=0.16
Gait difficulty at 
onset less 
common in 
YOPD
Abbreviations: YOPD = young onset Parkinson’s disease, LOPD = later onset Parkinson’s disease, AAO = 
age at onset, CI= confidence interval
This may reflect the confounding effects o f age and co-morbidity. Observations may also 
be biased due to the differential referral o f patients to secondary care and misdiagnosis 
and the presence o f tremor is likely to have a significant effect on referral and diagnosis 
by non-specialists. A community based study in the UK showed that 16% of patients 
with onset of tremor after the age o f 55 years who were diagnosed in the community with 
non-parkinsonian tremor (usually essential tremor) actually fulfilled the criteria for 
probable PD on specialist review (Schrag, Ben-Shlomo et al. 2002). Younger onset 
patients are more likely to be referred to specialists, so tremulous PD may be 
underrepresented in the later onset group ascertained from secondary care. A 
standardised population based study would attempt to eliminate referral or selection bias 
capturing data on all patients with PD, not just those referred to secondary care. The 
available evidence suggests that patients with YOPD have less gait difficulty early in the
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disease course than LOPD patients but there is no clear conclusion regarding tremor 
dominance in YOPD.
2.7 D ystonia
Dystonia, characterized by sustained contraction o f muscles leading to abnormal 
posturing, can occur either pre-treatment, or on treatment as peak-dose or off-period 
symptoms (Kidron and Melamed 1987). It has been proposed that rest or exercise- 
induced dystonia at onset (i.e. prior to starting L-dopa treatment) is a common feature of 
YOPD and was reported to be frequent in Japanese autosomal recessive juvenile 
parkinsonism (AR-JP) subsequently found to have parkin mutations (Yamamura, Sobue 
et al. 1973; Yamamura 1998; Bozi and Bhatia 2003; Khan, Graham et al. 2003). PD 
usually presents with symptoms related to bradykinesia, rigidity or tremor such as 
difficulty with handwriting or shoulder stiffness.
Dystonia at onset is presumably an alternative manifestation of dopamine deficiency 
relating to either disease differences or to age related biological differences in the extra- 
pyramidal system. Dystonia at onset occurs with a frequency of between 14 and 57% in 
YOPD (Table 2-5). Painful off period dystonia, particularly affecting the feet and ankles 
also appears to be more common in patients with YOPD occurring at a rate of 30-59% 
during treatment (Quinn, Critchley et al. 1987; Gibb and Lees 1988).
Clinical referral series, without systematic evaluation protocols are the only sources of 
evidence on dystonia in relation to YOPD. Older patients may be more likely to ascribe 
dystonia to “muscle cramps” than younger patients and may suggest under recognition or 
under reporting in LOPD. Overall, the available evidence suggests that both dystonia at 
onset and treatment related dystonia are more common in young onset PD.
37
Table 2-5 : Dystonia
Study YOPD/
LOPD
AAO
YOPD
Sourc
e
Dystonia at 
onset YOPD vs 
LOPD 
(95% C l for  
difference)
Treatment 
Dystonia YOPD vs 
LOPD
Conclusions
Gomez 
(Gomez 
Arevalo, 
Jorge et 
al. 1997)
3 4 /3 4 <40 Clinic 30.5% vs. 0% 
(95% Cl 15,46) 
p=0.0005
Dystonia at onset 
commoner in 
YOPD
Tanner 
(Tanner 
CM 1985)
21 / 21 <55 Clinic 57% vs. 10% 
(95% Cl 22, 72)
p=0.001
Dystonia at onset 
commoner in 
YOPD
Gibb
(Gibb and
Lees
1988)
46 / 52 <45 Clinic 4.3% vs. 0% 
(95% Cl -2 , 10) 
p=0.13
33% vs. 0% 
(95% Cl 19,47)
p<0.0001
Quinn 
(Quinn, 
Critchley 
et al. 
1987)
5 6 / - <40 Clinic 14% 59% Treatment 
related dystonia 
in nearly 2/3 of 
YOPD
Gershanik 
(Gershani 
k and 
Leist 
1987)
1 8 /- <40 Clinic 53% Dystonia at onset 
in over half o f 
YOPD
Gershanik 
(Gershani 
k and 
Nygaard 
1990)
30 / - Clinic 50% Treatment 
related dystonia 
in over half of 
YOPD
Kidron
(Kidron
and
Melamed
1987)
207 Clinic Early morning dystonia AAO = 53.4 yrs. 
O ff period dystonia AAO = 50 yrs.
No dystonia AAO = 60.9 yrs.
Abbreviations: YOPD = young onset Parkinson’s disease, LOPD = later onset Parkinson's disease, AAO = 
age at onset, CI= confidence interval
2.8 Sleep Benefit
Similarly to dystonia, sleep benefit (a period o f lessened disability or feeling “on” upon
waking from sleep(Currie, Bennett et al. 1997)) may relate to biological differences in
the extra-pyramidal systems of younger patients. A number o f authors comment that
sleep benefit is more common in YOPD, but again these observations are based on highly
38
selected clinic populations and may not be representative o f the true PD population 
(Yamamura, Sobue et al. 1973; Quinn, Critchley et al. 1987; Currie, Bennett et al. 1997; 
Yamamura 1998; Bateman, Levett et al. 1999).
2.9 D em entia and N europsychiatric Features
Cognitive impairment and neuro-psychiatric side effects from medication have been 
reported to occur less frequently in YOPD. A large body o f evidence suggests LOPD 
patients are at a higher risk of dementia (Granerus 1979; Pederzoli, Girotti et al. 1983; 
Zetusky, Jankovic et al. 1985; Hietanen and Teravainen 1988; Ebmeier, Calder et al. 
1990; Jankovic, McDermott et al. 1990; Biggins, Boyd et al. 1992), and that the 
incidence o f dementia in YOPD aged under 65 years is negligible (Lieberman, 
Dziatolowski et al. 1979; Elizan, Sroka et al. 1986; Portin and Rinne 1987; Quinn, 
Critchley et al. 1987; Hietanen and Teravainen 1988; Reid, Broe et al. 1989; Dubois, 
Pillon et al. 1990; Jankovic, McDermott et al. 1990; Mayeux, Denaro et al. 1992; Stem, 
Marder et al. 1993; Hely, Morris et al. 1995). There may be, however, evidence of subtle 
cognitive involvement in YOPD as compared with the normal population (Hietanen and 
Teravainen 1988; Dubois, Pillon et al. 1990).
In an incident cohort of PD patients defined by the Queen Square Brain Bank criteria 
observations suggest that older age at PD onset is a risk factor for developing cognitive 
impairment, although in this study only one patient had disease onset before 40 years 
(Foltynie, Brayne et al. 2004). In a population based study of PD the percentage of 
patients with dementia increased with age but the prevalent PD cases with and without 
dementia did not differ with disease duration suggesting that age at onset of PD 
influences the prevalence of dementia in these patients (Mayeux, Denaro et al. 1992).
This was challenged by Gibb et al (Gibb and Lees 1988) who report the prevalence of not 
only depression and dementia being similar in YOPD and LOPD but also personality 
characteristics, such as introversion-extroversion and obsessional qualities. Although 
some rare genetic subtypes of parkinsonism may involve dementia as a prominent feature 
such as alpha synuclein triplication or ATP13A2 related atypical parkinsonism (Kufor- 
Rakeb syndrome, PARK 9) (Muenter, Fomo et al. 1998; Farrer, Kachergus et al. 2004;
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Ramirez, Heimbach et al. 2006), the overwhelming evidence suggests that YOPD 
patients suffer less dementia and neuropsychiatric features than LOPD patients, but 
whether this is a function o f ageing rather than age at symptom onset is not fully 
understood.
2.10 Treatm ent Response and Related Com plications
It is widely perceived that YOPD patients have an excellent response to L-DOPA 
treatment, but that this is marred by the early and severe development of treatment related 
dyskinesias and motor complications (Table 2-6) (Granerus 1979; Pederzoli, Girotti et al. 
1983; de Jong, Meerwaldt et al. 1987; Gershanik and Leist 1987; Quinn, Critchley et al. 
1987; Gibb and Lees 1988; Giovannini, Piccolo et al. 1991; Kostic, Przedborski et al.
1991; Hely, Morris et al. 1995).
However, studies comparing differences in YOPD and LOPD treatment response are 
confounded by the widespread practice of delaying L-DOPA treatment in YOPD patients, 
differences in total L-DOPA dosage and the use o f concurrent dopamine agonists. In an 
attempt to overcome this Kostic and colleagues carried out a carefully matched study of 
YOPD (onset between 21-40 years) and LOPD (onset > 40 years) ; matched for gender, 
duration o f disease, mode of onset, Hoehn and Yahr stage, duration of treatment and dose 
o f L-DOPA (Kostic, Przedborski et al. 1991). Twenty five patients were identified in 
each group. The study showed a significantly higher frequency of both dyskinesias and 
response fluctuations in the YOPD group as compared to the LOPD group. The YOPD 
group developed complications substantially earlier than patients with LOPD, however 
the severity of dyskinesia was not significantly different between the two groups.
A further population based study and meta analysis showed a higher 5-year dyskinesia 
incidence (i.e. in patients who had been on L-dopa for five years) with younger age at 
onset but did not have any patients with onset before age 40 years and included any 
appearance o f dyskinesia, whether reversible or not on manipulation o f medication 
(Ahlskog and Muenter 2001; Kumar, Van Gerpen et al. 2005). Fifty per cent of patients 
with disease onset between 40-59 years had dyskinesia within 5 years of starting L 
DOPA, and only 16% o f those with onset over 70 years ( 40% with onset 40-49, 53%
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with onset 50-59, 26% with onset 60-69, 16% with onset 70-70 and 14% with onset 80- 
89 years).
Table 2-6 : Dyskinesia and Motor Fluctuations
Study YOPD/
LOPD
AAO
YOPD
Source
o f
Patients
Dyskinesia
YOPD
Dyskinesia
LOPD
Fluctuations
YOPD
Fluctuations
LOPD
Yokoshi 
(Yokochi M 
1981)
32/- <40 32%
Quinn 
(Quinn, 
Critchley et 
al. 1987)
56/- <40 Clinic 55% at 1 y 
100% at 6 y
Perderzoli 
(Pederzoli, 
Girotti et al. 
1983)
Increased
Tanner 
(Tanner CM 
1985)
91%
Gibb (Gibb 
and Lees 
1988)
4 6 /5 2 <45 Clinic 91%
Gershanik 
(Gershanik 
and Leist 
1987)
75%
Kostic 
(Kostic, 
Przedborski 
eta l. 1991)
2 5 /2 5 72% at 3 y* 28% at 3 y 64% 3 y** 28% at 3 y
Hely (Hely, 
Morris et al. 
1995)
9 0 /3 3 <70 Sydney 
Multice 
ntre trial 
(referral 
)
No
differences
Barbeau
(Barbeau
and
Pourcher
1982)
42% at 2 y 35% at 2 y
Abbreviations: YOPD = young onset Parkinson’s disease, LOPD = later onset Parkinson’s disease, y = 
years
* p-value for difference =0.002 
** p-value for difference=0.01
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The available evidence based on clinic series suggests that patients with YOPD develop 
dyskinesias earlier than LOPD patients but the impact on quality of life has yet to be 
clarified.
2.11 Fam ilial Aggregation
Twin studies have been influential in evaluating the genetic contribution to the 
pathogenesis of PD. Low PD concordance in monozygotic/dizygotic twin studies have 
leant support to the idea that late onset PD is not hereditary (Tanner, Ottman et al. 1999; 
Wirdefeldt, Gatz et al. 2004). The situation differs in YOPD. In PD diagnosed under the 
age of 50 the monozygotic concordance was 1.0 based on only 4 twin pairs compared 
with 0.16 in twelve dizygotic twin pairs (Tanner, Ottman et al. 1999). This strongly 
indicates that genetic influences are important in YOPD although this is based on small 
numbers. In both the monozygotic and dizygotic pairs the interval to diagnosis of the 
second twin was similar, and no statistically significant difference in mean interval to 
diagnosis was reported when stratified for age at diagnosis. However, in general terms 
twin studies and first degree relative studies have a limited power to detect the effects of 
genes of low penetrance which may act differently in young onset and late onset disease 
(Johnson, Hodge et al. 1990).
The advantages of extended genealogy were used in a study o f familial recurrence of PD 
in the Icelandic population (Sveinbjomsdottir, Hicks et al. 2000). Twenty percent o f the 
patients in the study on whom onset data were available were classed as YOPD, but 
attempts to cluster these patients into pedigrees did not show a highly penetrant 
Mendelian pattern o f inheritance, although patients with PD were more related to each 
other than the controls. A number of studies have suggested a higher incidence of 
familial occurrence of PD in patients with younger onset disease compared to older onset 
although a few have failed to confirm this (Mjones 1949; Martin, Young et al. 1973; 
Yokochi, Narabayashi et al. 1984; Quinn, Critchley et al. 1987; Stem, Marder et al.
1993; Payami, Zareparsi et al. 2002; Marder, Levy et al. 2003; Rocca, McDonnell et al. 
2004). The Mayo Clinic study showed that by using the higher age at onset of 66 years 
relatives o f YOPD had a relative risk of 2.62 o f developing PD compared to relatives of 
controls whereas those o f LOPD (onset >66) had a similar risk of familial recurrence to
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the general population (Rocca, McDonnell et al. 2004). Interestingly, analysis in the 
same study using onset at 50 years as a cut off showed a relative risk of 3.03 for relatives 
o f YOPD compared to 1.62 for LOPD. This highlights the importance o f defining and 
standardizing the age definition for YOPD and LOPD groups.
It is important to note the potential bias in comparing familial aggregation in YOPD and 
LOPD. It may be harder to obtain accurate detailed information in relatives of LOPD as 
the family members may be deceased and the diagnosis may have been incorrect or kept 
quiet from family members as seems to be more the case in older generations. In younger 
patients there is more likelihood that relatives would be alive and available for direct 
interrogation of symptoms. This may lead to an underestimation of familial occurrence of 
PD in older patients.
Overall there is a suggestion that familial recurrence is higher in YOPD than LOPD and 
this varies with the age definition used.
2.12 D ifficulties in com paring current evidence
Most conventional population based prevalence studies o f PD describe patients based on 
their age at ascertainment rather than their age at onset. Most incidence studies, while 
collecting accurate data on age of onset, only identify small numbers o f patients with 
YOPD. Many of the studies on which observations about YOPD are made are based on 
highly selected specialty clinic based populations. Differences in referral pattern of 
YOPD and LOPD patients to specialist services may confound observations in those 
studies based on specialty clinics populations which appear to be the majority 
contribution to the current evidence base. This is further compounded by misdiagnosis 
rates within the community. A community based study performed in London UK, 
suggested, surprisingly, that atypical patients were less likely to be referred to secondary 
care and that twenty percent of patients with PD who had already come to medical 
attention had not been diagnosed as such. On review of the initial diagnosis 15% 
diagnosed with PD did not fulfill strict clinical criteria for PD (Schrag, Ben-Shlomo et al. 
2002). In addition, variation in methodology causes difficulty in comparing data from 
different studies, such as inclusion/ diagnostic criteria, age definitions and disability
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measures. To overcome difficulties in the future we believe standardised population 
based studies are essential.
2.13 Conclusions
The available evidence suggests that, compared with LOPD, patients with YOPD are 
more likely to a) show slower disease progression , b) develop dystonia at onset, c) 
develop early dyskinesias in response to L-DOPA treatment, d) have a concordant family 
history , but less likely to a) develop gait disturbance as an early clinical feature, b) have 
neuro-psychiatric and cognitive involvement. However many o f the available studies are 
based on age at ascertainment rather than their age at onset, involve small numbers of 
patients , include highly selected specialty clinic based populations and are subject to 
variation in methodology which all cause difficulty in comparison across studies and 
introduce bias at ascertainment. Another source of bias related to the way in which the 
articles were found. The search strategy was limited to the Ovid Medline databases and 
only articles published in the English language. A better method would have been to 
include databases in EMBASE as the journals in these two database sources do not 
generally overlap and articles may have been missed. Limiting articles to the English 
language obviously introduces further bias.
The identification of Mendelian PD genes has led to a critical re-evaluation of the 
concept o f PD, and raised the possibility that different pathologies and aetiologies 
underlie the clinical concept o f PD. YOPD comprises a heterogeneous group of patients.
It is likely that a subset o f YOPD have a different disease based on genetic aetiology and 
pathology but currently there is not enough evidence in the reported literature to 
differentiate these subgroups and there is little evidence to suggest that “non- familial” 
cases of PD without a known genetic mutation are patho-physiologically different to 
typical LOPD. The description of genes responsible for autosomal recessive 
parkinsonism and the identification of some cases of genetic autosomal recessive 
parkinsonism among YOPD case series raises the possibility o f dissecting the 
heterogeneity o f PD on a genetic basis. Ultimately this may lead to a more directly 
patient-centred approach to the management o f PD, with specific advice on familial risk, 
prognosis, likelihood of disease related complications and appropriate disease modifying 
therapies based on genetic background and age at onset.
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Reviewing the published data have illustrated a clear need for large scale standardised 
population based case control studies of YOPD and LOPD. This is highlighted by the 
variation in methodologies leading to difficulties in comparisons between published 
studies.
Some o f the points suggested by Twelves at al (Twelves, Perkins et al. 2003) to improve 
the quality and consistency o f future incidence studies of PD can clearly be applied to 
future case control studies investigating features o f YOPD, and these include 1) as many 
of the possible cases as possible should be seen by an expert in movement disorders, 2) 
cases should be defined by a specific symptom onset rather than date of diagnosis, 3) 
clear and consistent inclusion and exclusion criteria should be applied, and 4) ideally 
there should be some follow up to give information to support the diagnosis of PD as per 
Queen Square Brain Bank Criteria and to assess for symptoms suggestive of a 
Parkinsonian plus syndrome.
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Chapter 3 Methods
3.1 O verall Study Design
The work in this thesis comprises two main parts:
1. A prevalence study of Parkinson’s disease in Cardiff analyzed by age at onset
2. A population based case control study o f early compared to late onset Parkinson’s 
disease
The prevalence study used primary care as the main ascertainment source supplemented 
by secondary care resources. This provided a population based pool o f Parkinson’s 
disease (PD) patients by age at onset for the case control study. As the numbers of early 
onset patients was anticipated to be small, supplementary ascertainment of cases was 
made from secondary care sources outside Cardiff. These supplementary cases were used 
for the second part o f the study and did not form part o f prevalence study.
Data were collected on symptom onset, progression, treatment response and related 
complications, cognitive function and non-motor symptoms.
The data collected will have an immediate and direct impact on the care of patients with 
PD providing guidance on treatment and help plan service provision.
3.2 Sam ple Size and Power Calculation
Cardiff has a population of 340,000 and an estimated target pool of 571 patients with PD 
(previous UK prevalence estimate 168/100,000 (Schrag, Ben-Shlomo et al. 2000), of 
whom approximately 86 (6.6%) will have an age at onset of less than 55 years. In 
calculating sample size, we assumed a 60% recruitment rate. Therefore, we anticipated 
recruiting 343 PD patients in Cardiff, o f whom a minimum of 52 will have an age at 
onset of less than 55. The secondary care cases o f YOPD were established from the rest 
o f Wales using referrals from physicians (neurologists and geriatricians) running PD 
clinics and PD nurse specialists. We estimated 40% recruitment and identification of 
further 151 YOPD patients. Using these conservative figures for case ascertainment, we 
aimed to recruit a minimum of 203 patients with an age on onset of less than 55 years.
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The local series was used to validate the larger series, i.e. to ascertain if there were 
systematic differences in the primary and secondary care cases.
Power calculations were made using an on-line power calculator 
(http://www.stat.uiowa.edu/~rlenth/Power/index.html). For a disease feature which 
occurs in 10% of patients, this sample size (around 200) would have around 80% power 
o f detecting a twofold increase in frequency (20%) with significance set at the 5% level 
with a 1:1 ratio of young and late onset patients.
3.3 Unique Study Num ber
Each patient was allocated a unique seven digit study number. This consisted o f three 
parts:
the first three digits related to the GP practice code (see appendix Table 1) 
the middle digit related to case/control status ie PD case - 1, GP identified control 
- 2, case nominated control - 3 . The control data do not form part o f this thesis, 
the final three digits made up a unique patient code which is generated serially.
For those patients identified via the GP searches, these study codes were assigned once 
the unique list was compiled from the two independent electronic searches. For those 
patients referred by secondary care, the study number was assigned before sending out 
the basic screening questionnaire.
The GP generated patients were assigned their study numbers before case notes were 
reviewed. This meant that the numbers o f patients excluded following case note review 
and GP screen could be documented as well as the reasons for exclusion. These data were 
needed for the prevalence analysis.
3.3.1 GP Study Codes 
C ardiff Practices
There are 54 functioning GP practices in Cardiff. These were assigned practice codes 
from 101 to 154 in the same order as they were listed according to their Local Health 
Board Code.
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Practices O utside C ardiff but w ithin W ales
There were eight divisions of study code that were available (2** to 8**) but twenty one 
Unitary Authorities outside Cardiff, so the Unitary Authorities were grouped according to 
geographical area. Some consideration had to be taken into account o f number of 
practices within each group as each study code division could only contain a maximum of 
99 practices (eg 201 to 299). Therefore, some of the areas with smaller number of 
practices had to be grouped together, rather than those with geographical proximity.
Practices outside W ales
Any practice outside Wales from which a referred case was registered was given a 
practice code o f 999.
3.4 Prevalence Study
The aim o f this part of the study was to estimate the prevalence o f PD in a defined 
geographical area of Cardiff in South Wales. In addition to providing information on the 
crude and age sex adjusted prevalence rates o f PD in Cardiff, information on disease 
onset was collected, providing an estimate o f YOPD prevalence.
3.4.1 Pilot GP searches
In order to find the most effective search strategy for searching GP databases, a pilot 
study was initiated. This was carried out in three GP practices in Cardiff which varied in 
size and level o f coding accuracy. All Cardiff GP practices used the 5-byte version 2 
Read Code edition. The Read Code was used to identify patients with PD based on 
individual symptoms and examination findings and also on diagnostic terms. The 
medication section was also examined to identify those used in PD.
Search Term s Used
Three main categories of search terms were used and the number of cases found with 
each were compared when terms were use singly and in combination to try and find the 
most sensitive and specific method of complete capture o f all patients with PD within the 
individual GP computerised databases.
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Pilot practice visit
The three pilot practices were visited and each search strategy was run separately and 
numbers o f cases identified were recorded. In Wales, there are very few computing 
systems used by primary care to store and organise patient data, so the majority of 
practices would use one of the three most common systems used by our pilot practices. 
Most o f the practices visited used the Vision software which was compatible with the 
majority of the systems used across Cardiff.
Patient unique data were used to ascertain which cases were identified on more than one 
list and to see which search strategy or combination o f search terms were the most 
effective at capturing the most cases.
At each practices, the patients case notes from those cases identified via the search 
strategies were checked for diagnostic accuracy and to establish whether miscoding had 
occurred.
All pilot practices were visited in autumn 2005.
Ely Bridge Practice
The first pilot search was performed at Ely Bridge Practice. This practice had a total list 
size o f approximately 13,000 and claimed up to date coding and accurate diagnostic 
labelling and data entry, having taken part in many research projects in Cardiff. The 
system used here was TOREX.
Roath House Practice
The second pilot practice visit took place at Roath House Practice. This had a total 
practice list size of approximately 7,200. The system used here was EMIS.
Saltmead Practice
The last pilot practice visit took place at Saltmead Practice. This had a total practice list 
size o f approximately 3,000 and was a single handed practice at this time under 
considerable pressure due to staff shortages. The system used here was GANYMEDE.
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Pilot Search Results
Table 3-1 : Results from pilot search strategies from three Cardiff GP practices
SEARCH TERM Read code Number o f  
cases identified
True PD cases using 
case notes for  
verification
Parkinson’s disease F12 29 25
Parkinson’s disease and below F12 -  F12z 35 26
- Paralysis agitans F120 0 0
- Parkinsonism 2ry to drugs F121 1 0
- Malignant neuroleptic syndrome F122 0 0
- Post encephalitic parkinsonism F123 0 0
- 2ry parkinsonism due to other external agents F12w 0 0
- 2ry parkinsonism, unspecified F12x 1 0
- Parkinson’s disease, NOS F12z 7 1
History -  difficulty walking N097 21 0
History -  difficulty walking NOS N097z 0 0
O/E muscle rigid cogwheel 2944 1 0
O/E Parkinsonian tremor 297A 2 0
O/E Parkinsonian flexion posture 2987 0 0
O/E festination Parkinson gait 2994 0 0
Extrapyramidal movements 29M 0 0
Other extrapyramidal disease and abnormal 
movement disorders
F13 0 0
Parkinsonism and orthostatic hypotension FI 303 0 0
Progressive supranuclear ophthalmoplegia FI 304 0 0
Lewy Body disease FI 16 0 0
Multi system atrophy F174 0 0
Restless leg syndrome 55 0
Other basal ganglia degenerative disease 0 0
History -  has a tremor 1B22 81 0
Tremor NOS R0103 76 0
O/E fine tremor 2975 3 0
Involuntary movements NOS 2972 7 0
Senile tremor R20 1 0
Benign Essential tremor F 1310 4 0
Familial tremor F1311 0 0
Drug induced tremor F 1312 0 0
Essential and other specified forms o f tremor 
NOS
F 131 z 3 0
Parkinsonian dopaminergic drug dq 58 30
Parkinsonian anticholinergic drug dv 54 0
Modafinil dzl 5 0
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Table 3-1 shows the number of cases identified by each individual search term for the 
three pilot practice visits.
3.4.2 Refinement of Search Strategy Following Pilot Visits
Using the PD and below strategy found one extra case in Ely Bridge as compared to 
searching for PD alone. Searching on prescription codes identified six cases more than 
the PD and below search. In Roath House, using the PD and below search did not identify 
any additional cases, neither did the prescription search, although two cases were 
identified on the diagnostic search who were not on medication.
Following the pilot visits, it was concluded that a search strategy using “tremor” and “any 
tremor symptom” yielded a large number of patients who did not have PD. It is possible 
that some patients with tremor had undiagnosed PD but it was not possible to devote time 
to screen such a large number by examination to identify those patients with PD. Our 
prevalence estimate was based on medically diagnosed cases only. The terms “tremor” 
and “tremor symptom” were therefore removed from the diagnostic terms part o f the final 
search strategy.
It was found that on the whole patients who were diagnosed as having PD were coded for 
one of the diagnostic codes present in the F12 and hierarchical terms.
If patients had been miscoded for diagnosis, and were started on dopaminergic 
medication, it was possible to identify them via their prescription records. It was best to 
search for all previous and current prescriptions and to review the medical case notes in 
conjunction to verify the diagnosis on available information. Some patients were 
prescribed dopaminergic drugs for conditions other than PD such as restless leg 
syndrome and prolactinomas. These were very easily identified on either reviewing the 
electronic code assigned to these patients or on reviewing the hand written case notes.
It was found that the majority of patients that were prescribed anticholinergic medication 
suffered bladder problems and not PD or tremor. If the patient had concomitant bladder 
problems and PD, they were invariably prescribed a dopaminergic agent in conjunction.
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The anticholinergic group of medications was therefore removed from the medication 
search term list in the final search strategy.
Some patients were on certain dopaminergic drugs for conditions other than PD. For 
example bromocriptine is very rarely, if ever, used as a dopamine agonist in PD. Its use 
in PD has largely been superseded by newer agents such as ropinirole and pramipexole. 
However, some practices still use bromocriptine to stop lactation in women after 
termination of pregnancy or in mastitis. Therefore bromocritptine was removed from the 
dopaminergic group in the medication part o f the search strategy.
Amantadine may be used in PD patients when motor complications of L-DOPA use arise 
and so these patients are usually on combination o f dopaminergic drugs. It is not used in 
isolation in PD patients. However, it is sometime prescribed in isolation to patients with 
Multiple Sclerosis (MS) to help with fatigue. A patient with MS was identified using 
Amantadine as part of the search strategy. Those patients with PD on Amantadine would 
be identified via the search on the other dopaminergic drugs. Therefore Amantadine was 
removed from the dopaminergic group in the medication part o f the search strategy.
Whilst reviewing case notes from every case identified from the search strategies, it 
became clear that a significant proportion of patients appeared to be miscoded. A patient 
with W olf Parkinson White syndrome, a cardiological condition in which conduction 
abnormality presents in young adults or teenagers, was identified via the search terms 
piloted. There may have been some confusion with the “Parkinson” part of the syndromic 
name and this may have been manually coded as Parkinson’s disease. In any case, this 
highlighted the importance o f using the electronic search strategies as an initial screen to 
identify potential cases, and then to verify the diagnosis further by reviewing in detail the 
medical cases notes. This also gave the opportunity to obtain detailed information on 
onset age and symptom retrospectively from contemporaneous medical notes, which we 
assume to be accurate as these are recorded in real time.
The final search strategy was adopted to generate two separate lists generated from the 
following terms:
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1. Diagnostic terms -  Parkinson’s disease and subgroups (F12-F12z)
2. Medication prescription terms -  dopaminergic drugs (dq...) excluding 
Bromocriptine (dq5..) and Amantadine (dq4..).
3.4.3 GP contact
The heads of all 54 practices were contacted in September 2006 by letter explaining the 
purpose o f the study. This initial contact was followed by e-mail addressed to the practice 
manager outlining their proposed involvement. If a positive response was received, a 
telephone call was made to book a practice visit. Those practices who did not respond 
after 6 weeks were contacted again by e-mail and after a further 3 weeks were contacted 
by telephone directly. Those practices that declined to participate were not contacted 
again.
3.4.4 GP visit protocol
Once a mutually convenient appointment was arranged, both myself (MW) and the 
Project Administrator (COL) visited the practice. Two independent lists were generated 
by performing two queries from the population list o f all currently alive permanently 
registered patients.
The first list (diagnostic search) consists of all patients who are coded or ever been coded 
for the hierarchical Read codes F I2 to FI2z from the 5-byte version 2 Read Code 
directory. These are summarised in Appendix table 3.
The second list (drug search) was generated by running a query from the entire database 
o f current permanently registered patients who have ever been on or are currently on any 
o f the drugs listed in the group CNS drugs- parkinsonism dopaminergic drugs (dq...) 
excluding amantadine (dq4..) and bromocriptine (dq5..). These are listed in Appendix 
tables 4. If the practice could not search by Read code, they were asked to search by drug 
group, failing that to search by each individual drug name.
Once both lists were generated, duplicates were eliminated and a unique list assembled. 
These patients were assigned unique study codes and their anonymised details were 
entered into the Preadmin database. No personalized data left the practices.
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MW would personally screen through patient notes (usually both electronic and paper) of 
those on this list. MW would first determine whether or not the patient had Idiopathic 
Parkinson’s disease by reviewing details on symptoms and response to treatment, and 
secondly record details of symptom onset or when the diagnosis was first coded if this 
information was not clearly available. Patients with alternative diagnoses were eliminated 
and the final list was handed to the GP who was asked to exclude patients in whom it was 
felt inappropriate to contact (for example if they were terminally ill, demented or 
mentally ill) or if they did not have PD. The practice was contacted a week after the 
initial visit to obtain this information and this was directly entered into the Preadmin 
database using the appropriate study code identifier.
After this final screen was completed the practice sent out a postal pack (postal pack 1) 
which included an invitation letter from the GP, information about the study and a Basic 
Screening Questionnaire (BSQ) to the potentially eligible patients. This was used to 
collect information on diagnostic questions based on the Queen Square Brain Bank 
criteria for diagnosis o f Parkinson’s disease and more importantly, information on age at 
symptom onset as well as seeking written consent for further participation in the project 
and giving access to their medical records. If no response was received after three weeks 
o f the original invitation, the practice was asked to send a reminder letter to those who 
had not replied and then again at six weeks if still no response was received. These 
patients were identified only by their study code number (practice code and patient code) 
and details such as date o f birth, first four digits o f the postcode and gender were used to 
further verify the identity o f each patient until they returned the screening questionnaire 
with their intent to participate further.
Once the basic screening questionnaire was completed, data from this were entered into 
the Preadmin database. If it was felt on the basis of the patients’ answers on the BSQ 
(plus the medical notes from both the GP and secondary care if available) that the patient 
fulfilled the diagnostic criteria for possible PD and they had indicated that they would 
like to participate further in the project, their details were pulled though to the Main 
Admin Database and they were sent further correspondence regarding the case control 
study.
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3.4.5 Data extraction proforma
Patient identifiable data were not taken away from the GP practice so anonymised data 
and numbers within groups were recorded.
The following data were recorded from each GP visit:
the number of patients generated from the diagnostic code search
the number of patients generated from the drug search
the number of patients who were on both lists (duplicates)
the number of patients who were unique i.e. after duplicates taken away
the number o f patients found on one list and not the other and vice versa
the number of patients excluded by MW as not having Idiopathic Parkinson’s
disease after screening the notes
the number of patients excluded by the GP because they were terminally ill, 
psychiatrically ill, demented, a temporary resident, not PD or for another reason 
otherwise specified
the number of patients remaining who were invited 
the date the invitation letter was sent 
A list o f all study codes o f patients from that practice who were eligible to be invited was 
generated with the corresponding date o f birth, gender and first four digits o f the 
postcode along with data on onset symptoms and dates o f diagnosis. Also details of 
whether the patient had had secondary care contact and who if anyone was responsible 
for ongoing care o f their Parkinson’s disease was recorded.
3.4.6 Age at Onset Data
Data on age at onset was carefully and intensively sought out. The date pertaining to the 
first mention in the GP notes of any symptom relating to the four cardinal motor features 
o f PD (tremor, bradykinesia, rigidity and postural instability) was recorded. If the 
electronic GP notes were not detailed enough or just mentioned a diagnosis of PD at the 
start o f the electronic record, the paper GP notes were scrutinized to obtain more accurate 
onset data. Secondary care clinic letters were often scanned in to the GP electronic notes, 
and these were used as an additional source o f information if the GP had not recorded 
exact details o f symptom onset. If the secondary care letters were scanned in to the GP 
electronic records this was still classed as primary care information.
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Where accurate onset data was not available from the GP records, every effort was made 
to search secondary care notes in the hospital, especially for those prevalent cases that 
were additionally identified via secondary care sources.
3.4.7 Cross check with secondary care sources
Notes were screened for each patient attending the main secondary care PD Clinic in 
Cardiff over a 6 month period and the database kept by the PD nurse specialist serving 
Cardiff was utilised. Those living in the Cardiff area were cross-checked against the 
patients identified via the GP database searches using pseudo-identifiers. Any potential 
new or missed cases were invited to participate by the patient’s secondary care clinician. 
All physicians and health care professionals involved in the care of patients with PD, 
including care o f the elderly and general physicians and those working at the local day 
hospital, were contacted to request referral o f patients into the study. In addition, 
Neurology consultants who held general clinics in Cardiff were asked to recruit patients 
who resided in Cardiff into the study by handing out the screening questionnaire and 
where available diagnostic records were searched to enable further consultant recruitment 
of PD patients. A small number o f Consultant Neurologists allowed us to use their 
personal diagnostic databases (in the form o f excel spreadsheets) to identify patients with 
PD and some allowed the electronic hand search of clinic letters held on their secretaries 
computer hard drives (searching for the term Parkinson’s disease or parkinsonism in 
word documents). Unfortunately there is no comprehensive secondary care electronic 
diagnostic database that is comparable to that o f primary care and so many sources had to 
be contacted individually. Only patients that were registered with the participating 
Cardiff general practices were invited for the prevalence study.
3.4.8 Prevalent Cases
Cases were defined as prevalent if they (a) were alive and symptomatic during the period 
January to December 2006, (b) were registered with a participating practice, (c) had been 
diagnosed as having PD and (d) met the Queen Square Brain Bank criteria at clinic 
assessment or if the information held in the clinical notes were consistent with a 
diagnosis o f PD and without recognised exclusion criteria. In addition, a level of 
diagnostic certainty was applied according to the diagnostic information available.
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3.4.9 Statistical method
Data were stored using Access (Microsoft), and analysed using STATA 9 (StataCorp). 
Crude prevalence rates and 95% confidence intervals were calculated using the Poisson 
distribution. We calculated age and sex specific rates and standardised these to the 1997 
England and Wales population (taken from the Office of National Statistics publication) 
to allow direct comparison with the previous UK prevalence studies. Previous studies 
were re-analysed to determine age-standardized rates using the same standard population 
and the results (95% confidence intervals) were displayed on a forest plot. We calculated 
the between study variation from a mixed effects Poisson model to derive the p-value for 
heterogeneity. Comparison of differences in groups was made using the Chi-squared 
distribution and continuous variables using linear regression.
3.5 Clinical Features by Age at O nset Study
3.5.1 Recruitment of Non Prevalent Cases
Additional cases were recruited from secondary care sources from outside the prevalent 
GPs in Cardiff and from sources outside Cardiff. All hospital physicians and health care 
professionals who were involved in the care o f people with PD were approached about 
the study. In particular, the regional PD nurse specialists for Cardiff, Swansea, Newport 
and Bridgend were a significant case referral source. In addition, presentations were 
given to the regional Parkinson Disease Society Branch meetings about the study and 
advertising methods of recruitment. In addition, the study was advertised via the PDS 
newsletter. Patients were able to self refer in to the study by completing the BSQ. 
Initially, emphasis was placed on recruiting cases with onset below 55 years from non 
prevalence Cardiff GPs and outside Cardiff referral sources, but in the later stages o f the 
study, all ages o f onset were accepted from these sources in order to obtain target 
numbers for the clinical features study.
3.5.2 First contact with the study group
Once the patient had returned their completed BSQ, met inclusion criteria from initial
screening and had indicated they would like to take part in the case control study, they
were first contacted by telephone. If cases were unable to attend the clinic in person they
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were given the opportunity to provide information on some sections of the assessment via 
postal questionnaire. During the first telephone contact patients were given a choice o f 
location as to where they could attend the clinical assessment and a clinic date was 
booked. A summary of what was to be expected at the clinical assessment and estimated 
duration of the assessment was discussed and the patient had ample opportunity to ask 
questions at this stage. Once a clinic date was set, Postal Pack 2 (PP2) was sent out.
3.5.3 Postal Pack 2
Postal Pack 2 (PP2) contained the full Patient Information Sheet (PIS), two copies o f the 
Consent forms, the Life History Questionnaire (LHQ) along with a letter confirming the 
clinical date, time and location. The patients were asked to read through the PIS in order 
to discuss any queries in person at the time of the clinical assessment before signing the 
consent forms. Patients participating by questionnaire only had the opportunity of 
discussing issues for clarification over the phone, by letter or via e-mail. A stamped 
addressed envelope was sent with PP2 so that the completed questionnaire could be 
returned prior to the clinical assessment. The life history questionnaire contained 
questions concerning early life housing, water supply and exposure to pets, smoking and 
alcohol consumption, physical exercise in school, occupational history and exposure, past 
medical history and incorporated the SF-36 v2 (Ware and Sherboume 1992; Jenkinson, 
Stewart-Brown et al. 1999), (a generic quality of life scale), and the Epworth Sleepiness 
Scale designed to investigate sleep dysfunction, an important non-motor symptom of PD 
(Johns 1991). Also obtained was information on consanguinity, place o f birth and ethnic 
origin as well as whether family members suffered from PD or tremor. It is envisaged 
that this environmental, quality o f life and family history data will be analysed following 
completion of collection of group matched control data and are not reported in this thesis.
3.5.4 Clinical Assessment
On the day of the clinical assessment patients were asked to continue their normal 
medication and they were assessed in a practically defined “on” motor state. A 
standardised clinical assessment protocol was followed for each assessment.
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Consent
Firstly, the PIS and consent forms were discussed and the opportunity was given for 
patients and their carers to ask questions. The consent forms were signed by the patients 
following this discussion and countersigned by the researcher.
H istory
Details about handedness and referral source were initially recorded and then a detailed 
freehand clinical history was taken. Questions from a checklist o f exclusion criteria were 
asked. These were taken from the Queen Square Brain Bank Diagnostic Criteria for 
Idiopathic Parkinson’s disease. Standardised questions on dystonia, hallucinations and 
sleep benefit were incorporated into the history taking. Details on PD medication were 
then recorded including drug name, dosage, times taken, and start date. Perceived 
effectiveness of L-DOPA was scored using the appropriate section o f the Unified 
Parkinson’s Disease Rating Scale (UPDRS) (Fahn, Elton et al. 1987), a standardised 
validated rating scale commonly used in the assessment of PD. Also from the UPDRS 
were questions on the development and presence o f motor complications related to L- 
DOPA use. A detailed family tree was drawn in those cases who reported a family history 
o f PD.
Exam ination
A standardised examination protocol was followed for each assessment. A detailed 
neurological examination was performed and elements recorded on a standardised 
proforma. A video recording was made of the UPDRS motor examination and hand 
writing ability o f each patient and the scores for each individual section recorded.
Two further validated standardised scales were used. The thirty point Mini Mental State 
Examination (MMSE) (Folstein, Folstein et al. 1975) was administered by the researcher 
along with the Lang and Fahn Activities o f Living Dyskinesia Quality of Life Scale 
(2001). The patient was then asked to complete the PDQ-39 (Peto, Jenkinson et al. 1995), 
a disease specific quality of life questionnaire and the Beck’s Depression Inventory 
(Beck, Ward et al. 1961).
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3.5.5 Postal Questionnaires following Clinic
If the patient had indicated that dyskinesias were present during the clinical assessment, 
they were asked to fill out a three day patient home diary to record their motor state at 
half hour intervals during this period. A stamped addressed envelope was provided for 
the patient to send this back to the study group once completed.
In addition, every participant was sent a Family History Questionnaire. This requested 
details on every first and second degree relative including screening questions to 
determine whether any o f these relatives had PD, age at onset and current age. The data
from the family history questions are not discussed in this thesis.
3.5.6 Drug Information
Information regarding medication doses and start times were taken at the clinical 
assessment. Supplementary information was requested from GP electronic records and 
was sent to us as printouts from the appropriate GP surgery electronic database after the 
patient attended for clinical assessment.
Analysis using start dates for treatment duration used the dates taken from the clinic 
assessment. If this date was missing, the GP data were used. However, in a small number 
o f cases the electronic records stated medications were started after the clinic date but 
patients were clearly on the medication at the time o f assessment. In these instances the
start date was estimated as a year from diagnosis.
3.5.7 Data Entry
Once data were collected and recorded on the clinic proformas, this was entered on to the 
Main Admin Database by the research doctor, the research administrator and, mainly, 
trained medical students.
3.5.8 Data analysis
Data were analysed using STATA 9 (StataCorp). For the clinical features study, Chi- 
squared tests were used to compare heterogeneity and trend, and means were compared 
using the unpaired t-test. The effect of age at onset was studied in two ways: either in 
four groups with onset <45, 45-54, 55-64 and >65 years, or in two groups with age above
60
and below 45 years. This was to see whether associations show a dose-response effect 
with age or whether there is a bi-modal distribution with differences only seen in the 
youngest group. Multiple regression analyses were used to assess the confounding effects 
o f both disease and treatment duration.
3.6 Database Design
The database was designed in collaboration with Peter Shiarly (Department o f Social 
Medicine at Bristol University).
There were two linked databases allowing for the initial anonymous data entry for the 
prevalence study (Preadmin Database) then linking to the main project database which 
required patient identifiers and consent for coordinating the administration of the project. 
It was possible to extract all data in an anonymised format for analysis. The database was 
written in Microsoft Access and largely comprised numerical codes for categorical data, 
including flag fields for subject status.
3.6.1 Preadmin Database
This was designed to store all data collected from the prevalence study and so was 
designed to contain only anonymised data.
A section relating to GP practice visit details contained fields for dates o f each part of the 
visit protocol. This facilitated the administration process o f the project allowing queries 
to be generated to aid the smooth running o f the GP protocol whereby several practices 
may have been in different stages at any given time. Coordination of the practice visits 
was possible through recording dates and details of practice visits, when initial letters 
were sent inviting patients and when reminders were due. This all had to be conveyed to 
the individual practice on an anonymised basis at the correct intervals.
Also entered in this section were data collected through the ascertainment process, which 
allowed us to look at case numbers generated from each individual search strategy and 
exclusions.
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Anonymised data from any potential patient identified or referred into the study were 
entered into the Preadmin database. Anonymous data were collected from each subject 
including date o f birth, gender and partial postcode. Each subject was assigned a unique 
study code under which data were entered into the database. The GP practice at which the 
subject was registered formed the first part of this study code.
Data gathered at the GP visit were entered, the patients’ response to being invited into the 
study, along with data from the basic screening questionnaire when this was completed 
by the patient. Those patients who consented to taking part in the main study and who 
were eligible by diagnostic criteria were pulled through to the Main Admin Database and 
were sent further instructions for continued participation.
3.6.2 Main Admin Database
This contained identifiable patient details to help the administration o f the project, such 
as generating clinic and thank you letters, along with monitoring the patients’ journey 
through the numerous steps involved in the data collection process. All data collected 
after the basic screening questionnaire were entered on to this database, and all patients 
seen in clinic and invited to participate via questionnaire only were captured here. Dates 
at which patients were seen in clinic, sent various questionnaires and when these were 
returned were also recorded.
3.7 Specific Ethical considerations
As the data collected were similar to what may be collected in routine clinical practice, 
the main ethical considerations arose from how the initial patient contact was made and 
also concerns about the potential consequences o f any genetic analysis. Patient 
confidentiality and data protection issues were also a concern.
Particular issues involved the following points:
In the prevalence study:
The patients identified via the GP database searches may not have been known by 
the research team or the department o f neurology so had to be approached by their 
GP directly as the first point o f contact to be informed about the study. A
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standardised letter was produced which came from the patients’ own GP who 
signed by them personally.
Once the patients were identified, no identifiable data could be taken out of the 
practice until the patients had replied to the research team directly giving written 
consent to be involved in the study. Only anonymous data were taken regarding 
numbers o f patients identified at each stage o f the ascertainment protocol, in line 
with the Data Protection Act.
Patients could only be contacted by the research team once they had replied 
directly back to us with their contact details and written signed consent indicating 
that they were willing to participate in this study.
Secondary care referrals
Professionals referring patients directly into the study were asked to obtain 
written signed consent that the patient had agreed to be contacted to receive 
further information regarding the study. This was achieved via completion of 
pamphlets or completion of the basic screening questionnaire, both o f which 
request written signed consent from the patient.
On occasion the study team may have sent out the basic screening questionnaire 
with a cover letter from the appropriate consultant or PD nurse specialist on their 
behalf as the first point of contact, after obtaining the appropriate professional’s 
consent and signature on the cover letter.
Presentations at patient group meetings
At these meetings the project was explained in detail in lay terms and the patients 
were given the opportunity to ask questions at the time. If they were happy to 
participate from the information given at the meeting they were handed a basic 
screening questionnaire at that point.
All patients having filled in the BSQ and having indicated they were agreeable to 
participate further in the study were sent the full patient information sheet (PIS) and were 
asked for more detailed written signed consent.
Third party consent
63
For those patients who did not have full capacity to give informed consent but 
where their carers or relatives felt it was in the best interest o f the patient to 
participate in the study, it was possible to obtain assent from the appropriate 
relative or carer. There was a specific section in the PIS to address this issue.
Implications of genetic testing
The potential for a diagnostic test to be developed arising from genetic analysis of 
patients DNA was explicitly explained along with the possible implications of a 
positive test result.
Currently there is no cure for PD nor is there any proven neuroprotective agent 
available and so the development for a preclinical diagnostic test has limited value 
in PD at this time.
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Chapter 4 Prevalence Study of Parkinson’s Disease in Cardiff 
by Age at Onset
4.1 Chapter Sum m ary
Although there have been many previous UK epidemiological studies of PD, none have 
studied the prevalence of YOPD and several have been limited as discussed in Chapter 1. 
This chapter describes a community based prevalence study undertaken in Cardiff, South 
Wales, particularly focussing on age at onset. Data on age at onset and onset symptom, as 
the cases are established prevalent cases, have been collected retrospectively and may not 
be as accurate as data gathered from an incidence study. However, age at onset data have 
been obtained from several sources including contemporaneous primary care records, 
specialist clinic letters and the patients’ own recall o f events. Age at onset, symptom 
onset and disease burden on healthcare of PD patients in Cardiff is described. We found 
the crude prevalence o f PD in Cardiff to be 130 per 105 (95% Cl 117,144) and 142 per 
105 (95% Cl 128,156) when standardised to the 1997 population of England and Wales. 
The prevalence of YOPD (onset <50) was 6.2 per 105 accounting for 5.4% of the 
prevalent cases. Neurologists were responsible for diagnosing 44% and following up 17% 
of the total prevalent group, but diagnosing 90% and following up 56% of those with 
onset before 45 years. Overall, the majority of follow up care was provided by the 
geriatrician led clinic (63%). Comparison to previous UK studies showed our prevalence 
rates to be close to the weighted average. There was no obvious temporal trend in 
prevalence rates over the past 42 years in the UK.
4.2 Introduction
Data from a community-based prevalence study o f PD in Cardiff, South Wales are 
presented. The aims of this study were to 1) add further information on the potential 
geographical and temporal variation of PD prevalence across the UK, 2) specifically 
examine what proportion of prevalent cases had young onset disease, 3) examine how age 
at onset influences source o f health care and 4) undertake a meta-analysis of all published 
UK prevalence studies.
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Methods are described in Chapter 3. This study has a number of strengths, following the 
desirable features described by Twelves and colleagues in their review of UK incidence 
studies : 1) a large population size (>250,000), 2) multiple source case ascertainment, 3) 
attempted review o f all cases by movement disorders specialist, 4) definition of specific 
symptom onset date as well as diagnosis date, 5) clearly defined inclusion criteria, 6) use 
o f Queen Square Brain Bank Diagnostic Criteria in clinic assessment (although this was 
limited in application to case note review), and 7) reporting of standardised age strata and 
confidence intervals.
4.3 Results
4.3.1 Practice participation
Forty-five out of 54 (83%) eligible practices participated in this study. This provided a 
population denominator of 292,637, representing 96% of the Cardiff population.
Although only 83% of practices participated, it was possible to capture practices serving 
96% of Cardiff as smaller single handed practices were more likely to decline 
participation.
4.3.2 Electronic database searches and notes review in primary care
The diagnostic search (Read Code F12-F12z) generated 412 case records and the 
prescription search (Dopaminergic Drugs excluding Bromocriptine and Amantadine) 
provided 633 case records. This gave a total o f 731 unique individual potential cases (see 
Figure 1). Two hundred and ten patients were identified as having been prescribed 
dopaminergic agents for an alternative diagnosis. An additional 96 patients were 
identified with parkinsonism due to a secondary cause under this search strategy: 42 
vascular parkinsonism, 32 drug induced parkinsonism, 13 Lewy Body Dementia, 2 
dementia with parkinsonism, 3 Multiple System Atrophy, 2 Neuroleptic Malignant 
Syndrome, 1 Neurosyphilis, and 1 Progressive Supranuclear Palsy. A further 72 patients 
did not have PD on case record review: 26 patients were miscoded and did not have a 
movement disorder, 35 had essential tremor (but were identified via the drug search 
because they had undergone a trial o f L DOPA) and 11 further patients were initially 
diagnosed and coded as PD but the diagnosis was revised at specialist review, and the 
Read code had not been updated.
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4.3.3 Additional Cases recruited via secondary care sources
In addition, a further 49 cases were identified from sources other than the GP databases. 
Twenty cases were identified from general neurology clinics, 27 from the geriatrician run 
PD clinic, 1 self referral and 1 from another source. These cases had been registered with 
the prevalent general practices but had not already been identified from the GP database 
search strategies. This resulted in 402 potential cases in total.
4.3.4 Exclusion as not PD
Fifteen patients were excluded before examination as not having PD (9 by general 
practitioner and 6 by patient stating that they did not have PD). One hundred and thirty 
two of the 387 potential prevalent cases were examined in clinic (35%) of which 7 
additional patients (5%) were excluded as not having PD (including the self-referral 
case). Only one diagnosis-revised case had not seen a secondary care specialist. This 
resulted in 380 prevalent cases (182 females, 198 male) of which 168 were identified by 
more than one referral source.
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Figure 1 : Summary of number of cases prevalent during January -  December 2006 
identified via search GP Database Strategy
Unique patients 
identified n=731
7 Excluded at clinic 
assessment
Possible PD from 
GP notes n= 353
Duplicates
eliminated
n=314
Total prevalent cases 
n = 380
Total number of 
patients identified 
n=1045
Additional PD 
cases identified via 
secondary care 
n=49
Patients identified via 
Diagnostic Search 
n=412
Excluded as not PD after 
GP notes reviewed 
n=378
Patients identified via 
Drug Search 
n=633
Total possible PD 
cases identified from 
GP and secondary 
care n=387
15 Excluded as not PD 
(By GP -  9, 
by patient returning 
questionnaire= 6)
GP database population 
N = 292637
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4.3.5 Crude and age and sex standardised prevalence
For both men and women, prevalence rates increased with age group, though male rates 
were greater in all groups. The crude prevalence rate was 130 per 100,000 (95% Cl 117, 
144) overall; men 134 per 100,000 (95% Cl 116, 154) and women 126 per 100,000 (95% 
Cl 108, 145). The age adjusted rates rose to 142 per 100,000 (95% Cl 128, 156) overall, 
and male and female rates increased to 171 (95% Cl 147, 195) and 120 (95% Cl 103, 
138) respectively (see Table 4-1) adjusted to the 1997 population of England and Wales. 
The male to female age adjusted prevalence rate ratio was 1.43 (95% Cl 1.17, 1.76, 
p=0.001).
Table 4-1 : Age, sex specific and standardised prevalence rates of PD
Age (yrs)
Total Men Women
PD
cases
Population
size
Age- 
specific 
rates per 
100,000
PD
cases
Population
size
Age-
specific
rates
per
100,000
PD
cases
Population
size
Age- 
specific 
rates per 
100,000
0-29 0 122,571 0 0 61,661 0 0 60,910 0
30-39 1 44,399 2.3 0 23,397 0 1 21,002 4.8
40-49 4 40,523 9.9 4 21,429 19 0 19,094 0
50-59 24 32,249 74 14 16,901 83 10 15,348 65
60-69 63 23,155 272 38 11,616 327 25 11,539 217
70-79 129 17,481 738 68 8,193 830 61 9,288 657
>80 159 12,259 1297 74 4,413 1677 85 7,846 1083
Crude rate 
per 100,000 380 292,637 130 198 147,610 134 182 145,027 126
Age
standardized 
rates per 
100,000* 142 (128, 156) 171 (147, 195) 120(103, 138)
4.3.6 Diagnostic Certainty
A level of diagnostic certainty was assigned to the prevalent cases depending on the 
information available. The highest level o f certainty applied to those patients seen in the 
research clinic, meeting Queen Square Brain Bank diagnostic criteria (level 1 - 33% of 
prevalent cases). The next level of certainty involved contact and diagnosis or
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management by a neurologist or PD specialist (level 2 - 52%). Some patients’ records 
indicated that they had been diagnosed and managed entirely in primary care (level 3 -  
15%). In total 85% of PD patients, identified in primary care had been seen by a 
neurologist or PD specialist.
4.3.7 Age at onset
Age at symptom onset was obtained for 336 o f the 380 (88%) prevalent cases (Table 4- 
2). O f this 336 cases, onset data was obtained from contemporaneous primary care 
records in 325 cases (97% ) and from separate secondary care records in 11 cases (3%). 
The mean age at onset of our cohort was 68.6 years (95% Cl 67.5, 69.8). For men, mean 
age at onset was 67.7 years (95% Cl 66.0, 69.3 years) and for women mean age at onset 
was 69.7 years (95% Cl 68.1, 71.4 years). There was a bimodal distribution of age at 
onset with peaks at 40-44 years and 75-79 years. The average disease duration for the 
prevalent group was 6.2 years (range 0.7-28.1 years). The YOPD group (onset <45 years) 
had longer disease duration (11.1 years, 95% Cl 7.9, 14.4 years) than the LOPD group 
(onset > 45 years), (6.0 years, 95% Cl 5.4, 6.5) with a significant difference of 5.1 years 
(95% Cl 2.2, 8.0, p=0.0006). Cases who did not attend the research clinic had an older 
age at onset but similar disease duration (see table 4-3).
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Table 4-2 : Age at onset frequency of all prevalent cases where data available from 
GP and hospital records
Age at Total Men Women
onset No (% ) Cumulative
frequency
(% )
No (%) Cumulative
frequency
(% )
No (%) Cumulative
frequency
(% )
25-29 1 (0.3) 0.3 1 (0.6) 0.6 0 (0.0) 0
30-34 1 (0.3) 0.6 0 (0.0) 0.6 1 (0.6) 0.6
35-39 1 (0-3) 0.9 0 (0.0) 0.6 1 (0.6) 1.2
40-44 9 (2.7) 3.6 7 (4.0) 4.6 2 (1.3) 2.5
45-49 6 (1.8) 5.4 4 (2.3) 6.9 2 (1.3) 3.8
50-54 15 (4.5) 9.9 8 (4.5) 11.4 7 (4.4) 8.2
55-59 34 (10) 19.9 18 (10.2) 21.6 16 (10.0) 18.2
60-64 38 (11.3) 31.2 23 (13.1) 34.7 15 (9.4) 27.6
65-69 50 (14.9) 46.1 25 (14.2) 48.9 25 (15.6) 43.2
70-74 73 (21.7) 67.8 40 (22.7) 71.6 33 (20.6) 63.8
75-79 59 (17.6) 85.4 25 (14.2) 85.8 34 (21.2) 85
80-84 36 (10.7) 96.1 20 (11.4) 97.2 16 (10.0) 95.1
>85 13 (3.9) 100 5 (2.8) 100 8 (5.0) 100
Total 336(100.0) 176(100.0) 160(100.0)
Table 4-3 : Mean age, age at onset and disease duration by gender and whether or 
not patients were seen in research clinic.
Age Age at onset Disease duration
Mean
(95%CI) P value
Mean
(95%CI) P value
Mean
(95%CI) P value
Male 74.0 (72.5, 75.4)
0.03
67.7 
(66.0, 69.3)
0.08
6.0 
(5.3, 6.8)
0.61
Female 76.1 (74.7, 77.6)
69.7 
(68.1, 71.4)
6.3 
(5.5, 7.1)
Seen in clinic 72.2 (70.5, 73.9)
0.0001
65.9 
(63.9, 67.9)
0.0006
6.2 
(5.3, 7.0)
0.9
Not seen in clinic 76.4 (75.2, 77.6)
70.2 
(68.7, 71.6)
6.2 
(5.5, 6.9)
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4.3.8 Diagnosing and Follow up Care provision
Neurologists were most likely to have made the diagnosis of PD (44%). For YOPD, a 
neurologist made the diagnosis in 90% of cases (p<0.001), though in a substantial 
number o f cases (41%) there was no information available. There was a substantial 
increase in the rate o f GP diagnosis of PD with increasing age at onset (Table 4-4).
Overall follow up care was mainly provided by the geriatrician led PD clinic (63%) and 
neurologists (17%) although again details were not available on follow up care in 39% 
(Table 4-4).
4.3.9 Misdiagnosis rates amongst those seen in research clinic
O f those patients assessed in the research clinic, 45.5% were under follow up by the 
movement disorder geriatrician, 22.7% by neurologists, 4.5% by GPs, 1.5% by general 
geriatricians and 0.8% by general medical physicians. In 7/132 (5.3%) o f patients, the 
diagnosis of PD was revised to an alternative diagnosis at the research clinic - 1 (3.3%) of 
those followed up by neurologists, 4 (6.7%) o f those followed up by the movement 
disorder geriatrician, 1 (16.7%) o f those followed up by GPs and 1 (100%) of those 
followed up by the general physicians.
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Table 4-4 : Distribution of diagnosing and follow-up specialty by age of disease onset
Whole group 
n (%)
Onset <45 
yrs
n (%)
Onset 45-64 
yrs 
n (%)
Onset >65yrs 
N (%)
Diagnosing physician n=223 n=10 n=74 N=139
Neurologist 99 (44) 9(90) 47 (64) 43 (31)
Movement disorder 
geriatrician 64 (29) 1(10) 15 (20) 48 (35)
Geriatrician 15(7) 0 3 (4) 12 (9)
GP 28(13) 0 8 (11) 20 (14)
Medics 15(7) 0 1 (1) 14 (10)
Other 2 (1) 0 0 2 (1)
Follow-up care n=231 n=9 n=70 N=152
Neurologist 40 (17) 5 (56) 21 (30) 14 (9)
Movement disorder 
geriatrician 146 (63) 4 (44) 40 (57) 102 (68)
Geriatrician 13 (6) 0 2 (3) 11 (7)
GP 28 (12) 0 5 (7) 23 (15)
Medics 3 (1) 0 1 (1.5) 2 (1)
Other 1 (1) 0 1 (1.5) 0
GP = general practitioner
Details on diagnosing physician available on 223 patients (p<0.001).
Details on follow up physician available on 231 patients (p<0.001).
4.3.10 Comparison with other UK PD Prevalence Studies
A comparison was made of these results with all previously published UK prevalence 
studies (Figure 2). The crude rates varied from 113 to 164 per 100,000, however after 
standardization to the 1997 population of England and Wales, this increased to 105 to 
178 per 100,000. Our prevalence rate at 142 per 100,000 was very close to the global 
average but there was evidence of statistical heterogeneity between these standardised 
rates (p-value for between study heterogeneity ="0.0006). There was no obvious temporal 
trend suggesting that prevalence rates showed no systematic change over the last 42 
years.
73
Figure 2 : Forest plot of age-standardized PD prevalence rates in the United 
Kingdom (1966-2008)
Age-standardised
Study (year) Crude prevalence per
100,000 (95% Cl)
Cases Denominator prevalence
Brewis (1966) 80 71101 113 129 (99, 159)
Sutcliffe (1985) 226 193047 117 ■» 134 (116, 151)
Mutch (1986) 249 151644 164 i---------------  178 (155, 201)
Sutcliffe (1992) 384 316930 121 A-------- 140 (126, 154)
Schrag (2000) 156 121608 128 169 (142, 195)
Hobson (2005) 112 76158 147 ------ ♦ 105 (85, 124)
Porter (2006) 161 108597 148 135 (115, 156)
Wickremaratchi 380 292637 130 * ----- 142 (128, 156)
(2008)
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4.4 Discussion
This prevalence study is one of the largest UK studies using computerized records in 
primary care and supplemented by secondary care data.
Our data confirm the previously accepted observations that age specific rates increase 
with age, particularly after age 55 years. In every age band, the age specific rates are 
higher in men than women as is consistent with incidence data (Wooten, Currie et al. 
2004). Our male to female prevalence rate ratio of 1.43 (95% Cl 1.17, 1.76, p=0.001) is 
comparable to data from incidence studies (1.9 in a US incidence study, 2.3 (95%CI 1.55- 
3.28) in a UK incidence study) (Twelves, Perkins et al. 2003; Van Den Eeden, Tanner et 
al. 2003; Taylor, Counsell et al. 2006). However, one must bear in mind that differential
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survival between male and female cases may affect prevalence rates, and so incidence 
and prevalence gender specific rates may not be strictly comparable. Greater survival of 
females influence female prevalence rates ie will be higher, whereas incidence rates are 
not affected by survival. The standardised rates suggest the Cardiff population have a 
larger proportion of older female residents than the 1997 population o f England and 
Wales used for standardisation. Age at onset was a major focus of this study and relied on 
contemporaneous primary care records where available, or subsequently from secondary 
care clinic letters. Nevertheless, age at onset is likely to be less accurate than data 
derived from incidence studies. The mean age at onset in our prevalent patients was 68.6 
years. These estimates are comparable to data from UK and US incidence studies (mean 
age at diagnosis 70.5 in the US incidence study, mean AAO 67.8, mean age at diagnosis
70.3 in the Cambridge incidence study and mean age at diagnosis 76.1 years in the 
Aberdeen incidence study) (Van Den Eeden, Tanner et al. 2003; Foltynie, Brayne et al. 
2004; Taylor, Counsell et al. 2006). Our data suggest the possibility of a bimodal pattern 
o f age at onset with a peak at 40- 45 and again at 75-79 years, but numbers are very small 
at the younger onset ages and so this observation could be consistent with chance. It is 
important to note that previous incidence studies have not shown a significant 
observation of bimodal age at onset in PD.
The major finding of this study is that the prevalence o f PD in Cardiff is similar to other 
studies in the United Kingdom (at around 140 per 100,000). Although the prevalence of 
young PD cases is much lower than that for older cases, 5.4% and 31.2% of the total 
prevalent PD population have their disease onset before 50 years or 65 years o f age 
respectively. Around 1 in 20 PD patients develop disease before the age of 45, normally 
considered to be a cut-off at which genetic autosomal recessive PD should be considered. 
Whilst the rate of PD in those whose current age is below 50 in Cardiff is 2.4 per 
100,000, the prevalence of those whose disease started before the age of 50 is three times 
higher at 6.2 per 100,000. These figures equate to approximately 3700 people in the UK 
currently alive with YOPD and means that YOPD, defined by an age of onset below 50, 
is at least as common as Motor Neuron Disease, Huntington disease and Progressive 
Supranuclear Palsy. These data have implications for both genetic testing and the need 
for greater provision of support for patients in employment.
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A period prevalence was given as opposed to a point prevalence. This was because cases 
had to be identified in the GP practice and only anonymised data could be extracted. In 
order to provide a point prevalence, identifiable data would be required to check that 
those cases were resident and alive on the prevalence date. As cases were collected over a 
period of twelve months it was only possible to provide a period prevalence over this 
period. Period and point prevalence estimates may not be strictly comparable. Estimates 
o f period prevalence may be higher as they include patients alive and symptomatic over a 
substantial period who would not have been prevalent if an estimate was taken at the mid 
point o f that period, ie those captured in the latter part of the period would not have been 
captured on the point prevalent date.
The search strategy used in this study was not designed to identify Parkinson plus 
syndromes such as Progressive Supranuclear Palsy and Multiple System Atrophy. 
However, a number o f these cases were identified using the codes for Parkinson’s disease 
and below (F I2 -F12z). It is important to note that the figures obtained from this study 
for the Parkinson plus syndromes do not represent the true prevalence o f PSP or MSA but 
are an underestimate as the specific diagnostic codes for the Parkinsonian plus syndromes 
were not used. Therefore, an estimate was not given for the prevalence o f the Parkinson 
plus syndromes.
This case finding approach highlighted the need for multiple source case ascertainment as 
relying only on primary care cases alone would have led to missing an additional 13% of 
potential cases. Also direct assessment of primary care data was essential since 37 cases 
were miscoded as having PD (11% of total prevalent primary care cases) due to data 
entry error, or failure to change or remove inapplicable diagnostic codes. The NHS is 
often cited as a good environment in which to perform epidemiological research because 
o f uniform health care provision and coding, but the degree of miscoding was high when 
identifying PD patients. Relying solely on GP codes would have led to substantial errors 
in our prevalence estimates. This suggests that a great deal of caution is needed in relying 
on non-specialist diagnostic code databases.
The meta-analysis o f all UK studies suggests that the prevalence of PD in the UK has 
been relatively stable over the past 40 years. This is somewhat surprising given the
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increase in overall life expectancy and the better management o f PD, which would if 
anything also increase survival and therefore prevalence. There are several possible 
reasons for this observation, (a) Decline in incidence: As prevalence is a function of 
incidence and disease survival, assuming that survival has increased then the true 
incidence may have actually declined over time. This hypothesis is not supported, 
however, by analysis of the incidence trends from 1976 to 1990 Rochester, Minnesota 
(Rocca, Bower et al. 2001), (b) Greater awareness of other Parkinsonian conditions: Over 
the last forty years there has been far greater awareness o f other conditions such as 
multiple system atrophy which may be misdiagnosed as PD. Although these conditions 
contribute at most 10% of all patients with parkinsonism (Schrag, Ben-Shlomo et al.
1999), more recent studies are likely to have excluded such cases more thoroughly and 
this may therefore counterbalance any increase in prevalence due to greater survival. A 
balancing of the prevalence inflating effects o f increased survival with the prevalence 
diminishing effects o f increased diagnostic precision seems the most likely explanation 
for the stable UK prevalence rate.
It is likely that the heterogeneity between studies can be explained by methodological 
differences. The study from Aberdeen, with the highest rate, actively searched for cases 
in nursing homes, which will have an over-representation of PD cases, and may have 
been overlooked in primary care records (Mutch, Dingwall-Fordyce et al. 1986). In a 
Norwegian study looking at nursing home residents, 5% of residents had PD, nearly 20% 
of whom were previously undiagnosed (Larsen 1991). In contrast, the study from rural 
Wales (Hobson JP 1999) had the lowest prevalence rate. This study did not use diagnostic 
databases but relied on prescription records and referrals possibly leading to under 
ascertainment of cases. In addition, it is not known whether PD survival is worse in rural 
as compared to urban areas. However, our data derived from an urban Welsh population 
compared to the North Wales study, do not support the notion that a rural environment 
increases the risk of developing PD (Ben-Shlomo 1996).
The UK has a relatively low provision of specialist neurologists in comparison to 
Western Europe and the USA. Geriatricians, general physicians and general practitioners 
as well as neurologists diagnose and care for PD patients. In addition, there is a cadre of 
well-trained geriatricians who have a special interest in movement disorders and are
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possibly better suited to the complex multi-faceted needs o f elderly patients with PD. Not 
surprisingly, almost all of the YOPD patients were diagnosed by a neurologist but only 
one third of later onset patients. Neurologists only looked after around half of the YOPD 
patients, but few (9%) whose disease started after the age of 65. A substantial minority 
(15%) o f PD patients were followed up solely by their general practitioners. It is harder to 
know whether follow-up by a general practitioner is desirable but at some stages in the 
disease this may be appropriate especially for frail elderly patients who have difficulty 
attending out-patient clinics. Recent national guidelines (Royal College of Physicians 
2006) suggest that the diagnosis of PD should always be made by a specialist but this was 
not the case at the time of our study. The actual proportion diagnosed by a general 
practitioner is probably an under-estimate as it is likely that GP diagnosis also occurred in 
cases where a specific diagnosing clinician was not recorded. These results reflect local 
PD service provision but are likely to be mirrored to some extent through the UK and 
overseas. Overall diagnostic accuracy among those patients assessed in our research 
clinic was high with around 95% of patients meeting the Queen Square Brain Bank 
criteria for PD. We do not know whether this would be true for those patients who did not 
attend the research clinic or the patients with “tremor” who were not evaluated. A small 
number o f patients carried a diagnostic label o f PD, but had alternative diagnoses.
Patients under follow-up in neurology clinics were most likely to fulfil diagnostic criteria 
for PD, based on a small number o f re-classified patients. A small number of patients 
(15%) had been diagnosed and were under follow up with their general practitioner and 
the diagnostic accuracy in this group is not known.
4.4.1 Limitations
A number of limitations of this study can be identified.
Firstly, a more accurate prevalence estimate could have been obtained from performing a 
door-to-door survey of households in Cardiff. However, time and financial constraints 
did not make this a feasible option. In the UK, health care is available to all and free of 
cost at the point of access. This suggests that primary care records theoretically should 
represent the health of the whole community assuming those who require medical advice 
consult their GP. Our prevalence study was designed to identify medically diagnosed 
cases of PD and not designed to screen and pick up undiagnosed cases in the community
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who had not yet sought medical advice. These undiagnosed cases, although contributing 
to the true prevalence of the disease, have not yet come to medical attention and so have 
not yet influenced health care burden.
Although a very high rate o f participation from primary care practices in Cardiff was 
obtained, only around a third of all the cases were clinically examined. This introduces 
problems with diagnostic accuracy especially given the substantial miscoding and 
misdiagnosis rates discovered in primary care during the course of this study. This 
highlights the need for supplementing primary care case notes with secondary care 
records and face to face examination of the patients, to obtain the most accurate 
diagnostic and case definition data. Secondary care records are filed in primary care 
notes, allowing assimilation of case data from an expert assessor. It is unfortunate that in 
today’s busy primary care environment difficulties in recording and coding patient 
consultation data accurately and in sufficient detail exist, as this would be a prime source 
of epidemiological data captured in real time, and provide a way of retrospectively 
collecting onset data. Better IT data capture systems could improve this. In order to get 
the most accurate estimate o f disease prevalence multiple sources are needed -  some 
cases are not picked up in primary care alone. If these details were recorded accurately 
and in enough detail this could provide a way of approximating incidence data 
retrospectively, obviously not accounting for survival rates.
This study also highlighted limitations of undertaking a prevalence study solely in 
secondary care. Hospital diagnostic coding information is only kept on those patients 
who are admitted to hospital and even then the reason for admission may be the sole 
diagnostic code recorded. In general, PD is a chronic disease which tends to be mainly 
managed in the outpatient setting. If patients with PD are admitted to hospital it is usually 
for another reason, and so their diagnosis of PD may not be recorded. Thus current 
hospital coding records are not an adequate source of diagnostic information on which to 
base prevalence ascertainment. Only a minority of neurology consultants kept their own 
diagnostic database. This proved to be a very useful ascertainment resource. However, 
for the majority of the neurology department, clinic letters stored on hard drives of the 
individual secretaries had to be hand searched in order to identify those with PD. This 
proved to be a time consuming exercise that only yielded few additional cases although
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the detail o f information gathered from this source was far superior to that of primary 
care records.
Although it was identified at the start of the study that using only primary or only 
secondary care sources would not provide an accurate prevalence estimate, the individual 
problems in both primary and secondary care coding systems were not appreciated until 
the study began. By obtaining as much information from as many sources as possible 
about the patients’ symptoms and disease course, it was possible to overcome some of 
these problems but this led to an increase in workload that had not been anticipated.
Methodological developments suggest that capture-recapture methods using primary and 
secondary care data may be useful to estimate the number o f missed cases and can be 
used in sensitivity analyses though they add to the complexity of the study design, 
statistical methods and ideally require non-anonymised identification. This technique 
relies on source independence and the randomness of identification of cases from each 
source (Tilling, Sterne et al. 2001). As the diagnosis of PD was confirmed in secondary 
care in the vast majority of the cases, this implies that there is not true source 
independence or randomness of identification, as the sources are interlinked.
Due to ethical constraints, it was not possible to take non-anonymised data from the GP 
practices, thus performing capture-recapture analysis would have been difficult, although 
we were able to describe how many cases had been identified by more than one 
ascertainment source. However, this information was not systematically collected. 
Although from the primary care records it was suggested that 85% of the prevalent cases 
had contact with secondary care at some point during their disease course, not all of these 
patients were identified as being captured via the secondary care referral source in 
addition to the primary care source. This may have been because these patients had been 
discharged from active follow up from secondary care as it may have been felt once the 
diagnosis was confirmed the uncomplicated stable phase o f the condition could be 
managed in primary care, and so the searching of secondary care clinic notes and letters 
may not have identified these cases. It is also likely that the specific secondary care team 
was not identified for some patients and therefore these data were missing in our database 
thus leading to those cases not being identified as coming from secondary care source. It
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is possible that incompleteness of the secondary care recruitment has lead to further 
under estimation of the true prevalence of PD.
This study design only allowed for those cases that were correctly identified and 
diagnosed as having PD to be included in the prevalence estimate. Due to the 
misdiagnosis o f patients who have already come into contact with medical care but have 
not been recognised as having PD this has no doubt lead to an under estimation of true 
PD prevalence. It is possible that some of the patients labelled as Parkinsonian plus 
syndromes actually may have had PD but these notes were not screened, and these 
patients were not invited for clinical review. These diagnostic labels are generally applied 
by specialists rather than primary care physicians, nevertheless this may potentially have 
been a source of underestimation of the true prevalence o f PD, though the suspicion is 
that the number would be small. Cases with a diagnosis of essential tremor were not 
invited to be examined due to time constraints, though the previous London study 
(Schrag A 2000) identified patients with unrecognized tremor dominant PD by screening 
patients who developed tremor after the age of 50 years. In that study 11 of the 56 
patients who had previously been diagnosed to have non-Parkinsonian tremor had 
probable or possible PD and their inclusion increased the number of PD cases by 7.9%. 
Due to the time and resource constraints of this study, it was not feasible to screen 
patients with tremor in every prevalent GP practice, and is likely to have led to an 
underestimation of true PD prevalence. Although the confidence intervals for our study 
overlapped with the London study a crude adjustment o f our prevalence figure, 
accounting for undiagnosed tremor dominant PD of leads to a corrected figure of 169 per 
105 , very close to the results of Schrag and colleagues.
We are likely to have included cases in our prevalence figure who did not have PD. Only 
35% of patients identified via database and record searching were examined face to face 
in the research clinic, and those cases had a 5% diagnosis revision rate. This would lead 
to a reduction in our total case figure of 12 cases (5% of 247 non-clinic cases) and a small 
reduction in the overall crude prevalence of 3% (12/380). The highest mis-diagnosis rates 
were in those patients followed up by non neurologists, although this analysis is based on 
a very small number of cases. The diagnostic accuracy of those patients who were solely 
followed up in primary care and did not attend the research clinic is unknown, and the
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prevalence estimate may well have included cases o f parkinsonism who did not fulfil 
Queen Square Brain Bank Criteria for PD. In addition, there may have been cases coded 
as PD who, despite the vigorous screening o f primary care and secondary care records 
but did not attend the research clinic, and were included in the prevalence estimate but 
did not have PD.
The emphasis of this study was to obtain accurate onset data and estimate the prevalence 
of YOPD. Some of the constraints outlined above related to the need for a large 
denominator population to provide a reasonable estimate of the prevalence of young 
onset disease. As the majority of YOPD patients are referred to neurologists or a 
physician with an interest in movement disorders, the prevalence estimate, diagnosis and 
information on onset symptoms obtained is likely to be reasonably accurate.
4.4.2 Impact of Prevalence study on Furthering Knowledge of YOPD
This prevalence study is unique in that information on age at onset has been collected.
We can therefore provide an estimate of YOPD prevalence. This information is essential 
in the planning of service provision for younger onset patients and may help also to 
define health care burden in this group of PD patients. This prevalent cohort provided the 
basis on which the community based case control study would be performed, studying the 
differences between YOPD and LOPD in a representative group of patients who were 
subject to less selection bias than many previous highly selected clinic based studies. 
Studying the clinical differences between YOPD and LOPD in this way may reveal some 
aetiological clues but will also identify specific management issues relating to differences 
in the social, financial and psychosocial demands between these groups. Also in the 
planning and executing o f this study we have helped to raise the awareness of PD in the 
younger population both in the community and to health care workers, hopefully leading 
to earlier diagnosis and more appropriate referral to specialist services.
4.4.3 Conclusion
The UK healthcare system offers an opportunity to study the epidemiology of disease by 
offering access to health care free of charge to everyone. Future researchers should be 
aware of difficulties if solely relying on primary or secondary care electronic diagnostic
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coding records and recognise that supplementation o f detailed clinic letters and face to 
face examination of patients is essential to increase accuracy of estimates.
In conclusion, the prevalence estimate form this study provides further evidence on the 
geographical and temporal distribution of PD and suggests that rates have remained 
relatively constant over the last 40 years.
Although PD is seen as a disease of the elderly, YOPD is far more common than 
appreciated in the prevalent PD population and the provision of health and social care for 
these patients should be an important consideration.
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Chapter 5 Non Motor Features of Young versus Late Onset 
Parkinson’s Disease
5.1 Chapter Sum mary
We analysed PD patients from the prevalence study and a regional cohort. The presence 
of non motor features was examined and compared in groups separated by age at onset. 
We also compared prevalence and regional cohort patients to look for evidence of 
selection bias. Direct questions were used to gather information on the presence of 
prodromal features including constipation, loss of smell, sleep disorders, depression, pain 
and paraesthesiae. In addition, validated standardised scales were used to investigate 
cognition at time of assessment (MMSE), daytime sleepiness (Epworth Sleepiness Scale) 
and depression (Beck’s Depression Inventory). Chi squared and t test analyses were used 
to compare proportions and mean scores across different onset groups. Significant 
differences were seen between YOPD and LOPD. Hyposmia, constipation and sleep 
disturbance was reported to occur more commonly by LOPD patients in the premotor 
phase. In established disease, depression, paraesthesiae and sleep disturbance was more 
common in YOPD and dementia was less common than in LOPD.
5.2 Introduction
PD is a motor disorder, with diagnostic criteria based on motor impairment and response 
to treatment (Litvan, Bhatia et al. 2003). In recent years it has become clear that some 
non-motor features are very common in patients with PD, and this has been related to the 
presence of Lewy body disease. Williams and colleagues identified hallucinations to be a 
very common feature in Parkinsonian disorders, particularly associated with Lewy body 
pathology (Williams, Warren et al. 2008). Other important non-motor features include 
REM (rapid eye movement) sleep behaviour disorder, constipation, depression, 
autonomic disturbance and sensory disturbance (Poewe 2008). Our concept of PD is in 
the process of changing from a motor disorder to one in which multiple brain systems are 
affected by Lewy body degeneration with a characteristic clinical and pathological 
pattern associated with Lewy body disease. Degeneration of the cholinergic basal 
forebrain structures may lead to depression and/or cognitive involvement, Lewy body 
degeneration of the olfactory bulbs causes hyposmia, involvement of the myenteric
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plexus of the gut causes constipation, and involvement of the lower brainstem may relate 
to sleep disturbance (Braak, Del Tredici et al. 2003; Braak, Bohl et al. 2006; Poewe 
2008). The Braak hypothesis suggest that non-motor non-dopaminergic brain areas 
(dorsal motor nucleus of the vagus, lower brainstem nuclei, olfactory bulb) are involved 
in the pre-nigral phase (stages 1 and 2). This corresponds to reports by some patients of 
prodromal constipation, hyposmia, REM sleep behavioural disorder and depression 
before the onset of motor symptoms of PD (Ansari and Johnson 1975; Doty, Stem et al. 
1992; Schenck, Bundlie et al. 1996; Ashraf, Pfeiffer et al. 1997; Gonera, van't Hof et al. 
1997; Olson, Boeve et al. 2000; Abbott, Petrovitch et al. 2001; Nilsson, Kessing et al. 
2001; Nilsson, Kessing et al. 2002; Schuurman, van den Akker et al. 2002; Hawkes 
2003; Leentjens, Van den Akker et al. 2003; Lauterbach, Freeman et al. 2004; Ponsen, 
Stoffers et al. 2004; Sommer, Hummel et al. 2004; Ueki and Otsuka 2004; Chaudhuri, 
Healy et al. 2006; Iranzo, Molinuevo et al. 2006; Ishihara and Brayne 2006; Kaye, Gage 
et al. 2006; Ross, Abbott et al. 2006; Ross, Petrovitch et al. 2008). It has been 
hypothesized that future disease modifying treatment will need to be given very early in 
the disease course and understanding this pattern of symptom progression is likely to 
become very important in the early symptomatic diagnosis of PD. It is possible that the 
pattern of prodromal and motor-associated non-motor symptoms will be valuable in the 
differentiation of clinical sub-types of PD. To date no published study has systematically 
compared the prevalence of non-motor symptoms in YOPD and LOPD. This chapter 
reports the findings of our study of non motor symptoms in YOPD and LOPD.
5.3 Results
5.3.1 Study Cohort
Our total sample size was 450 (358 clinic assessments, 92 questionnaire only). Almost 
all (98%) patients had a disease duration of one year or more at the time of assessment, 
but the mean interval from onset to diagnosis was 4 years, and from diagnosis to 
assessment was 7 years. Delay to diagnosis was significantly longer in those with onset 
under 45 (5.2 vs. 3.7 p=0.009) as was the interval from diagnosis to study assessment 
(10.4 vs. 6.4, p<0.0001). The patients were approximately evenly distributed in the four 
age bands with the youngest onset patients having the longest disease duration (Table 5- 
1).
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Table 5-1 : Clinical Characteristics of Study cohort
Total Onset <45 Onset 45-54 Onset 55-64 Onset >65 p - value
n (M:F) 450 (1: 0.6) 96(1: 0.7) 119(1: 0.6) 114(1: 0.7) 121 (1: 0.6) 0.98
Mean age at 
onset (range, 
yrs)
56 (8-85) 39(8-44.9) 51 (45-54.9) 60 (55-64.9) 72 (65-85) <0.0001
Mean current 
age (range, yrs)
65 (28-90) 52 (28-66) 60 (48-79) 67 (58-85) 78 (67-90) <0.0001
Mean disease 
duration (range, 
yrs)
9 (0.5-39) 13 (1-39) 10(1-28) 8(1-24) 6 (0.5-22) <0.0001
Mean Motor 
UPDRS score 
(range/108)
29 (2-72) 25 (4-57) 28 (3-72) 28 (2-62) 32 (12-71) 0.0016
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Clinical Characteristics of Prevalent and Non Prevalent Cohorts
Prevalent Cohort
Onset <45 Onset 45-54 Onset 55-64 Onset >65
n 10 14 42 87
Mean age at onset 
(range, yrs)
40.5 (29-44.9) 50.3 (45.7-54.1) 60.3 (55.1-64.9) 72.7(65-85.3)
Mean current age 
(range, yrs)
51.4 (43-55.6) 61.8(49.7-79.4)
67.6(58.3 -  
85.1)
78.9 (76-90.3)
Mean disease duration 
(range, yrs)
10.9 (2.7-25.8) 11.6 (2-27.1) 7.3 (1.2-23.7) 6.2 (0.4-21.7)
Mean Motor UPDRS 
score (range/108)
26.9(14-57) 28.1 (15-42) 28 (2-62) 31.6(12-71)
Non Prevalent Cohort
Onset <45 Onset 45-54 Onset 55-64 Onset >65
n 86 105 12 34
Mean age at onset 
(range, yrs)
38 (8.1-44.9) 50.7(45.1-54.9) 59.1(55.1-64.9) 70.1 (65.8-84.1)
Mean current age 
(range, yrs)
51.8(27.8-
66.4)
60.2 (47.5-77.5) 66.8 (57.8-82.1) 74.2 (68.2-87.3)
Mean disease duration 
(range, yrs)
13.5 (1.1-38.7) 9.5 (1.1-28.3) 7.8 (0.9-27.3) 4.1 (0.7-13.4)
Mean Motor UPDRS 
score (range/108)
24 (4-57) 28.2 (3-72) 28.2 (9-60) 33.1 (15-58)
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5.3.2 Prodromal Non Motor Features
Constipation, depression, fatigue, sleep disturbance, hyposmia, parasthesiae and pain or 
cramps were common as prodromal features affecting between 13-31% of all PD patients 
(Table 5-2). The commonest reported prodromal NMS in our total study population was 
hyposmia (31%). A quarter of the patients reported fatigue as a feature occurring before 
the onset of motor symptoms, and sleep disturbance and constipation were reported in 
about 20%.
In YOPD, sleep disturbance was reported less frequently prior to the onset of motor 
symptoms than in LOPD. The negative association between prodromal hyposmia and 
YOPD was particularly striking with a significant increase in the frequency of prodromal 
hyposmia in PD patients with age at onset greater than 45. Similarly, constipation was 
reported as a prodromal symptom more frequently with advancing age (table 5-2).
Table 5-2 : Frequency of Prodromal NMS
Onset group
Symptom Total 
Group n 
(%)
<45
n( % )
45-54
n (% )
55-64
"(%>)
>65
n( % )
Heterogeneity 
(X2 test> P)
Trend
(X2
test, p)
<45 vs 
>45 (X2 
test, p)
Hyposmia 109(31) 11(16) 39 (40) 28(32) 31(32) 0.017 0.20 0.004
Constipation 71 (20) 11 (16) 15(15) 19(22) 26(27) 0.18 0.043 0.39
Cramps/pain 82 (29) 13 (26) 26 (35) 21(26) 22(27) 0.60 0.75 0.59
Fatigue 86 (25) 13 (19) 30 (30) 20(22) 23(24) 0.40 0.97 0.28
Sleep
disturbance
79 (23) 9(13) 28 (28) 21(24) 21(22) 0.16 0.51 0.048
Depression 55 (16) 13 (20) 16(16) 14(16) 12(12) 0.68 0.24 0.35
Parasthesiae 47(13) 8(12) 18(18) 11(13) 10(10) 0.41 0.38 0.73
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5.3.3 Current Non Motor Features at time of assessment
Constipation, depression, fatigue, sleep disturbance, hyposmia, parasthesiae and pain or 
cramps were common features affecting between 19-70% of all PD patients at time of 
assessment.
A significantly higher proportion of YOPD patients reported depression, sleep 
disturbance and parasthesiae at time of assessment than LOPD, and there was a 
significant trend for decreasing frequency o f these symptoms with increasing age at onset 
(Table 5-3).
Table 5-3 : Current NMS by age at onset
Onset group
Symptom Total
Group
n(%)
<45
n( % )
45-54
n(% )
55-64
n(% )
>65 yrs  
n ( % )
Heterogeneity 
( t f  test, p)
Trend 
( t f  test, p)
<45 vs >45 
( t f  test, p)
Fatigue 186(67) 34(71) 46(73) 57(69) 49(60) 0.33 0.12 0.58
Sleep
disturbance
192 (70) 40(82) 44(70) 63(76) 45(56) 0.006 0.004 0.04
Cramps/pain 144 (53) 25(52) 36(57) 43(52) 40(50) 0.86 0.62 0.92
Constipation 127 (46) 21(43) 29(46) 40(49) 36(43) 0.85 0.94 0.66
Hyposmia 124 (45) 18(37) 36(57) 38(46) 32(39) 0.097 0.60 0.21
Parasthesiae 57 (21) 16(33) 13(21) 16(20) 12(15) 0.11 0.023 0.023
Depression 53 (19) 15(30) 16(26) 14(17) 8(10) 0.016 0.0015 0.032
Dementia 
(MMSE <24)
22 (6) 2(3 ) 6 (6 ) 3 (3 ) 11(11) 0.07 0.043 0.20
\1MSE > 27 302 (84) 63 (90) 92 (89) 75 (85) 72 (74) 0.011 0.0022 0.15
Depression
(BDI>10)
218 (49) 56 (60) 63(53) 46(41) 53 (44) 0.032 0.008 0.021
Hallucinations 67 (19) 12(17) 26(25) 15(17) 14(14) 0.23 0.28 0.71
Epworth >10 224 (55) 43 (58) 66(58) 55 (53) 60 (56) 0.64 0.62 0.28
Insomnia 175 (49) 38(54) 54(53) 47(53) 36(37) 0.055 0.026 0.33
RBD 168 (47) 33(47) 50(49) 49(56) 36(37) 0.087 0.26 0.97
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5.3.4 Neuropsychiatric features
Hallucinations were reported by 19% of all PD patients but there was no significant 
difference between YOPD and LOPD groups (p=0.23) (Table 5-3).
Six percent of all patients had dementia as defined by a MMSE score of less than 24 
(clinical dementia), and 84% had a score of 27 and above (clinically normal). Those with 
onset under 45 had significantly higher proportion of cases with clinically normal MMSE 
than those with onset above 65 years (90% vs. 74%, p=0.01), and there was a significant 
trend with increasing age at onset (p=0.002) (Table 5-3).
The frequency of YOPD with clinical dementia defined as MMSE < 24 was significantly 
different between YOPD and LOPD, 3% in onset <45 years compared with 6% in onset 
>45 years and 11% in onset over 65 years (Table 5-3).
Comparing the mean MMSE score in groups divided at onset below 45 years and at or 
above 45 years showed a small but significant difference (YOPD mean MMSE 28.7, 
LOPD mean MMSE 27.9, p=0.02) (Table 5-4).
Table 5-4 : Mean MMSE scores in onset groups split at onset before and at or above 
45 years
N Mean MMSE (95% Cl) p value
Onset <45 years 69 28.7 (28.2-29.1)
0.02
onset > 45 years 287 27.9 (27.6-28.2)
However, these data may be confounded by differences in disease duration and current 
age. Having adjusted for disease duration, the association between age of onset and 
MMSE becomes stronger, with LOPD patients have lower MMSE scores (Table 5-5). 
Conversely, correcting for age at onset shows the correlation between longer disease 
duration and deterioration in MMSE (coefficient 0.19, p<0.001, 95%CI 0.12-0.28).
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Therefore both older age at onset and longer disease duration are associated with 
deterioration in MMSE.
Table 5-5 : Multiple Regression Analysis showing effect of onset group on MMSE 
after adjusting for disease duration
Onset <45 used as baseline group Adjusted for disease duration
Coefficient P value 95% Cl Coefficient P value 95% Cl
Onset 45-54 0.06 0.58 -0.15 to 0.27 0.16 0.14 -0 .05-0 .37
Onset 55-64 0.22 0.048 -0.002 to 0.44 0.37 0.001 0 .1 5 -0 .5 9
Onset > 65 0.41 <0.001 0.20 to 0.63 0.66 <0.001 0.44 -  0.89
When depression was assessed using the BDI 50% of all PD patients were depressed 
(BDI > 10); 32% had mild depression, 8% moderate and 1% severe (Table 5-7).
When divided by onset at 45 years, YOPD patients have significantly higher mean BDI 
scores than LOPD (11.8 vs. 8.8, p=0.0003) (Table 5-6).
Table 5-6 : Mean BDI scores in onset groups split at onset before and at or above 45 
years
N Mean BDI score (95% 
Cl)
p value
onset <45 years 80 11.8(9.9-13.6)
0.0003
onset > 45 years 308 8.8 (8.1-9.4)
The proportion of patients with depression as defined by a BDI score of over 10 was 
significantly higher in younger onset patients and decreased with increasing age at onset. 
(Table 5-3).
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Table 5-7 : Depression by BDI Score
Total
Group
N ( % )
Onset 
<45 yrs  
n(%)
Onset
45-54
yrs
n( % )
Onset
55-64
yrs
n ( % )
Onset 
>65 yrs
n ( % )
Het X  2 
p  value
Onset <45 vs 
>45, H e t X 2 
p  value
none/minimal 
(BDI < 10)
111
(59)
38 (48) 56 (53) 65(68) 68 (64)
0.01 0.001
mild-moderate 
(BDI 10-18)
127
(33)
28 (35) 40(38) 26 (27) 33 (31)
moderate- severe 
(BDI 10-29)
29 (8)
10(13) 8(8) 5 (5) 6 (6 )
Severe (BDI > 30) 5(1) 4 (5 ) 1(1) 0 (0 ) 0 (0 )
Longer disease duration was associated with higher BDI scores when controlled for age 
at onset (coefficient 0.11, p<0.05, 95% Cl 0.002-0.22). However, adjusting for disease 
duration only slightly attenuated the difference with YOPD patients were still more likely 
to be depressed on the BDI than LOPD (Table 5-8).
Table 5-8 : Multiple regression analysis showing effect of onset group on BDI Score 
after adjusting for disease duration
Onset <45 used as baseline group Adjusted for disease duration
Coefficient P value 95% Cl Coefficient P value 95% Cl
Onset 45-54 -0.29 0.04 -0.57 to 0.08 -0.24 0.10 -0.53 to 0.04
Onset 55-64 -0.52 <0.001 -0.81 t o -0.24 -0.43 0.005 -0.73 to -0.13
Onset > 65 -0.44 0.002 -0.72 to -0.16 -0.31 0.05 -0.62 to 0.004
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5.3.5 Sleep Disturbance
Excessive daytime sleepiness was common overall in the whole group of PD patients 
affecting 55 % (ESS score > 10) but there was no significant difference between YOPD 
and LOPD groups at time of assessment (Tables 5-9 and 5-10).
Table 5-9 : Mean Epworth Sleepiness Scales Scores in onset groups split at onset 
before and at or above 45 years
N mean (95% Cl) p value
onset <45 years 87 10.2 (8.9-11.6)
0.68
onset > 45 years 324 10.5(9.9-11.2)
Table 5-10 : Sleepiness scores from Epworth Sleepiness Scale Scores
Total
Group
n(% )
onset 
<45 yrs 
n( %)
onset
45-54
yrs
n( %)
onset
55-64
yrs
n (% )
onset 
>65 yrs  
n(% )
Heterogeneity 
X 2 p  value
Onset <45 
vs >45, 
X 2 p  value
not sleepy 
(ESS<10)
187
(42)
44 (47) A l (40)
48
(43)
48(40)
sleepy
(ESS=10-17)
166
(37)
29 (31) 49 (41)
39
(35)
49 (41)
0.78 0.34
very sleepy 
(ESS>18)
92 (21)
21(22) 23 (19)
22
(22)
24 (20)
Table 5-11 : Multiple regression analysis showing effect of onset group on Epworth 
Score after adjusting for disease duration
Onset <45 used as baseline group Adjusted for disease duration
Coefficient P value 95% Cl Coefficient P value 95% Cl
Onset 45-54 0.14 0.27 -0.11 to 0.40 0.25 0.06 -0.01 -0.51
Onset 55-64 0.01 0.93 -0.25 to 0.27 0.18 0.21 -0 .10-0 .45
Onset > 65 0.06 0.65 -0.20 to 0.32 0.31 0.04 0.02 - 0.60
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Longer disease duration was significantly associated with higher Epworth scores when 
controlling for age at onset (coefficient 0.18, p<0.001, 95%CI 0.08-0.27). When disease 
duration was adjusted for, LOPD patients had significantly higher scores (more sleepy) 
than younger onset groups (Table 5-11).
Insomnia affected 49% of all PD patients. There was a significant trend for the younger 
onset groups to report more insomnia, but this lost statistical significance when the older 
onset groups were merged. REM sleep behavioural disorder was common (47%) overall 
but was not significantly different in YOPD and LOPD (Table 5-3).
5.3.6 Cardiff Community based vs Non Cardiff Supplementary secondary 
care referred cases
Cases from outside Cardiff were specifically recruited to increase the number of patients 
with YOPD. As these cases were ascertained from secondary care, this may have 
introduced an element o f selection bias, so analysis was performed to investigate whether 
there were any significant differences between prevalent and non prevalent cases.
Cardiff cases were significantly older at time of assessment (72 vs. 60 years, p=0.0001), 
had older age at onset (65 vs. 51, p=0.001) and had a shorter disease duration (7 vs. 10 
years, p=0.002) than non prevalent cases (Table 5-12).
Table 5-12 : Baseline Characteristics of Cardiff vs Non-Cardiff Cases
C ardiff Cases N on-C ardiff Cases P value
n (M :F) 153 (1:0.6) 292(1:0.6)
M ean age at onset 
(range, yrs)
65 (29-85) 51 (8-84) 0.0001
M ean cu rren t age 
(range, yrs)
72 (43-90) 60 (28-87) 0.0001
M ean disease 
dura tion  (range, yrs)
7 (0.5-27) 10(0.7-39) 0.002
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5.3.7 YOPD (onset <45) Cardiff vs Non-Cardiff cases
As YOPD cases were supplemented from secondary care sources in addition to the 
community based prevalent cohort, it was important to see if any differences existed 
between the YOPD patients ascertained from the Cardiff and non-Cardiff sources. 
Comparing the Cardiff and non-Cardiff cases in those with onset under 45 did not show 
any significant differences in the frequencies of non motor symptoms or in mean MMSE, 
Epworth or BDI scores (Table 5-13).
Table 5-13 : NMS in Cardiff and Non-Cardiff Cases with onset <45
C ardiff Cases 
(total 10) 
N (% *)
N on-C ardiff Cases 
(total 86)
N (% *)
P value
Prodrom al C onstipation 2(20) 9(15) 0.66
Depression 1(10) 14(22) 0.39
Fatigue 2(20) 15 (23) 0.81
Sleep D isturbance 3 (30) 8(13) 0.16
Hyposmia 0 12(19) 0.13
Parasthesiae 0 13 (20) 0.14
Pain/cram ps 0 18(35) 0.05
At time of 
assessment
C onstipation 4(57) 25 (48) 0.65
Depression 2(29) 19(37) 0.65
Fatigue 6(86) 41(75) 0.52
Sleep D isturbance 6(86) 51 (86) 0.96
Hyposmia 2(29) 24 (46) 0.38
Parasthesiae 3(43) 25 (45) 0.93
Pain/cram ps 5(71) 36(63) 0.67
Hallucinations 2(20) 20 (25) 0.71
M M SE <24 0 2(2 ) 0.62
MM SE >27 10(100) 77 (92) 0.34
Epw orth >10 3 (33) 40 (51) 0.31
BDI > 10 5 (50) 51 (61) 0.51
M ean M MSE 28.2 28.6 0.8
M ean Epw orth 9 10.4 0.5
M ean BDI 10.2 12.0 0.53
* note not all cases provided information on every feature thus percentages relate to variable total numbers
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5.3.8 YOPD (onset <55) Cardiff vs. Non-Cardiff cases
Comparing the Cardiff and non-Cardiff cases in those with onset under 55 did not how 
any significant differences in the frequencies of non motor symptoms or in mean MMSE, 
Epworth or BDI scores (Table 5-15).
Table 5-14 : NMS in Cardiff vs. Non-Cardiff cases with onset <55
C ardiff Cases 
(total 24)
N( % *)
N on-C ardiff Cases 
(total 191)
N(%*)
P value
P rodrom al Constipation 5(24) 24(15) 0.33
Depression 4(18) 32 (20) 0.84
Fatigue 10(43) 42 (27) 0.09
Sleep D isturbance 9(41) 34 (22) 0.05
Hyposmia 7(32) 49 (31) 0.95
Parasthesiae 4 (20) 30(19) 0.90
Pain/cram ps 4(20) 46 (37) 0.13
At time of 
assessment
Constipation 11 (58) 53 (48) 0.41
Depression 7(39) 37 (33) 0.65
Fatigue 14 (74) 90 (76) 0.86
Sleep D isturbance 16(84) 96 (79) 0.58
Hyposmia 10(53) 62 (54) 0.89
Parasthesiae 6(35) 39 (34) 0.91
Pain/cram ps 12 (33) 77 (64) 0.93
Hallucinations 8(33) 45 (25) 0.37
MM SE <24 0 8(4) 0.30
MM SE >27 23 (96) 172 (91) 0.42
Epw orth >10 12(52) 97 (55) 0.81
BDI > 10 12(50) 107 (57) 0.54
M ean MMSE 28.7 28.5 0.7
M ean Epw orth 10.6 10.7 0.97
M ean BDI 9.8 10.7 0.6
* note not all cases provided information on every feature thus percentages relate to variable total numbers
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These data suggest that the use of non-Cardiff cases did not introduce significant bias in 
the assessment in the variation of non-motor symptoms.
5.4 Discussion
NMS have commonly been reported in studies of PD patients from specialty hospital 
based populations. With the exception of dementia and neuropsychiatric features (see 
Chapter 2) NMS have not been systematically studied in YOPD. We have explored the 
occurrence of NMS, both predating the motor symptoms of PD and at time of assessment 
in established disease, and the differences between YOPD and LOPD in a large 
community based study. NMS represent one domain in which there are significant 
phenotypic differences between YOPD and LOPD.
5.4.1 Prodromal non motor symptoms
In a retrospective case note study of pathologically proven PD, 21% of patients were 
found to have presented with NMS i.e. preceding the onset of motor symptoms of PD 
(O'Sullivan, Williams et al. 2008). In our study, about a third of patients with PD self 
reported the occurrence of NMS as predating their motor onset of PD, the commonest 
symptom being hyposmia. The preclinical phase of nigral degeneration in PD predicted 
from neuropathological studies and neuroimaging has been suggested to range between 5 
and 7 years (Feamley and Lees 1991; Morrish, Rakshi et al. 1998; Brooks 2000; Marek, 
Innis et al. 2001). Several non motor symptoms of PD have been reported to precede 
motor onset by many years suggesting the involvement of non dopaminergic systems. 
The retrospective nature of ascertaining the prevalence of prodromal non motor 
symptoms is a limitation in itself because o f recall bias, and most studies, including our 
own, may not accurately determine the prevalence of NMS. There are some estimates of 
the background population rate of some of these symptoms. For example, the prevalence 
of constipation in the general population of Europe has been reported between 5-35% 
(Peppas, Alexiou et al. 2008). The association of prodromal non motor symptoms with 
PD can only be satisfactorily studied with a large prospective cohort study. Olfactory 
dysfunction has been reported by some investigators as a preclinical marker of PD 
(Ansari and Johnson 1975; Doty, Stem et al. 1992; Hawkes 2003; Ponsen, Stoffers et al. 
2004; Ross, Abbott et al. 2006). One study reported hyposmia as a feature at PD motor 
onset in 68% of cases (Henderson, Lu et al. 2003). Amongst senior citizens who were
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screened for olfactory dysfunction, those with the worse olfactory tests scores had a four 
times greater risk of developing PD (Ross, Petrovitch et al. 2008). In first degree relatives 
of PD patients, 10% of those with olfactory dysfunction developed PD within 2 years and 
so the authors suggested the presence of hyposmia in the at risk population could be used 
as a preclinical marker of PD (Ponsen, Stoffers et al. 2004). REM sleep behavioural 
disorder (RBD) has been reported to precede motor onset of PD in over 40% in some 
studies (Schenck, Bundlie et al. 1996; Chaudhuri, Healy et al. 2006). Excessive daytime 
sleepiness (EDS) has also been found to be a risk factor for developing PD (Abbott, Ross 
et al. 2005). Constipation has been shown to be associated with a threefold risk of 
developing PD over a ten year interval (Abbott, Petrovitch et al. 2001). Depression had 
also been shown to precede the onset of PD (Gonera, van't Hof et al. 1997; Nilsson, 
Kessing et al. 2001; Schuurman, van den Akker et al. 2002; Leentjens, Van den Akker et 
al. 2003; Lauterbach, Freeman et al. 2004; Ishihara and Brayne 2006). About 20% of PD 
patients report mood disturbance years before PD motor onset, especially during 3-6 
years before diagnosis of PD (Mindham 1970; Robins 1976; Santamaria, Tolosa et al. 
1986; Shiba, Bower et al. 2000; Leentjens, Van den Akker et al. 2003). Depression has 
been associated with a 2-3 fold increased risk of developing PD (Nilsson, Kessing et al. 
2001; Leentjens, Van den Akker et al. 2003). Anxiety has been shown to precede the 
motor onset of PD (Shiba, Bower et al. 2000; Weisskopf, Chen et al. 2003). In one study 
50% of PD patients reported anxiety, the mean onset of which was 1 year before PD 
motor onset (Henderson, Lu et al. 2003). Apathy and fatigue have also been suggested as 
pre motor manifestations of PD (Cooper, Sagar et al. 1991; Shiba, Bower et al. 2000; 
Chaudhuri, Healy et al. 2006).
In order to accurately evaluate prodromal symptoms a detailed large scale study of the 
general population or a smaller study of high risk individuals, for example those at risk of 
familial PD, would be needed. The frequency of NMS become much higher as the 
disease course extends, and the profile of prodromal NMS differs from that of NMS in 
established disease. Hyposmia and cramps or pain (recalled by approx 30%) are the 
commonest reported NMS predating the onset of motor symptoms whereas sleep 
disturbance and fatigue (both reported by 70%) are more common in established disease. 
This may reflect the progression of pathology with time (Braak stages) with increasingly 
frequent involvement of the lower brainstem nuclei. The preclinical diagnosis of PD may
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be aided by the recognition of these prodromal features and become important when 
considering the impact o f disease modifying treatments and neuroprotective agents.
Our study is the first to show that the profile o f prodromal NMS differs between YOPD 
and LOPD. In our cohort, prodromal hyposmia, constipation and sleep disturbance are 
more common in late onset disease. This may be explained if these features are more 
common purely with advancing age and control group comparison would be needed to 
clarify this issue. It is possible that the observations seen in our cohort may reflect 
differences in regional pathological change early in the disease course based on age at 
onset. Recent studies suggest an increase risk of developing PD if a combination of 
hyposmia, RBD and constipation were present, but our data suggest this is more relevant 
to LOPD (Ahlskog 2007).
5.4.2 Non motor symptoms in established disease
The rates of many of the NMS in our PD patients as a whole were similar to those 
reported previously. Sleep disturbance was reported in 70% of our cohort at time of 
assessment, excessive daytime sleepiness in 55%, REM sleep behavioural disorder in 
47% and insomnia in 49%. The overall prevalence of sleep disturbance in PD has 
previously been reported as 60-98% (Lees, Blackburn et al. 1988; Factor, McAlamey et 
al. 1990; Nausieda 1992; Schenck, Bundlie et al. 1996; Tandberg, Larsen et al. 1998; 
Olson, Boeve et al. 2000; Stocchi, Vacca et al. 2001; Oerlemans and de Weerd 2002). 
Excessive daytime somnolence has been reported in 50% of PD patients (Abbott, Ross et 
al. 2005).
Hyposmia was self reported by 45% of our cohort at interview. However there is likely to 
be a marked discrepancy between awareness of hyposmia and its presence since, 
hyposmia, when tested objectively with smell tests, has been reported in over 90% of PD 
patients (Ansari and Johnson 1975; Doty, Stem et al. 1992; Montgomery, Baker et al. 
1999; Abele, Riet et al. 2003; Hawkes 2003; Ponsen, Stoffers et al. 2004; Ross, 
Petrovitch et al. 2008).
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In our cohort, constipation was reported by 46% of PD patients. Constipation has been 
previously reported in 57% of PD patients (Kaye, Gage et al. 2006).
Only 6% of our cohort had clinical dementia. This reflects the fact that our initial 
exclusion criteria excluded patients with severe dementia or psychiatric disease, which 
has lead to an underestimate of the prevalence of dementia in PD. The incidence of 
dementia in PD has previously been reported as 15-40% (Pollock and Homabrook 1966; 
Aarsland, Tandberg et al. 1996; Rippon and Marder 2005; Ziemssen and Reichmann 
2007). In a community based study of PD, dementia was reported in 41%, and the risk of 
developing dementia by age 85 was as high as 65% (Apaydin, Ahlskog et al. 2002). In a 
prospective study of PD patients, 26% developed dementia after 9 years, 52% after 13 
years and 78% after 17 years (Aarsland, Andersen et al. 2003). A further study suggested 
that patients with PD had a 2-6 fold increased risk of developing dementia as compared 
to age matched controls (Emre 2003). However, although our study identified higher 
rates of cognitive impairment in later onset disease, we identified a small number of 
patients (3%) with disease onset below 45 with dementia. This indicates that the risk of 
dementia in YOPD although small is not negligible (see Chapter 2).
When asked at interview whether they thought themselves depressed, only 19% of our 
cohort answered yes. However, when assessed using the BDI, 49% of our cohort has 
depression as defined as a BDI score of over 10. Previous studies report depression in 4- 
70% of PD patients (Habermann-Little 1991; Cummings 1992; Hantz, Caradoc-Davies et 
al. 1994; Kostic, Filipovic et al. 1994; Tandberg, Larsen et al. 1996; Aarsland, Larsen et 
al. 1999; Slaughter, Slaughter et al. 2001; Bum 2002; Remy, Doder et al. 2005). Anxiety 
has been reported in at least 40% (Aarsland, Larsen et al. 1999; Walsh and Bennett 
2001).
Comparing the frequency of NMS in YOPD and LOPD, depression, sleep disturbance 
and parasthesiae were reported more often by YOPD patients at time of assessment. This 
is different to the profile of self reported prodromal NMS seen in YOPD and LOPD 
which may suggest different rates of progression of regional pathology.
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Significant differences between YOPD and LOPD were found when using validated 
rating scales to evaluate clinical dementia and depression. Clinical dementia was more 
common in LOPD and depression was more common in YOPD even when adjustments 
were made for disease duration. These differences may relate to age or disease 
heterogeneity. Socio economic factors may play an important role in adding to depression 
in the YOPD group who are more likely to have a greater financial and social 
responsibility to their younger families.
5.4.3 Limitations
This study was primarily designed to be conducted on a community based cohort of 
patients ascertained for the prevalence study. However, only about a third of cases were 
obtained via this source and so not all cases were strictly community based in the 
comparison study of clinical features. Because the numbers o f YOPD cases were small, 
this had to be supplemented by referral from secondary care sources from South Wales. 
This had the potential to introduce selection bias when integrating the secondary care 
cases, but we feel that this study is more representative study than the majority of 
previously published studies on YOPD based on very specialist clinic series. Analysis of 
the prevalent and non prevalent cases in the YOPD group showed no significant 
differences.
As this study examines established prevalent cases, one limitation of this study is the 
retrospective nature o f estimating frequency of prodromal features. This relies on patient 
recall and awareness o f symptoms and there may be differences according to age at onset 
and disease duration. This introduces an element of recall bias which may differ in the 
YOPD and LOPD groups. The younger onset cases had significantly longer disease 
duration and so may differentially influence how accurately details about symptom onset 
are remembered. Reporting bias may also occur, where YOPD cases may be more aware 
o f symptoms and therefore report them more frequently, where older patients may ignore 
them by being put down to part of the ageing process. One possible way of overcoming 
this problem could be to follow up prospectively pre-symptomatic mutation carriers e.g. 
LRRK2 G2019S, to record the exact age at which prodromal symptoms are first 
recognised.
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There are obvious dangers in regrouping the data by age at onset bands as the differences 
seen may be artificially produced, for example where there is no overall heterogeneity 
seen between age bands but where regrouping onset over 45 years a significant 
difference is seen. This can be illustrated by the presence of prodromal sleep disturbance. 
Here there is no overall heterogeneity across the 4 age groups, but the youngest onset 
group reports significantly less prodromal sleep disturbance, and this is borne out by the 
heterogeneity test when comparing onset under 45 with all onset over 45. There is a 
danger in artificially inducing significance by arbitrarily using 45 as a cut off, but this 
was a cut off decided prior to collecting the data. In any case, the data do suggest a 
threshold effect with significant differences seen in the younger onset group. This is in 
keeping with the theory that the younger onset group may have a different disease 
process. A second data set o rmeta-analysis would be needed to confirm these 
observations were not seen by chance.
We aimed to give an overview of the prevalence o f a broad range of non motor 
symptoms, and so the detail and depth in which each symptom could be examined was 
limited due to available time and resources. Each clinical assessment took on average two 
hours to complete and the majority of patients felt fatigued by the end o f the session, so 
lengthening the assessment was not feasible. In addition, it would not have been possible 
to collect data on as many individual subjects given the constraints o f the project 
timeline. There are many areas where more detailed assessments would have been 
beneficial. For example, instead of relying on patients recall regarding hyposmia, which 
has likely led to an underestimate of true prevalence, a more objective assessment using 
standard smell tests could have been used. This underestimation however applies to both 
YOPD and LOPD although it is unclear as to whether this occurs at a differential rate. 
Unfortunately, using severe dementia as an exclusion criteria at the GP ascertainment 
stage has led to a gross underestimation of dementia prevalence in our PD cohort. It is 
likely that a larger proportion of LOPD cases were excluded at the ascertainment stage, 
either due to physical or cognitive/neuropsychiatric morbidity. In addition, the cognitive 
assessment could have been improved by using the slightly longer but more sensitive 
cognitive screening tool the ACE-R (Addenbrooke’s Cognitive examination revised 
version). In those patients where additional cognitive assessments were required, there
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are vast arrays of tests available but require a great deal of time to perform and require 
the patient to be rested and comfortable for results to be reliable. During the course of 
this study the NMS-Quest was published (Chaudhuri, Martinez-Martin et al. 2006). This 
is a standardised validated self completion questionnaire designed to address the presence 
o f non motor symptoms in PD. However, this questionnaire was created to aid the 
physician identify clinical problems relating to non motor symptoms, not as a research 
tool to investigate frequencies of non motor symptoms in PD. There are many 
questionnaires available to screen for depression and sleep disturbance. In this study we 
chose the most widely used scales in PD research, the Beck’s Depression Inventory and 
the Epworth Sleepiness Scale. Both these scales are general self completion 
questionnaires, not specific for PD but have been validated in assessment for PD patients. 
Subsequently, PD specific scales have been published, for example the Sleep-PD 
questionnaire which tailors questions to PD sufferers.
It is likely there is a relationship between sleep disturbance, depression and cognitive 
dysfunction, all three commonly coexisting in PD. The effects of this interaction were not 
investigated in this thesis.
5.4.4 Strengths
Our study is based on a large community based sample of PD patients, although 
supplemented by secondary care resources in South Wales, we still believe this to be 
more representative than the highly selected hospital clinic based studies that make up 
most o f the published data to date.
Data have been obtained on the frequencies of a broad range of non motor symptoms in 
PD. The aim was to describe a phenotypic profile for YOPD and LOPD by identifying 
the presence of as many non motor symptoms as possible rather than concentrating on a 
few symptoms in detail.
5.4.5 Pathophysiology
The Braak staging hypothesis offers some insights into non-motor symptoms in PD. This 
hypothesis suggests PD pathology begins in the lower brainstem (medulla) then ascends
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to involve the midbrain, forebrain then the limbic cortex and neocortex. The nigro-striatal 
dopaminergic systems only become involved in the intermediate stages (stages 3 and 4).
Stages 1 and 2 are the pre-nigral stages involving non dopaminergic systems. Stage 1 
includes involvement of the dorsal motor nucleus of the vagus nerve in the lower 
medulla, the small GABAergic nuclei of the pons and the anterior olfactory structures. 
Degeneration of these areas relate to constipation, REM sleep behavioural disorder and 
hyposmia respectively. In stage 2 the pathological process extends to areas mediating 
sleep homeostasis and mood disturbance such as thalamo-cortical pathway, 
pedunculopontine nucleus, locus coeruleus, subcoeruleus and the raphe nuclei. In stage 3 
the noradrenergic and cholinergic systems become involved and may be implicated in the 
pathophysiology of cognitive and neuropsychiatric features. The pars compacta of the 
substantia nigra first become involved in stage 3, when motor symptoms begin. This 
provides an explanation as to why some NMS, the clinical manifestation of non 
dopaminergic involvement, may precede motor symptoms o f PD. Cortical structures then 
become involved. In the final two stages, severe damage to the autonomic, limbic and 
somatomotor systems can be compounded by functional deficits in neocortical 
association areas (Braak, Del Tredici et al. 2003), possibly explaining why the frequency 
of some NMS increases with disease progression, such as cognitive, sleep and 
neuropsychiatric involvement. There have not been any detailed pathological studies 
looking at the staging processes or neuropathology as a whole in YOPD compared to 
LOPD but our results suggest that there may be significant differences in PD patients 
according to age at onset.
5.4.6 Further work
There is scope for more detailed evaluation of NMS in PD particularly in certain areas. 
Detailed smell testing can be performed not only to characterise the nature of smell 
deficit but also to identify hyposmia which may be asymptomatic.
The prevalence of dementia in the community based cohort can be estimated by 
ascertaining patients with severe cognitive dysfunction. It may be difficult to establish
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new PD cases with established dementia and this may be best achieved with a 
longitudinal cohort study.
There are a variety of cognitive tests available which can help to define the exact 
domains involved in cognitive decline in some detail. Suggestions that subtle cognitive 
involvement in YOPD as compared with the normal population present another avenue of 
investigation (Hietanen and Teravainen 1988; Dubois, Pillon et al. 1990). Cognitive 
assessments in an incident cohort of PD patients only involved one patient with onset 
below 40 (Foltynie, Brayne et al. 2004) and so there exists a need for detailed cognitive 
assessments in large community based samples patients of YOPD.
Further non motor features on which frequencies were not reported on in this thesis 
include urinary dysfunction, sexual dysfunction, thermoregulatory dysfunction, 
orthostatic hypotension, cardiovascular involvement, psychosis, anxiety, apathy, panic 
attacks, impulse control disorders, obsessive compulsive disorder, dopamine 
dysregulation disorder and sleep apnoea.
The prospective follow up of presymptomatic mutation carriers may increase our 
accuracy in estimating frequency of prodromal NMS in the premotor phase of PD. 
Patterns of NMS manifestations studied in more detail may correlate to certain genetic 
aetiologies of PD and this may only become apparent as our understanding of PD risk 
factors increases.
5.5 Conclusions
Significant differences are seen in the profile of non motor symptoms of YOPD and 
LOPD, both prior to the development of cardinal motor features of PD and during the 
course of the disease. These data suggest that the pattern of prodromal and motor- 
associated non-motor symptoms will be valuable in the differentiation of clinical sub- 
types of PD separated by age at onset. This provides the basis on which investigating 
specific clinico-genetic correlations can be performed.
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Chapter 6 Motor Features of Young versus Later Onset 
Parkinson’s Disease
6.1 Chapter Summary
PD onset is defined by symptoms of motor involvement, namely tremor, rigidity, 
bradykinesia and postural imbalance. This chapter reports data on the clinical motor 
features of YOPD and LOPD in the community based prevalent cohort with 
supplementary cases from secondary care. Direct patient interview and correlation with 
medical case records were used to obtain information on onset symptoms, dystonia and 
dyskinesia. All cases were examined face to face in the research clinic in a practically 
defined “on” state. Standardised neurological examination, including the motor part of 
the UPDRS, was performed. Particular features of interest were presentation symptom, 
symmetry of signs and frequency of dystonia and treatment related dyskinesia. The 
relationship between dyskinesias and disease duration, age at onset, L DOPA dose and 
treatment duration was studies. The impact on quality of life was assessed using the Lang 
and Fahn activities of daily living (ADL) questionnaire. Significant differences are 
reported in the clinical motor features of YOPD and LOPD. YOPD patients presented 
more frequently with symptoms relating to akinesia and rigidity whereas LOPD more 
commonly presented with tremor. YOPD patients had more frequent dystonia and 
treatment related dyskinesias. Exercise induced dystonia is a specific characteristic of 
YOPD.
6.2 Introduction
PD is likely to be a heterogeneous disorder. It is likely that some patients with YOPD 
have a non-Lewy body disorder with distinct pathological and imaging characteristics. 
Parkin disease, which accounts for up to 20% of YOPD, has been associated with more 
severe and widespread dopaminergic depletion than typical LOPD and most cases do not 
have Lewy Bodies at post mortem (Mori, Kondo et al. 1998; Hayashi, Wakabayashi et al. 
2000; van de Warrenburg, Lammens et al. 2001; Sasaki, Shirata et al. 2004). A few 
studies have described differences between the clinical motor features of YOPD and 
LOPD. The majority o f these studies are based on hospital based study populations using 
a small number of cases. These previous observations may not reflect the true spectrum
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of YOPD, as unusual cases may be overrepresented in these clinical settings. To try and 
address these issues, we have undertaken a community based study comparing clinical 
features o f YOPD and LOPD.
6.3 Results
6.3.1 Study Cohort
Three hundred and fifty eight patients attended for clinical assessment. The mean age at 
assessment of the whole study population was 65 years (range 28-88), mean age at onset 
56 years (8-84), mean disease duration was 9 years (1-39) and mean motor UPDRS 
28/108 (2-72). There was no significant difference in these parameters between men and 
women.
Table 6-1 : Baseline characteristics of study population
Total Onset <45 
years
Onset 45-54 
years
Onset 55-64 
years
Onset >65 
years
N (M :F) 358 (1:0.6) 70(1:0.7) 103 (1:0.6) 88(1:0.6) 97(1:0.6)
M ean age at 
onset (range)
56(8-84) 38 (8-44.9) 51 (45-55.9) 59 (55-64.9) 72 (65-85)
M ean curren t 
age (range) 65 (28-88) 51 (28-64) 61 (47-79)
67 (58-82) 77 (67-88)
M ean disease 
duration  (range) 9 (1-39) 13 (1-39) 10(1-28)
8(1-24) 6(1-27)
M ean m otor 
UPDRS score
28 (2-72) 24 (4-57) 28 (3-72) 28 (2-62) 32(12-71)
6.3.2 Onset Symptom
LOPD usually presents with tremor and YOPD usually presents with an akinetic rigid 
syndrome. Tremor is twice as common as a presenting symptom in patients with LOPD 
as compared to YOPD (onset over 65 vs. under 45), and akinetic rigid presentation is 
twice as common in YOPD as compared to LOPD (Tables 6-2 and 6-3).
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Table 6-2 : Frequency of onset symptom by age at onset
Whole
group
n( %)
Onset 
<45 yrs 
n(%)
Onset
45-54
yrs
n(%)
Onset
55-64
yrs
n (% )
Onset > 
65 yrs 
n(% )
P  value 
fo r  het
P  value 
fo r  
trend
P  value 
fo r  > 45 
yrs
Tremor 175 (49) 21 (31) 41 (40) 53 (61) 66 (62) 0.001 0.0001 0.001
Slowness 21(6) 6(9) 6(6) 3 (3 ) 6 (6 ) 0.57 0.45 0.26
Stiffness 64 (18) 24 (35) 19(18) 10(11) 11(11) 0.001 0.0001 0.001
Balance 2(1) 0 0 1(1) 1(1) 0.6 0.23 0.5
Walking 22 (6) 1(1) 4 (4 ) 7 (8 ) 10(10) 0.08 0.07 0.009
Frozen
shoulder
25(7) 8(12) 10(10) 7 (8 ) 0 0.012 0.0022 0.09
Handwriting 22 (6) 5(7) 10(10) 2 (2 ) 5 (5 ) 0.19 0.21 0.6
Reduced
manual
dexterity
24 (7) 3 (4 ) 13(13) 4 (5 ) 4 (4 ) 0.048 0.29 0.39
When grouping akinetic rigid symptoms together, there were significant differences 
between onset groups. YOPD presented more commonly with akinetic rigid symptoms 
whereas tremor was the more common presentation for LOPD (Table 6-3).
Table 6-3 : Frequency of Tremor vs akinetic rigid onset by age of onset
Whole
group
n(%)
Onset 
<45 yrs 
n( %)
Onset
45-54
yrs
n(%)
Onset
55-64
yrs
n( % )
Onset > 
65 yrs 
n( % )
P  value 
fo r  het
P  value 
fo r  
trend
P  value 
fo r  > 45 
yrs
Tremor onset 175 (49) 21 (31) 41 (40) 53 (61) 66 (62) 0.001 0.0001 0.001
Akinetic 
Rigid onset
156 (44) 46 (68) 58 (56) 26 (30) 26 (27) 0.001 0.0001 0.001
Balance/
walking
24 (7) 1(1) 4 (4 ) 8 (9 ) 11 (ID 0.04 0.05 0.004
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6.3.3 Asymmetry of Parkinsonian signs
Asymmetry scores were calculated using the UPDRS motor score at assessment and 
comparing right and left sided scores for tremor, bradykinesia and rigidity in the limbs. 
If the ratio of the most affected side to the least affected side was over 1.5 this was 
classed as asymmetric. Based on the UPDRS motor examination, there was no evidence 
that disease asymmetry differed with age at onset. This was the case even after 
adjustment for disease duration (Table 6-4).
Table 6-4 : Asymmetry at assessment by age at onset stratified by disease duration
Disease duration 
(yrs)
Onset <45 years Onset >45 years Total P value
< 5 80% 78% 79% 0.9
5-10 82% 70% 72% 0.3
>10 59% 49% 52% 0.3
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6.3.4 Dystonia
Dystonia of any kind was reported by 35.5% of the total cohort. Twenty seven percent 
reported dystonia before commencement of L dopa therapy, and 33.5% during treatment. 
In YOPD, dystonia occurring prior to treatment with L-dopa was significantly more 
common than in LOPD (at onset, within the first two years and exercise induced 
dystonia). During treatment with L-dopa, off period (including early morning) and peak 
dose dystonia were also significantly more common in YOPD. There was a significant 
trend for these types of dystonia to become less common with increasing age at onset 
(Table 6-5). The threshold for dystonia at onset and during the first two years of 
treatment (early dystonia) seemed to occur at an age at onset of 55 -  dystonia at onset 
affected 20% of those whose disease started before the age of 55, and 4.3% of those 
whose disease started over the age of 54.
Table 6-5 : Frequency of Dystonia by age at onset
Whole
group
n( %)
Onset 
<45 yrs 
n (% )
Onset
45-54
yrs
n (% )
Onset
55-64
yrs
n( % )
Onset > 
65 yrs 
n(% )
P
value
fo r
het
P  value 
fo r  
trend
P  value 
fo r  >45
yrs
Dystonia a t onset 41 (12) 14 (20) 20(20) 5(6) 3 (3) 0.001 0.0001 0.012
Dystonia within 2 
yrs
21(6) 8(11) 9(10) 4 (5 ) 1(1) 0.014 0.0012 0.03
Exercise induced 
dystonia
33 (9) 13 (18) 15 (15) 5(6) 1(1) 0.001 0.0001 0.003
Early m orning 
dystonia p rio r to 
treatm en t
2(1) 1(2) 0 0 1(1) 0.47 0.88 0.26
O ff period dystonia 44 (13) 19(30) 21(20) 4 (5 ) 0 0.001 0.0001 0.001
Peak dose dystonia 15(4) 7(11) 4(4 ) 2 (2) 2 (2 ) 0.031 0.01 0.004
Early m orning 
dystonia during 
trea tm en t
26 (8) 14(21) 7(7) 4 (5 ) 2 (2 ) 0.001 0.0001 0.001
Dystonia not dose 
related
34 (12) 4 (9 ) 19(15) 14(17) 6 (7 ) 0.22 0.65 0.41
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Exercise induced dystonia is a specific feature of YOPD occurring in a fifth of patients 
with onset below 45.
6.3.5 Dyskinesia
Eighty patients (23%) in our total cohort reported the presence of dyskinesia at the time 
of assessment. We obtained data on the frequency of dyskinesias and the impact on 
quality of life. When asked to clarify what proportion o f the waking day dyskinesias 
were present 45 patients (13%) stated that dyskinesias were present for less than a 
quarter of their day, 24 patients (7%) between 26-50%, 5 patients (1%) between 51-75% 
and 6 patients (2%) reported dyskinesias to be present between 76-100% of their waking 
day. YOPD patients had reported significantly higher rates of dyskinesia than LOPD. 
There was a significant trend for this to diminish with advancing age at onset (Table 6-6).
Table 6-6 : Proportion of waking day reported to be affected by dyskinesia
Whole
group
n
(%)
Onset 
<45 yrs 
n(% )
Onset
45-54
yrs
n (% )
Onset
55-64
yrs
n (% )
Onset
>65
yrs
n(%)
P  
value 
fo r  het
P  value 
fo r  
trend
P  
value 
fo r  > 
45 yrs
Dyskinesia present 80 28 (42) 32(31) 13(15) 7 0.001 0.0001 0.001
(23) (7)
Dyskinesia present 45 10(15) 20(19) 9 6
between 1-25% of (13) (10) (6)
w aking day
Dyskinesia present 24 14 6 3 1
between 26-50% of (7) (21) (6) (4) (1)
waking day
Dyskinesia present 5 3 2 0 0 0.001
between 51-75% of (1) (5) (2)
waking day
Dyskinesia present 6 1 4 1 0
between 76-100% of (2) (2) (4) (1)
waking day
Average num ber of 4.7 5.5 4.9 4.0 2.7
waking hours in
dyskinetic state
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There was also a significant difference in the proportion of the waking day spent in a 
dyskinetic state between the onset groups (p=0.001), with the average number of hours 
spent in this state diminishing with as age at onset increased (Table 6-6).
O f those patients having reported dyskinesias (n=80), the mean Lang and Fahn ADL 
Dyskinesia quality of life scale score was 9/20 (s.d. 5.4). This significantly differed 
between onset groups, with YOPD having higher scores therefore reporting more 
disruption to their everyday quality of life then LOPD (4.2 vs. 1.7, p=0.001).
Relation to disease duration
In the whole group of patients regardless of whether dyskinesia was present or not, the 
YOPD patients had significantly longer disease duration. In the subset of patients who 
had dyskinesias, YOPD patients had a significantly longer disease duration than LOPD 
using both 45 and 55 as age definitions (15.6 vs. 12.2, p=0.02 and 14.4 s 10.4, p=0.01). 
This raised the possibility that the observed differences in dyskinesias were confounded 
by other factors. Further analysis was carried out.
Relation to L DOPA treatm ent duration and dose
In the subset of patients in whom dyskinesias were present and on whom data on L 
DOPA use were available, the dose of L DOPA was significantly higher and the duration 
of L DOPA treatment was significantly longer in the YOPD group using both 45 and 55 
as age definitions.
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Table 6-7 : Mean L DOPA treatment duration and dose in YOPD and LOPD in 
those with dyskinesia
YOPD onset <45 LOPD onset > 45 P value
Mean duration of L DOPA 
treatment (years)
7.2 4.5 0.002
Mean total L DOPA dose 
when seen in clinic (mgs)
470 418 0.004
YOPD onset <55 LOPD onset > 55 P value
Mean duration of L DOPA 
treatment (years)
5.9 4.1 0.004
Mean total L DOPA dose 
when seen in clinic (mgs)
472 388 0.004
Logistic regression examining factors associated with an increased risk  
of developing dyskinesia
Using logistic regression to look at the individual effects of age at onset, disease duration, 
duration of treatment with L DOPA and total L DOPA dose at time of clinic, all four 
factors were independently associated with an increased risk of developing dyskinesias. 
The effect of age at onset was seen more clearly in the onset division at 55 than 45 and 
this may be related to the smaller numbers in the under 45 age group. There is an 
apparent effect of dyskinesias becoming less common in the fourth quartile of disease 
duration in the multivariate analysis but the confidence intervals are wide.
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Table 6-8 : Risk factors for developing dyskinesias
Univariable Multivariable
Odds ratio 95% Cl p-value Odds ratio 95% Cl
P-
value
age at onset <45 2.9 1.6, 5.1 <0.0001 2.1 1.0, 4.8 0.07
Male 0.7 0.4, 1.1 0.13 0.6 0.3, 1.2 0.18
disease duration
quartile median (yrs)
1 2.4 1.0 1.0
2 5.7 1.4 0.3, 6.3 0.69 0.8 0.1, 4.6 0.76
3 9.4 19.3 5.7, 65.9 <0.0001 6.7 1.3,33.8 0.02
4 16.3 22.6 6.6, 77.0 <0.0001 3.9 0.7,21.2 0.12
p-value for trend <0.0001 0.004
levodopa duration 
quartile median (yrs)
1 0.5 1.0 1.0
2 1.8 0.9 0.3, 2.5 0.82 0.9 0.3, 2.9 0.81
3 4.5 3.3 1.4, 7.9 0.008 1.8 0.6, 4.9 0.27
4 11.9 6.3 2.7, 14.9 <0.0001 2.8 1.0, 7.8 0.05
p-value for trend <0.0001 0.03
dose o f levodopa 
quartile mean/ median(mg)
1 4 9 /0 * 1.0 1.0
2 282/ 300 1.9 0.8, 4.7 0.15 1.8 0.5, 7.3 0.38
3 430/ 400 4.1 1.8,9.1 0.001 2.2 0.6, 8.0 0.22
4 746/ 700 9.8 4.4, 21.8 <0.0001 5.4 1.5, 19.7 0.01
p-value for trend <0.0001 0.001
age at onset <55 3.9 2.3, 6.8 <0.0001 3.8 1.8, 8.0 0.001
Male 0.6 0.3, 1.2 0.14
disease duration (quartiles)
1 1.0
2 0.6 0.1, 3.5 0.54
3 4.9 1.0, 25.2 0.06
4 0.6 0.3, 11.6 0.5
p-value for trend 0.04
levodopa duration (quartiles)
1 1.0
2 0.8 0.2, 2.6 0.7
3 1.8 0.6, 5.3 0.26
4 3.6 1.2, 10.4 0.02
p-value for trend 0.01
dose of levodopa (quartiles)
1 1.0
2 1.8 0.4, 7.4 0.41
3 2.0 0.5, 7.6 0.29
4 4.9 1.3, 18.3 0.02
p-value for trend 0.003
* first quartile includes cases who were not on L DOPA
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6.3.6 Cardiff Community based vs Non Cardiff Supplementary secondary 
care referred cases
In our power calculations we anticipated recruiting 343 PD patients in Cardiff in whom 
52 would have an age at onset <55 based on a 60% recruitment rate. In fact only 126 
Cardiff cases were assessed in clinic of whom 20 had age at onset of under 55. Our 
recruitment from prevalence practices was 126/380 (33%) necessitating the need to 
identify more cases from outside Cardiff. All the cases from which these clinical features 
were collected attended a clinical assessment. Only one third of cases who attended for 
clinical assessment were recruited from the community based prevalence study and two 
thirds were ascertained from secondary care sources. This may have introduced an 
element of selection bias, so analysis was performed to investigate whether there were 
any significant differences between the Cardiff community based sample and the non 
Cardiff supplementary secondary care referred cases.
The community based cases were significantly older at time of assessment (72 vs. 61 
years, p=0.0001), had older age at onset (65 vs. 51, p=0.001) and had a shorter disease 
duration (7 vs. 10 years, p=0.003) than non-Cardiff cases (Table 6-9).
Table 6-9 : Baseline characteristics of Cardiff vs. Non-Cardiff cases
C ardiff Cases Non C ardiff Cases P  value
n (M:F) 126(1:0.7) 233 (1:0.6)
Mean age at onset in yrs 
(range)
65 (29-85) 51(8-84) 0.0001
Mean current age in yrs 
(range)
72 (43-88) 61 (28-87) 0.0001
Mean disease duration 
in yrs (range)
7(1-27) 10(1-39) 0.0003
6.3.7 YOPD (onset <45) Cardiff vs Non-Cardiff cases
Comparing the Cardiff and non-Cardiff cases in those with onset under 45 did not how 
any significant differences in the frequencies of motor symptoms or in mean Lang and
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Fahn or UPDRS motor scores, except for peak dose dystonia which was more common in 
the Cardiff cases, although this was not corrected for multiple testing (Table 6-10).
Table 6-10 : Motor features in Cardiff vs non Cardiff cases with onset <45
C ardiff Cases N on C ardiff Cases P value
Onset symptom
- tremor 5 (50) 16(27) 0.14
- slowness 0 6(10) 0.30
- stiffness 2(20) 22 (37) 0.30
- balance difficulties 0 0 -
- walking difficulties 0 2 (3 ) 0.56
- frozen shoulder 1(10) 7(12) 0.88
- handwriting 
difficulty
2(20) 3(5) 0.09
- difficulty turning in 
bed
0 0 -
- reduced manual 
dexterity
0 4 (7 ) 0.40
Akinetic rigid onset 5 (50) 42 (70) 0.21
W alking/balance 
onset
0 2(3 ) 0.56
Dystonia at onset 4(40) 10(17) 0.10
Dystonia within 2 
years o f onset
1(11) 7(13) 0.88
Exercise induced 
dystonia
3 (30) 10(17) 0.34
Early morning 
dystonia pre L dopa
0 1(2) 0.69
Off period dystonia 5 (56) 14(25) 0.06
Peak dose dystonia 3 (33) 4 (7 ) 0.02
Early morning 
dystonia on L dopa
4(44) 10(18) 0.08
Dystonia not related 
to L dopa dose time
0 4(10) 0.39
Sleep benefit 12(7) 2 (8) 0.29
Symmetry 6(67) 35 (64) 0.86
Dyskinesia present 5 (50) 24 (41) 0.58
Mean L+F score 
whole group (95%CI)
5.9(1-11) 3.9 (2-5) 0.35
Mean L+F score in 
those with dyskinesia 
(95% Cl)
11.8(6-17) 9.7 (7-12) 0.47
Mean UPDRS score 
(95% Cl)
26.9(18-36) 24 (21-27) 0.43
L+F = Lang and Fahn Dyskinesia ADL score
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6.3.8 YOPD (onset <55) Cardiff vs Non-Cardiff cases
Comparing the Cardiff and non-Cardiff cases in those with onset under 55 did not how 
any significant differences in the frequencies of motor symptoms or in mean Lang and 
Fahn or UPDRS motor scores (Table 6-11).
Table 6-11 : Motor features in Cardiff vs non Cardiff cases with onset <55
C ardiff Cases N on C ardiff Cases P value
Onset symptom
- tremor 9 (45) 53 (35) 0.36
- slowness 0 12(8) 0.19
- stiffness 5(25) 38 (25) 0.99
- balance difficulties 0 0 -
- walking difficulties 0 6(4) 0.38
- frozen shoulder 3(15) 15 (10) 0.47
- handwriting 
difficulty
3(15) 12(8) 0.29
- difficulty turning in 
bed
0 0 -
- reduced manual 
dexterity
0 17(11) 0.12
Akinetic rigid onset 11 (55) 94 (61) 0.58
Walking/balance
onset
0 6 (4) 0.37
Dystonia at onset 7(35) 27(18) 0.07
Dystonia within 2 
years of onset
1(6) 16(12) 0.48
Exercise induced 
dystonia
3(15) 25 (17) 0.86
Early morning 
dystonia pre L dopa
0 1(1) 0.72
O ff period dystonia 6(32) 34 (23) 0.39
Peak dose dystonia 3(16) 8(5) 0.09
Early morning 
dystonia on L dopa
4 (21) 17 (12) 0.25
Dystonia not related 
to L dopa dose time
1 (6) 13 (13) 0.44
Sleep benefit 2 (10) 12(8) 0.75
Symmetry 14 (74) 86(60) 0.25
Dyskinesia present 6 (30) 55 (36) 0.59
Mean L+F score 
whole group (95% Cl)
4 (1-7) 4 (3-5) 0.91
Mean L+F score in 
those with dyskinesia 
(95% Cl)
13 (8-17) 10(8-11) 0.21
Mean UPDRS score 
(95% Cl)
28 (23-32) 27 (25-29) 0.77
L+F = Lang and Fahn Dyskinesia ADL score
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6.4 Discussion
6.4.1 Clinical features
Significant differences in the clinical motor features of YOPD and LOPD were seen.
Age at onset seems to affect PD presentation. In this study cohort YOPD was much more 
likely to present with symptoms related to bradykinesia and rigidity whereas tremor onset 
was more common with increasing onset age. Previously published data have shown 
conflicting results regarding tremor presentation in YOPD. However, the majority are in 
agreement with our work and suggest tremor onset to be commoner in LOPD (Gibb and 
Lees 1988; Friedman 1994; Hely, Morris et al. 1995). However, Quinn et al showed 
tremor to be present in 52% of YOPD at presentation, and Giovaninni found tremor to be 
commoner in YOPD at presentation (Quinn, Critchley et al. 1987; Giovannini, Piccolo et 
al. 1991). However, our study is unique in that it is the only one to describe data from a 
community based cohort. Previously published data may be subject to selection bias as 
these studies are based on selected hospital based populations and may not be 
representative of the true YOPD population. Our data showed an agreement with the 
majority of previous studies -  tremor was less common in YOPD. This was seen in both 
the community based cohort and non Cardiff supplementary cases, though only about 
forty percent of the cases identified as prevalent consented to participate in the clinical 
features study potentially introducing a degree of selection bias. However, we believe our 
study to be more representative than the majority of studies on which previous reported 
literature is based. The pathophysiological basis o f Parkinsonian tremor is unknown but 
functional imaging and pharmacological studies suggest that Parkinsonian tremor may 
have a different pathological basis to Parkinsonian bradykinesia or rigidity (Fishman
2008). Tremor may well be a good marker for disease heterogeneity.
It has been suggested that parkin disease is more symmetric than typical late onset PD on 
the basis of autopsy data and functional imaging (Scherfler, Khan et al. 2004) (Sasaki, 
Shirata et al. 2004). In general terms genetically mediated diseases are usually 
symmetric (e.g. hereditary spastic paraparesis), presumably reflecting a homogenous 
effect of a pathogenic genetic mutation. From these data, there was no evidence to
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suggest that YOPD was more symmetrical clinically than LOPD. However, our method 
of measuring clinical symmetry involved comparing side by side variation in UPDRS 
scores which is likely to be influenced by the non-linear nature of the UPDRS motor 
score and by the examiner’s expectation that PD is an asymmetric disease. A more 
accurate measure may be made using surrogate markers such as neuro-imaging, or by 
using quantitative motor measures such as timed tap tests. It is likely that our data do not 
portray an accurate representation of disease symmetry and progression, and that 
prospective follow up of incident cases would more accurately identify whether YOPD 
cases became more symmetrical earlier on in their disease course than LOPD. Such a 
study (Giovannini, Piccolo et al. 1991) looking at time to bilateral clinical involvement 
suggested that YOPD affects both sides of the body earlier in the disease course. This is 
not quite the same as saying LOPD remains more asymmetric for longer nor is it the 
same as saying YOPD has a more aggressive disease course as suggested by the authors. 
Some dopamine transporter studies have however suggested earlier bilateral involvement 
of the dopaminergic pathways in YOPD but this may not necessarily correspond to the 
clinical picture. The basis of asymmetry in PD is unknown but may well reflect a 
fundamental aspect o f the disease pathogenesis.
A third of our cohort reported the presence of dystonic symptoms. Twenty percent of the 
YOPD group reported dystonia at onset and a further 11 % within the first two years of 
first cardinal motor symptom. This is very likely an underestimation of the true 
prevalence of dystonia amongst PD patients as this study had relied on patients 
recognising this phenomenon and self reporting symptoms at interview. Asymptomatic 
dystonic posturing is likely to go unnoticed by most patients and may only be evident on 
examination. Previous published reports quote a figure of between 14-57% of dystonia 
at onset in YOPD (Table 2-5). Similarly, 30% of our YOPD cohort reported L-dopa 
related off period dystonia. Previous published figures are reported as 30-59% (Quinn, 
Critchley et al. 1987; Gibb and Lees 1988). However, the majority of these published 
figures are based on specialist clinic series and are likely to represent a high percentage 
of atypical YOPD cases that have been referred for specialist management. Less than 3% 
of the LOPD group reported dystonia of any kind and again this is slightly lower than 
published figures which range from 0-10% (Table 2-5).
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A standardised method to assess dystonia in PD has not been established to date and one 
relies on the patients’ awareness of symptoms to establish its presence. It is possible that 
these data are confounded by an increased awareness of subtle symptoms by younger 
onset patients. It is clear from examining these patients that a degree of dystonic 
posturing is extremely common but the functional and prognostic relevance of this in 
asymptomatic patients are unclear.
6.4.2 Response to treatment
Reported rates of dyskinesia vary, but a recent analysis of previously published data 
suggested that there is a 40% risk of developing dyskinesia after for 4-6 years of L dopa 
treatment (Ahlskog and Muenter 2001). About 20% of our PD cohort reported 
dyskinesias to be present which, considering that the mean disease duration was 9 years, 
is surprisingly low. This may reflects active observation and recording of dyskinesia in 
pharmaceutical studies with multiple follow up visits. Significantly more dyskinesias 
were reported by patients with YOPD and this rate fell with increasing age at onset.
These data reflect previous studies. Many previous studies have reported the frequency of 
dyskinesia in YOPD but few have reported the impact on quality of life. In those with 
dyskinesias, the YOPD group were affected for larger proportions of the waking day. 
YOPD reported more disruption to their daily quality of life by the presence of dyskinesia 
as scored by the Lang and Fahn ADL QOL scale.
To this day, controversy exists as to whether the occurrence of dyskinesia and motor 
fluctuations is primarily related to PD itself or its treatment. It has been common practice 
to delay L DOPA treatment for as long as possible, especially in YOPD patients due to 
reports from small clinic series studies suggesting YOPD patients develop dyskinesias 
earlier than LOPD patients. One such study carefully corrected for disease and treatment 
duration in 25 YOPD and 25 LOPD patients (Kostic, Przedborski et al. 1991). Gomez et 
al performed retrospective analysis and acute L DOPA challenge in 34 YOPD (onset 
<40) and 34 LOPD (onset >60) and found that motor fluctuations and dyskinesias were 
more common in YOPD. The latency to L DOPA response during the acute challenge 
was no different between YOPD and LOPD patients. From the retrospective analysis, it 
was found that dyskinesias developed earlier in YOPD patients, within 4 years of disease 
onset and 2 years of treatment onset (compared to 5 and 4 years in LOPD) (Gomez
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Arevalo, Jorge et al. 1997). These authors also described a difference in dyskinesia type 
between YOIPD and LOPD, noting that ballistic, dystonic, off period and biphasic 
dyskinesia were more common in YOPD. This led the authors to conclude that this was 
due to an age related phenomenon rather than due to disease heterogeneity.
Schrag et al concluded from their community based study of 124 patients with PD that 
motor fluctuations were strongly related to disease duration and L DOPA dose and that 
dyskinesias were related to treatment duration (Schrag and Quinn 2000).
Our data confirm the important effect of age at onset on the development of dyskinesias. 
Multivariate analysis suggests that the major risk factors are independently associated 
with the risk of developing dyskinesias. However, it is important to note that the 
cumulative L DOPA dose was not calculated, only the total daily dose of L DOPA at 
time of the assessment.
6.4.3 Limitations
This study was limited by its retrospective nature. It would have been more representative 
to prospectively follow up cases from disease onset to study development of bilateral 
involvement. However, prospective follow up of cases to allow for any meaningful data 
would require long follow periods. With the limited resources and time assigned to this 
project, a retrospective assessment of a large number o f PD patients was a reasonable 
approximation.
The frequencies of both dystonia and dyskinesias in this study were reliant on patient self 
report at interview and so are likely to be underestimates. It is possible that this may be 
affected differentially by age or age at onset. Younger patients may be less likely to 
accept dystonia as a normal feature of ageing as older patients may. YOPD patients are 
more likely to be referred to a specialist clinic where physicians and therefore patients 
may be more aware of the presence of both dystonia and dyskinesias. There are no 
standardised methods to assess frequencies o f dystonia in PD and the UPDRS part IV 
relies on patient self report for the presence of dyskinesia. It was evident in the clinical 
assessment that often patients were unaware of mild non intrusive dyskinesias.
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At the time the study was commenced the standard UPDRS (Unified Parkinson’s Disease 
Rating Scale) was the most commonly used research tool to assess motor state. However, 
the nature of the scale is very insensitive. The UPDRS motor scale scores each 
component of the examination between 0 and 4 which are to some degree broadly 
dependant on the examiner. Since this study started, a new modified UPDRS has been 
designed which is far more detailed and may leave less scope for inter-examiner 
variability.
6.4.4 Strengths
The aim of this study was to compare YOPD and LOPD patients from a community 
based cohort. Although only a third of the patients were ascertained from the prevalence 
study, there was no significant difference between the prevalent and non prevalent cases.
A large number of patients with PD were assessed with a range of onset ages. All patients 
were assessed using standardised proformas and where available, validated scales were 
used e.g. UPDRS, Lang and Fahn ADL scale. Since the commencement of this study, 
new standardised scales have been published and validated which may have been utilised 
had they been developed in time for this study.
All clinical assessments were performed by one examiner. Therefore there was no 
concern regarding inter-rater variability. However, as the assessments were performed 
over a two year period there may have been an element o f intra-rater variation namely a 
learning effect. All clinical assessments were video taped and it can be possible to assess 
this issue although this was not done for this thesis.
6.5 Conclusions
Significant differences are seen in the profile of motor symptoms of YOPD and LOPD 
suggesting the differentiation of clinical sub-types of PD separated by age at onset.
YOPD commonly present with symptoms related to akinesia and rigidity, have slower 
disease progression and higher frequencies of both dystonia and dyskinesia. These 
findings are in keeping with previously published data. This information can help to 
further classify PD by investigating clinico-genetic correlations. On a more practical
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level, advice regarding earlier recognition and diagnosis of YOPD and tailoring 
management of medication based on age at onset can be developed from these data.
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Chapter 7 Conclusion
7.1 Major Findings
This study provides new data on patients with YOPD. Our data suggest temporal and 
geographical stability in the prevalence of PD over the past 42 years. This observation 
was made possible by performing analysis of the available raw data from these previous 
studies and highlights the usefulness of standardising methodologies in publishing data, 
for example publishing data for 5 year age strata.
The methods of case ascertainment are crucial in epidemiological studies and this has 
become apparent in this work. Neither primary nor secondary care alone provided 
accurate and complete data on prevalent cases. As discussed, our data cannot explain the 
variation in prevalence between rural North Wales and Cardiff. The ideal way to 
overcome this would be to use identical methodology in rural and urban settings.
Our prevalence estimates are in keeping with the weighted average from previously 
published data. Our crude prevalence estimate was 130 per 105 (95% Cl 117,144) and age 
standardised prevalence using the 1997 England and Wales population was 142 per 105 
(95% Cl 128, 156). Gender differences observed in this study suggest male 
preponderance, with a male to female prevalence ratio of 1.43 (95% Cl 1.17, 1.76, 
p=0.001). The mean age at onset of our cohort was 68.6 years (95%CI 67.5, 69.8), for 
men 67.7 years (95% Cl 66.0, 69.3) and for women 69.9 years (95%CI 68.1, 71.4).
Our study has identified a substantial prevalence of YOPD. These data should encourage 
the increase in awareness of PD developing at a younger than usual age and help shape 
appropriate health care services. A major outcome of this study has been engaging 
patients, physicians and PD nurse specialists in PD research in the South Wales area. We 
have engaged in a series of patient and carer educational activities which have assisted in 
research and aided in increasing awareness of YOPD.
Although this study was primarily designed to be a community based study the low 
recruitment rates required supplementation from secondary care resources, however
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analysis showed there were no significant differences between the cases from the 
prevalence study and the secondary care group. Our data have shown significant 
heterogeneity in the clinical features of PD by age at onset, both in the motor and non 
motor aspects of the disease.
Our data on non motor features suggest a different pattern of disease in YOPD and 
LOPD. The significance of this is uncertain but could be explored further by clinico- 
pathological and clinico-genetic correlations. Surprisingly, we have robust evidence to 
support the association of tremor with age at onset of PD suggesting the pattern of 
neurodegeneration may differ according to age at onset. We have identified a major 
association between dystonia and YOPD and again this must relate to fundamental 
biological differences. Though treatment related dyskinesias are commoner in YOPD, we 
have evidence to suggest that the development of dyskinesias can be predicted by four 
independent factors. These are age at onset, disease duration, dose of L DOPA and 
treatment duration. Although these are well recognised to be important, few studies have 
analysed their individual contributions.
7.2 Alternative Approaches
The information gathered from both the prevalence study and the comparative study of 
clinical differences of YOPD and LOPD has added to the existing knowledge base of 
YOPD. There are, however, several practical issues which could be improved if the study 
were to be performed again.
7.2.1 Prevalence Study
The initial recruitment of general practitioners could have been more efficient and 
focussed. General practitioners, like many busy professionals, may ignore non-urgent 
requests for assistance with research. The original mail shot to the head of practice may 
not have been the most effective way of introducing the study to the primary care setting. 
It became obvious as the study progressed that the practice manager was the best person 
to liaise with when requesting participation of the practice in the study. Initial contact by 
telephone, then an e-mail outlining the conversation including salient points of the study 
protocol and project paperwork followed up by a telephone call was probably the most 
effective method of recruiting practices. It was easier to target batches of specific
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practices and concentrate contact rather than to involve all practices at the same time, as 
was the original strategy.
Some practices in Cardiff did not join the study- we reached only 83% participation (45 
out of 54 practices). But the population denominator covered 96% of the Cardiff 
population, as the bigger practices were recruited, and subsequently this was the second 
largest prevalence study in the UK to date. However the recruitment period spanned 
fourteen months and a more efficient strategy may have accelerated this phase.
The study design did not fully capture individual case tracing from different referral 
sources. This was because patients were only given a unique study code after duplicate 
records were discarded in primary care. Our initial code used was a per individual code, 
but in order to maximise information from this initial phase we should have used a 
“potential case notification code”, related to case source with each individual associated 
with multiple case identification codes.
During the pilot searches, it would have been better to assess the accuracy of the 
individual search terms by using examination of the cases as the gold standard for 
diagnostic accuracy. However, in the interest of time, we could only be as accurate as the 
best recorded GP or secondary care clinic letter available.
We were unable to explain why some cases had been missed by the GP electronic 
database searches but had been identified via secondary care sources although registered 
with the GP practices who participated in the prevalence study. This was determined by 
the sequence of primary care screen, followed by secondary care screen. It may have 
been better to have had a list of cases known to secondary care registered at each 
practice, before visiting the practice to perform the GP database search in order to try to 
identify why cases were not pulled up by the search protocol. Unfortunately, at that time 
there was no efficient way of identifying cases from secondary care, so attempting to do 
this would have been more time consuming and delayed the start of the prevalence study. 
It appears, however, that reasonable ascertainment using both sources was reached.
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The prevalence of dementia was very low in our cohort of PD patients. This was likely 
due to the selection bias introduced by the exclusion criteria used at the GP screening 
stage. Once patients were identified as potential cases following the electronic database 
search and case note review, one GP per practice was asked to screen the list of patients 
to identify and exclude those patients they felt inappropriate to contact. The exclusion 
criteria included severe dementia, it may be that some GPs excluded patients perhaps 
who may have been suitable to be included in the study. Evidence for this was illustrated 
by one example where a patient was excluded by their GP because they were deemed to 
have severe dementia but this same patient was referred into the study by their secondary 
care physician and did not have significant cognitive impairment at assessment. Although 
patients such as this would have been included in the prevalence estimate, the exclusion 
of dementia patients from clinical assessment has undoubtedly led to an underestimation 
of the true prevalence of dementia in this study cohort and suggests that GPs use of 
dementia as an exclusion label may not be diagnostically accurate.
This prevalence study is the second largest in the UK. However, there is a trade off 
between study denominator size and degree of detailed screening possible. Ideally we 
would have liked to have examined all patients presenting with tremor for evidence of 
parkinsonism looking for undiagnosed PD as in the study conducted by Schrag et al 
(Schrag, Ben-Shlomo et al. 2000). Schrag et al suggested that approximately 20% of 
patients with Parkinson’s disease who had already come to medical attention had not 
been diagnosed as such but fulfilled Queen Square Brain Bank criteria at assessment 
(Schrag, Ben-Shlomo et al. 2002). This was reiterated by the Norwegian study screening 
for PD in nursing homes (Larsen 1991).
The initial basic screening questionnaire (BSQ) was designed to be administered as a 
screening tool incorporating some diagnostic questions from the Brain Bank Criteria. Its 
purpose was threefold - to screen patients with diagnoses other than PD, to obtain written 
consent to gain access to medical records, and to determine self reported age at onset.
The age at onset was initially part of the inclusion criteria as the protocol first intended to 
compare patients with onset before 55 and those with onset over 70, but this was changed 
early into the data collection phase to include all ages at onset because of rate of 
recruitment. By collecting data on patients with a spectrum of onset ages, it was possible
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to investigate for a continuous relationship between age at onset and clinical features as 
well as bimodal differences.
Our response rate from the prevalence study was disappointing, almost 40% of those 
invited did not respond at all (although of the 62% who did respond, 75% agreed to 
participate in the study).
7.2.2 YOPD vs. LOPD study
The number of prevalent patients agreeing to attend for clinical assessment was lower 
than expected. Out of the 380 cases identified as prevalent cases, only about one third 
attended for clinical assessment. It was envisaged that only a small number of YOPD 
patients would be recruited for clinical assessment from the prevalence study and so 
secondary care sources were involved primarily to ascertain further YOPD cases. 
However, because of the low participation rate of all onset ages, secondary care sources 
outside Cardiff were used to supplement cases of all onset ages.
Non M otor Symptoms
As the emphasis of the comparative study was to report frequencies of a wide spectrum 
of clinical features in a large number of PD patients by age at onset, it was not possible 
in the time frame of the study to look at any one feature in a great deal of depth. There is 
therefore a great deal of potential for further study within this cohort.
For the majority of the non motor symptoms, frequencies were calculated based on self 
report by the patients when directly questioned. Some standardised scales were also used 
such as the BDI, Epworth and MMSE. Clearly many of the clinical features assessed 
would benefit from more detailed assessment. For example, the use of a standardised 
clinical test, such as the University of Pennsylvania Smell Identification Tests (UPSIT) 
smell tests, will be more accurate than patient interview. There may be a differential 
reporting of hyposmia by age at onset as loss of smell tends to be regarded as part of the 
normal ageing process and so may be under reported in the older age groups. This may 
confound the assessment of non-motor features by interview.
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There is growing awareness of a wide range o f non-motor features affecting patients with 
PD. Further non motor features not studied in this thesis include urinary dysfunction, 
sexual dysfunction, thermoregulatory dysfunction, orthostatic hypotension, 
cardiovascular involvement, psychosis, anxiety, apathy, panic attacks, impulse control 
disorders, obsessive compulsive disorder, dopamine dysregulation disorder and sleep 
apnoea.
The MMSE was used as a screen for cognitive dysfunction. Although this is useful as a 
brief clinical screening tool, it does not provide any detailed assessment of frontal 
dysexecutive and visuo-perceptual function, known to be important aspects of cognitive 
impairment in PD. Studying incident cases and assessing the influence of disease 
duration prospectively in YOPD and LOPD may be revealing. The influence of age on 
cognitive function should also be taken into account. Ideally this should be done by 
comparing cognitive tests in PD patients and age matched controls.
M otor Clinical Features
Ideally, assessment of symmetry is best done in prospective way, on an incident cohort of 
PD patients. In this study, because the patients were established cases with varying 
disease durations the best estimate could only be performed at a contemporary 
assessment. This is likely to not represent the true disease pattern in these patients as the 
point at which symmetry develops is probably obscured with advancing disease duration 
and is likely to be missed in retrospective analysis. The UPDRS is likely to obscure 
differences in symmetry because of the categorical nature of the scale and the expectation 
of asymmetry by the examiner, and alternative methods of rating disease symmetry 
would be more helpful.
The assessment of dystonia in this study relied on self report when cases were directly 
questioned. This is dependant on the patients being aware and recognising the symptoms. 
Dystonia could have been more objectively assessed. It may have been possible to 
educate patients by giving them standardised training in recognising symptoms before the 
clinic assessment. Videotape recordings of each assessment were made which could be 
used to determine the presence of dystonic posturing but of course this only represents a 
snap shot of each patient’s motor state at any given time. PD patients can be in a dynamic
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variable motor state over course of the day and so relying purely on the video recording 
taken at a one off clinic visit will undoubtedly underreport the presence of dystonia.
A large amount of additional data that were not reported in this thesis have been 
collected. This includes data on family history, quality of life and environmental 
exposures. However, interpretation of these data are largely reliant on the comparison 
with control data. The recruitment of controls was more complicated and time consuming 
than first realised and so this part of the project could not be completed in the time frame 
for this thesis. We took the approach of seeking patient matched controls from primary 
care, asking the national body, Health Solutions Wales to identify suitable controls. This 
was a time-consuming approach which to date has yielded a low response rate.
7.3 Im pact of Study Findings on the managem ent o f YOPD
Awareness of PD starting at an earlier than usual age is increasing and recognition of the 
disease both by people with PD and by health care professionals, aids earlier diagnosis. 
Patients with YOPD may present with atypical features including prominent dystonia and 
prominent akinetic rigid symptoms. Though the incidence of YOPD remains relatively 
low making it a condition that the average general practitioner is rarely likely to see a lot 
of, the impact of accurate and early diagnosis to patients is significant. Educating both the 
general population and physicians regarding frequencies of these presenting features will 
improve diagnostic speed and accuracy, channelling diagnostic tests and referral to the 
appropriate health care services. A big element contributing to anxiety in symptomatic 
undiagnosed patients is the uncertainty o f diagnosis at presentation, and earlier 
recognition of symptoms will help to improve this.
In addition to reducing delay in diagnosis, identifying specific healthcare issues 
associated with YOPD should provide better care for these patients. Studying the 
frequencies of treatment related complications will help to inform both the patient and 
physician to reaching an educated rationale in treatment regimes. Understanding that 
YOPD may respond better to L DOPA treatment but involve development of earlier 
treatment related complications can influence individual treatment choices tailored to 
each patients unique needs. This is obviously dependant on the financial, social and
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psychological demands of the patient and one can imagine how this may differ with age, 
family commitments and employment status. A person in their thirties or forties with a 
young family to support may wish to start L DOPA medication early and benefit from 
better motor control during their working years whilst risking the development of 
dyskinesias, whereas an older individual who perhaps may be retired may prefer to avoid 
treatment related complications in doing so preferring to have suboptimal motor control 
which may be adequate for their pace of life. Information on the risk of developing 
treatment related complication and what impact these may have on quality of life are 
crucial to making as informed decision as possible regarding treatment strategies.
The identification o f non motor symptoms has become a major research focus over the 
past few years. They are an important aspect of PD management and cause a great deal of 
morbidity, which was previously under-recognised by the medical profession. PD was 
once thought to be a predominantly dopaminergic motor disorder, the symptoms of which 
were largely responsive to L DOPA treatment. It is becoming rapidly understood that the 
non dopaminergic systems are involved in a spectrum of non motor features, which are 
common in PD when looked for and cause a great deal of distress to patients. These 
symptoms do not respond well to L DOPA treatment but require alternative, maybe non 
pharmacological, interventions. The emphasis should be to address these issues, as often 
they cause the majority of morbidity in the later stages of the disease, and may be helped 
by simple measures. The differing profiles o f non motor symptoms in YOPD and LOPD 
should be acknowledged to help tailor specific management issues to PD patients 
according to age at onset. For example, it is important to recognise the high prevalence of 
depression and sleep disturbance in the YOPD population, both of which cause 
deterioration in quality of life but can be managed appropriately if recognised by patients 
and physicians.
The recognition of premotor symptoms will become important in the era of 
neuroprotection. Again the differing profile between YOPD and LOPD is important to 
bear in mind. Recent suggestions that the triad of hyposmia, REM sleep behavioural 
disorder and constipation may be a risk factor for developing PD will impact on how 
screening for PD may occur, but our study suggests that this triad may only be relevant 
for LOPD.
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7.4 Future Directions
Further analysis of our data could include cluster or factor analysis in an attempt to find 
clinical subtypes of PD, not defined by age at onset. A study looking at an unselected 
cohort of PD patients in the early stages of the disease demonstrated evidence of 
heterogeneity by performing cluster analysis (Lewis, Foltynie et al. 2005). This study 
identified 4 distinct subgroups of PD using the data driven approach, younger age at 
onset (<50) being one. This group was found to have slow disease progression, mild 
motor symptoms, no cognitive impairment and lower depression ratings. Our work 
collaborates some of these findings but not all. We found patients with YOPD had less 
cognitive impairment but higher depression ratings.
It seems likely that genetic analysis will clarify disease heterogeneity. However, 
surprisingly further studies looking at the clinical features of parkin positive and negative 
patients found no clinical way of distinguishing these groups (Lohmann, Thobois et al.
2009). This suggests that genetic heterogeneity may be less important than biological age 
in explaining clinical heterogeneity in PD. Genetic analysis of the cohort described in 
this thesis is ongoing and will provide a valuable correlation with the clinical data. 
Epidemiological data support the identification of further genetic factors in YOPD. 
Marder et al (Marder, Levy et al. 2003) report that siblings of YOPD patients have a 8 
fold increased risk of developing PD as compared to siblings of controls. This increased 
risk of familial aggregation was also found by others (Payami, Zareparsi et al. 2002; 
Rocca, McDonnell et al. 2004).
During the period of this study, a large amount of additional data were collected which 
await matched control data. The data collection for general population control is still 
underway and will provide control comparison data on quality of life, environmental 
exposures, daytime somnolence and depression.
All patients were also offered the opportunity to donate their brains to the Queen Square 
Brain Bank at the University College London/Queen Square. Although only a few
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patients (10%) recruited in this study have signed consent for donation to date, all have 
been approached about the importance of pathological confirmation of diagnosis and how 
this aids further understanding of PD. If a substantial number of patients subsequently 
consented to donate their brains for pathological examination it may be possible to 
examine for clinico-pathological correlations in this cohort. The relative importance of 
Lewy body and non-Lewy body disease in YOPD remains uncertain.
A further goal for future work is the longitudinal follow up of disease progression and 
drug responsiveness and development of drug related complications. A much more 
accurate picture of these aspects can only be gained from prospective study. Objective 
measure of disease progression performed at two points in time to can be used to estimate 
disease progression prospectively.
In addition, there is further scope to engage in more in-depth evaluation of areas of 
interest identified in this work. Detailed cognitive assessments, autonomic dysfunction, 
non motor aspects, sleep disturbances and psychiatric complications of dopamine 
replacement therapy are but a few possible areas for further study.
Although there are improvements that could have been made to the study design and 
there are future directions to be explored, this study has provided major insights into 
YOPD and paved the way for future research into this fascinating condition.
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Appendices 
Additional Tables
Appendix Table 1: Table of GP Study Codes
Unitary Authority Number o f  
practices
Total number o f  
practices within 
group
GP Study Code 
range available
Cardiff 54 54 101-154
Vale of Glamorgan 19 81 201-281
Rhondda Cynon Taff 43
Bridgend 19
Newport 22 22 301-322
Caerphilly 31 77 401-477
Torfaen 13
Blaenau Gwent 19
Monmouthshire 14
Methyr Tydfil 13 13 501-513
Neath Port Talbot 23 59 601-659
Swansea 36
Carmarthenshire 26 60 701-760
Pembrokeshire 18
Ceredigion 27
Powys 17 67 801-867
Wrexham 23
Gwenydd 27
Conwy 19 72 901-972
Denbighshire 17
Flintshire 25
Anglessey 11
Outside Wales unlimited unlimited 999
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Appendix Table 2 : Search terms used for
I) Diagnostic Codes
final search strategy
Search Term Read Code
Parkinson’s disease F 12
Parkinson’s disease and subgroups F 12 -  F 12 z
Paralysis Agitans F 120
Parkinsonism secondary to drugs F 121
Malignant Neuroleptic Syndrome F 122
Post encephalitic parkinsonism F 123
Parkinsonism secondary to external agents F 12 w
Secondary parkinsonism unspecified F 12 x
Parkinson’s disease not otherwise specified F 12 z
II) Tremor Symptoms
Search Term Read Code
Tremor not otherwise specified RO 103
Tremor symptom IB 22
On examination, fine tremor 2975
On examination, coarse tremor 2976
On examination, intention tremor 2977
On examination, Parkinsonian tremor 2974
Senile tremor R 20
Essential and other specified form of tremor F 131
III) Medication
Search Term Read Code
Dopaminergic drugs dq...
Anticholinergics dv...
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Appendix Table 3 : Diagnostic Read Codes 5-byte version 2 used to generate list 1
Diagnosis Read Code
Parkinson’s disease F12
Parkinson’s disease and below F 1 2 -F 12z
- Paralysis agitans F120
- Parkinsonism 2ry to drugs F121
- Malignant neuroleptic syndrome F122
- Post encephalitic parkinsonism F123
- 2ry parkinsonism due to other external agents F12w
- 2ry parkinsonism, unspecified F12x
- Parkinson’s disease, NOS F12z
Appendix Table 4 : Drugs Read Codes 5-byte version 2 used to generate list 2 
(otherwise Drug group CNS Drugs -  parkinsonism- dopaminergic drugs excluding 
amantadine (dq4..) and bromocriptine (dq5..))
Drug name Read Code
Levodopa dql..
Levodopa with benserazide / Co-beneldopa / Madopar dq2..
Levodopa with carbidopa/ Co-careldopa / Sinemet dq3..
Selegiline dq6..
Lisuride maleate dq7..
Pergolide mesylate dq8..
Apomorphine hydrochloride dq9..
Ropinirole hydrochloride dqA..
Cabergoline dqB..
Tolcapone dqC..
Entacapone dqD..
Pramipexole dqE..
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Project Paperwork
BSQ (Basic screening questionnaire)
Clinic Consent Forms 
Clinic assessment proformas
LHQ (Life History Questionnaire, includes Epworth Sleepiness Score)
Cardiff
u n i v e r s i t y
PRIFYSGOL
CA'RDYfi) ID:
Screening Movement Disorders Questionnaire
Section A : Personal Details
6GP name:
'Name:
2 Address: 7GP address:
'Postcode : ....
4Tel no : .........
'Mobile no : .. 
8Date of Birth:
Best day/ time to ring:
“Gender : 'M / 2F
“Place of Birth:
11 Hospital Consultant (for PD/tremor/movement problem if applicable, otherwise leave blank):
12Hospital (for PD/tremor/movement problem ):........................................
Section B : Consent
Please read and initial the boxes if you agree
• 'I give permission for my medical records to be looked at confidentially by members 
of the research team who would not normally be involved in my medical care.
» 2I agree that my GP and hospital consultant can be informed of my participation in 
this study
» 'I agree that my clinical details can be stored in a secure research database on the 
NHS hospital computer network. (You may ask for your personal information to be removed 
from this database at any time, in accordance with the Data Protection Act 1998).
• 4I would be willing to take part in the research project:
• aby filling in questionnaires about my condition
• bby filling in questionnaires and attending a specialist 
clinical assessment
Initials
Please circle
'Yes 2No
Yes No
► 1 do not have Parkinson’s disease □
Signed :
Name (please print)
BSQ V7 13/03/08
Date
1
Section C : Questionnaire
This questionnaire asks some questions about your symptoms, how they started and what treatment 
you have had. Some of the questions may not be relevant to you or your illness. We would be 
grateful if you could answer each question and answer no/don’t know if needed.
If you have any difficulty with the questions please call the research team on 02920 
743454/745821 or e-mail Dr M irdhu W ickrem aratchi on wpmmmw@cf.ac.uk
Symptom Ql.
YES NO
Q2. FIRST 
SYMPTOM 
(tick one box 
only)
1. Which of these symptoms have/ 
do you experience as part of your 
PD, tremor or difficulty with 
movement?
(please tick all boxes that apply)
2. Of these, which was the very first? 
(please only tick one symptom. If 
you had more than one symptom 
at onset, tick the one that was 
most severe)
(a) Tremor/shakiness of limb 
when relaxing or at rest o O
(b) Stiffness/rigidity of limb O o O
(c) Slowness O
(d) Walking difficulties o o o
(e) Handwriting problems o o
(f) Frozen shoulder o o o
(g) Stooped posture o □
(h) Reduced arm swing o - □
(i) Difficulty turning in bed o o
(j) Other symptom □ o io l j
f other symptom (please specify)
\  When did you notice the first symptom? 
e.g. Oct 2004 or Autumn 2004
a) M onth:....................................
b) Season:....................................
c) Y ear:........................................
4. Who first diagnosed you with having PD, tremor 
>r a movement disorder? Doctor’s name :.....................................................
Specialty: ‘Gp EZI, 2NeurologistlHI, 
’Geriatrician EH, "Other EH
5. What month and year was your diagnosis made? (a) M onth..................................  (b) Year................
How long after your first symptom was the 
diagnosis made? (indicate either in months or 
years)
(c) Months.......... (d) Y ears..................
What was the diagnosis?
(e ) .............................................................................
BSQ V7 13/03/08 2
Cardiff
UNIV1RSITY
D:
‘Yes 2No 3Don’t
know
6a) Did your symptoms s ta r t on one side first? □ □ □
6b) Do your symptoms remain worse on that side more than the other? □ □ □
7. Have your symptoms worsened since they started? □ □ □
8. Did you have the following within 2 years of your first symptom : 'Yes 2No 3Don’t
know
a) More than 2 falls per year not related to freezing up □ □ □
b) Urinary incontinence / retention □ □ □
c) Memory problems severe enough to affect your everyday life □ □ □
9. Have you taken L dopa containing medications
sinemet, madopar, co-careldopa, co-beneldopa, stalevo □ □ □
10a) If yes, did you have a good response to this medication within the first 12 
months of taking it? (good = 70 % improvement or better) □ □ □
10b) Has this good response been maintained for 5 years since starting?
(if you have taken it for less than 5 yrs, have you had a good response ever 
since you started)
□ □ □
11. Have you developed any problem s with either involuntary movements or 
fidgeting (dyskinesias) related to medication, or wearing off of your medication 
before the next dose is due or at other times (on/off fluctuations) ?
□ □ □
12) Around the time your symptoms started, were you taking any of the following?
‘Yes 2No 3Don’t
Know
13. Name of drug
12 a) Anti-sickness medication? □ □ □
12 b) Anti-dizziness medication? □ □ □
12 c) Anti depressants? □ □ □
12 d) Any medication for a psychiatric 
condition? □ □ □
14. Details of any other medication taken around the time your symptoms first started:
15. Details of any other events around the time your symptoms first started e.g. operations, head 
injuries, major infections?
Thank you for taking the time to fill out this questionnaire.
BSQ V6 23/10/06
For off ice use: fn\ Cl m I N u n  Cl in 2 Morc i n f o  3
ID: Date:
Departm ent o f Neurology, O phthalm ology and Audiological M edicine  
Head of D epartm ent Professor C M Wiles BSc PhD frcp
Lined Niwroleg ac Offthalmoleg Awdiolegol Meddygaeth  
Pennaeth Uned Yr Athro C M Wiles bsc PhD frcp
COMPARATIVE STUDY OF EARLY AND LATER ONSET PARKINSON’S 
ISEASE WITHIN THE GENERAL POPULATION
4TIENT CONSENT FORM
I have read the attached information sheet on the above project and been 
ven a copy to keep. I have had the opportunity to ask questions about the project and 
jnderstand why the research is being done and any foreseeable risks involved.
(now how to contact the research team if I need to.
I agree to give a sample of blood for research in the above project. I understand 
)wthe sample will be collected, that giving a sample for this research is voluntary 
d that I am free to withdraw my approval for the use of the sample at any time without 
/ing a reason and without my medical treatment or my legal rights being affected. This 
■mple will be used to study inherited material (DNA) and the chemical make-up of the 
x>d (Plasma/Serum).
I give permission for my medical records to be looked at confidentially by members 
the medical research team who would not normally be involved with my clinical care.
I give permission for a videotape examination, in which I am personally 
entifiable, to be stored as part of my clinical record and to be used for teaching 
jrposes, shown to doctors and health care workers.
I would like to be informed of research results that might indicate that a test for my 
xxJition could be developed which might be of use to me or my family.
I understand that I will not benefit financially if this research leads to the 
svelopment of new treatments or new tests.
I agree that the DNA, plasma, that I have given can
9 looked after and stored for use in future projects, as described in the information 
eet. I understand that this research may be carried out by individuals other than the 
iginal researchers and that this may include commercial companies.
I agree that my own doctor (GP and/or hospital) can be informed of clinical 
isessment, which takes place as part of this study and that this can form part of my 
edical records.
I agree that my clinical details can be stored in a clinical research database
i the NHS hospital computer network and understand that a separate anonymised 
search database will be used to store research results. I understand that I may ask for 
y personal information to be removed from this database at any time, in accordance with 
e Data Protection Act 1998.
Ca r d if f
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YES NO
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ID: Date:
I understand that information held by the NHS and records maintained by the General 
jistry Office may be used to keep in touch with me and follow up my health status.
I am happy to receive information on future research projects, by telephone or letter, 
lout any commitment to participation
Name of Subject Date Signature
Name of person giving assent if 
subject unable
Date Signature
Name of researcher Date Signature
Thank you for your participation in this study.
Patient Clinic Consent v5_EC p.2/5 12/03/08
ID: Date:
Department o f N eurology, O phthalm ology and A udiological M edicine
Head of D epartm ent P rofessor C M Wiles bsc PhD fr c p
Uned Niwroleg ac Offthalmoleg Awdiolegol M eddygaeth  
Pennaeth Uned Yr Athro C M Wiles bsc  PhD fr c p
DNA AND CELL LINE REPOSITORY INFORMED CONSENT FORM
I hereby consent to the collection of blood for submission to the European Collection of Cell Cultures 
(ECACC), a British based research resource.
I understand that the repositories collect, stores, and distribute cell cultures and DNA samples from 
people with many kinds of disorders, from unaffected family members, and from other healthy people and 
that the purpose of this collection is to make specimens available for use in research, teaching, 
therapeutics and diagnostic purposes to responsible investigators in the UK and around the world.
I understand that the ECACC will take measures to protect my privacy, and that my blood or tissue 
specimen will be given a code number, and my name will not be submitted to the ECACC. Some patient 
identification, such as age, sex, diagnosis, and race, will be made available to the Repository and 
scientists.
I understand that there will be no direct benefit or payment to me for participating, but my sample may 
benefit the community at large or some particular group. Because researchers will not have access to my 
identity, it will not be possible to provide me or my physician with the eventual results of studies that might 
be performed using my ECACC specimen. My sample will stay in the Repository indefinitely and I will not 
be able to withdraw it. If I have any questions or complications relating to collection of this specimen, I 
should contact Dr Huw Morris or a member of his team on 02920 743798, who collected the specimen.
    __________
Name of subject Date Signature
Name of researcher Date Signature
Cardiff
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Appendix 2
Consent form for use when staff other than medical photographers are making photographic/video 
recordings of patients.
Cardiff and Vale NHS Trust/University of Wales College of Medicine (UWCM) 
Photography/Video Recording of Patients
Cardiff and Vale NHS Trust/UWCM has adopted a policy to give you the right to control the future use of 
photographs/video recordings taken of you during the course of your treatment. Please sign in the 
appropriate place(s) below, once the purpose of the photography/video recording has been explained to 
you.
Consent: pl e a se  tick a s  a ppr o pr ia t e
I consent to photograph(s)/video recording(s) being taken for my personal medical 
  case-notes only.
I consent to photograph(s)/video recording(s) being taken for my personal medical
  case-notes and being used for teaching of medical, dental, nursing and healthcare staff and
students in the UK and abroad.
The patient has the right to withdraw consent at any time by contacting the Media Resources Centre.
Name of Patient (PLEASE PRINT) ____________________________________________________
Signature ________________________________________________________________________
Hospital Number DOB Date
  In addition, I consent to my photograph(s)/video recording(s) being published in an open
access journal, textbook or other form of medical publication (which may include the 
internet), and therefore may be seen by the general public as well as medical professionals.
I understand that once published, it will not be possible to completely withdraw this consent.
Name of Patient (PLEASE PRINT) ____________________________________________________
Signature ________________________________________________________________________
Hospital Number ________________________  DOB_____________  Date _______________
Full name and signature of medical practitioner requesting illustrations and obtaining consent.
Name (PLEASE PRINT) ________________________________________________
Department NEUROLOGY____________________________________________
Position (IF OTHER THAN CONSULTANT) ________________________________
Signature ___________________________________________________________
Date
Patient Clinic Consent v5_EC p.4/5 12/03/08
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A COMPARATIVE STUDY OF EARLY AND LATER ONSET PARKINSON’S 
DISEASE WITHIN THE GENERAL POPULATION
DNA AND CELL LINE REPOSITORY INFORMED CONSENT FORM 
(taken from NINDS HUMAN GENETICS RESOURCE CENTER)
I hereby consent to the collection of blood for submission to the NINDS Human Genetics Resource 
Center: DNA and Cell Line Repository at the Coriell Cell Repositories, a research resource supported by 
the Institute of Neurological Disorders and Stroke.
I understand that the repositories collect, stores, and distribute cell cultures and DNA samples from 
people with many kinds of disorders, from unaffected family members, and from other healthy people and 
that the purpose of this collection is to make specimens available for use in research, teaching and 
industry. I understand that the sample could be used to study any type of disease and not just Parkinson’s.
I understand that samples collected will be used to study genes and that the blood will be used for the 
preparation of DNA and possibly, an immortalised cell line.
I understand that the NINDS Repository will take measures to protect my privacy, and that my blood or 
tissue specimen will be given a code number and my name will not be submitted to the Coriell Cell 
Repositories, which is in accordance with HIPPA regulations. I also understand that the clinical and genetic 
data will be housed anonymously in a public database. Some patient identification, such as age, sex, 
diagnosis, and race, will be made available to the Repository and scientists.
I understand that this project has obtained a Confidentiality Certificate from the Federal Government to 
help ensure privacy. This Certificate means that the researchers/submitters cannot be forced to tell 
people who are not connected with the study about my participation, without my written consent. However, 
if there is threatened serious harm to myself or to others, it would be discussed with me, if possible, and 
disclosures would be made, if necessary, to protect me and other persons.
I understand that there will be no direct benefit or payment to me for participating, but my sample may 
benefit the community at large or some particular group. Because researchers will not have access to my 
identity, it will not be possible to provide me or my physician with the eventual results of studies that might 
be performed using my NINDS specimen. My sample will stay in the Repository indefinitely and I will have 
the option to withdraw at a later date, however I understand that it might not be entirely possible because of 
distribution and de-identification of samples and data. If I have any questions or complications relating to 
collection of this specimen, I should contact Dr Huw Morris or a member of his team on 02920 743798, who 
collected the specimen. If I have any questions about the Repository, I should contact Dr. Roderick 
Corrirear, Coriell Institute for Medical Research, 403 Haddon Avenue, Camden, New Jersey 08103. 
(Telephone: 00-1-856-757-9727).
Name of subject__________________ Date___________  Signature
Name of researcher Date Signature
Patient Clinic Consent v5_EC p.5/5 12/03/08
A Comparative Study of Early and Later Onset Parkinson’s Disease
ED: Clinic Date:
CONSENT CHECKLIST
Discussed By:
Information sheet
Chance to ask questions
Research project consent
NINDS consent
Video consent
Brain bank form
Consent to access medical notes
Consent to inform GP/ consultant
Database (NHS + University)
ONS database
Interest in further studies/ consent to be contacted again
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ID: Clinic Date:
DoB : Initials :
Clinic 
Assessment: 
Doctor 
Administered
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A Comparative Study of Early and Later Onset Parkinson’s Disease
ID: Clinic Date:
Clinical History 
and 
Examination
0a Referral Source
1 = GP search 6 = 2ry care - other
2 = WPG database 7 = self ref - pamphlet
3 = 2ry care -  Neuro 8 = self ref -  PDS meeting
4 = 2ry care -  Geri 9 = o th e r.............................
5 = 2ry care -  PDNS
Ob H andedness
1 = Right 2 = Left
Clinical History
(a) 1st PD 
symptom
1 = tremor 6 = frozen shoulder
2 = slowness 7 = handwriting
3 = stiffness/rigidity 8 = turning in bed
4 = balance 9= manual dexterity
5 = walking
Date of onset (b) M onth.........
(c) Year............
(d) First 
contact with 
medical 
practitioner
1 = GP 2 = Hospital 
(e) Name
Date first 
sought 
medical 
advice
(f) Month.........
(g)Yea r ..........
(h) Who
diagnosed
PD
1 = GP 2 = Hospital 
(i) Name
Date of 
diagnosis
(j) M onth.........
(k) Year............
(1)
Progression
1 = Yes 2 = No
(m)
Symmetry of 
onset
1 = asymmetric 2 = bilateral/ symmetric
(n) Side of 
onset
1 = Right 2 = Left
21.08.07 3
A Comparative Study of Early and Later Onset Parkinson’s Disease
ID: Clinic Date:
(1) Prodromal Duration before 
motor symptoms 
(months) (not 
entered)
(2) Current
l=Yes 2=No 3=D/K l=Yes 2=No
(a) Constipation
(b) Depression
(c) Fatigue
(d) Sleep
disturbance
(e) Loss of smell
(f) Paras thesia
(g) Other................
Further details o f history (free hand):
Cardiff
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ID: Clinic Date:
1=Y 2=N Details (not entered)
(a) Dopamine blockers within 6 months of 
onset
□ □
(b) Illicit drug use within 6 months of onset □ □
(c) Major head injury with LOC within 6 
months of onset
□ □
(d) Meningitis or Encephalitis within 6 
months of onset
□ □
(e) Sudden onset □ □
(f) Early cognitive disorder (significant 
impact on life within first 3 yrs or before 
onset)
□ □
(g) Early bladder disturbance (urinary 
incontinence/ retention within 1st year)
□ □
(h) Early postural instability/falls (within 1st 
year)
□ □
(i) Early postural syncope (within 1st year) □ □
Cardiff
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ID: Clinic Date:
Present
(a) At onset (b) Prominent 
within first 2 years
(c) Exercise 
induced
(d) Early morning
1=YD 2=ND
(if not at onset)
1=YD 2=ND 1=YD 2=ND
1=YD 2=ND
Location if present
1=Y 2=N 1=Y 2=N 1=Y 2=N 1=Y 2=N
1) RUL □ □ □ □ □ □ □ □
2) LUL □ □ □ □ □ □ □ □
3) RLL □ □ □ □ □ □ □ □
4) LLL □ □ □ □ □ □ □ □
5) Neck □ □ □ □ □ □ □ □
6) Oromandibular □ □ □ □ □ □ □ □
7) Blepharospasm □ □ □ □ □ □ □ □
8) Ocolugyric crisis □ □ □ □ □ □ □ □
9) Axial □ □ □ □ □ □ □ □
10) Other...................... □ □ □ □ □ □ □ □
Present (a) Off period 
1=YD 2=ND
(b) Peak dose 
1=YD 2=ND
(c) Early morning 
1=YD 2=ND
(d) Not dose-time 
related 
1=YD 2=ND
Location if present
1=Y 2=N 1=Y 2=N 1=Y 2=N 1=Y 2=N
1) RUL □ □ □ □ □ □ □ □
2) LUL □ □ □ □ □ □ □ □
3) RLL □ □ □ □ □ □ □ □
4) LLL □ □ □ □ □ □ □ □
5) Neck □ □ □ □ □ □ □ □
6) Oromandibular □ □ □ □ □ □ □ □
7) Blepharospasm □ □ □ □ □ □ □ □
8) Ocolugyric crisis □ □ □ □ □ □ □ □
9) Axial □ □ □ □ □ □ □ □
10)
Other......................
□ □ □ □ □ □ □ □
Cardiff
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ID: Clinic Date:
1=Y 2=N
(a) Present
□□
Start date: (b) M on th ............
(c) Year................
(d) Menacing
□□
(e) Insight retained
□□
(f) On medication when 
hallucinations occurred
□□
(gO) Hallucinations resolved with 
stopping/ reducing medication?
□□
1=Y 2=N
(g) Which medication (1)L dopa □ □
(2) Dopamine agonist □ □
(3) Anti-cholinergic □ □
(4) COMT inhibitor □ □
(5) NMDA □ □
(6) MAOB inhibitor □ □
(7) Other................... □ □
(h) Type of hallucination (1) Auditory □ □
(2) Visual □ □
(3) Olfactory □ □
(4) Tactile □ □
(5) Gustatory □ □
(i) If auditory: (1) Verbal □ □
(2) Musical □ □
(3) Other □ □
(j) If verbal (1) 1st person □ □
(2) 2nd person □ □
(3) 3rd person □ □
(k) If visual (1) Presence □ □
(2) Passage □ □
(3) Formed □ □
Cardiff
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ID: Clinic Date:
(a) Insomnia 1=y D  2=n D
(b) Shout out/ kick out in sleep □ to II □
(c) Vivid dreams
□zIICM□>HII
(d) Prominent nightmares 1=y D  2=n D
(e) Sleep paralysis □ to II □
(f) Has your partner had to move to another bedroom 
because of your sleep problems
□£IICN□><II
(a) What is the best time of 
the day?
1 = immediately after you’ve woken
2 = mid morning
3 = lunchtime
4 = mid afternoon
5 = tea time
6 = evening
(b) In general, how are you 
first thing in the morning?
1 = Cannot do much before medication ie off
2 = As good as with medication
(c) Sleep benefit present 1 = no
2 = yes
(d) If present, does this 
sleep benefit occur on a 
regular basis?
1 = no
2 = yes
(e) If so, what proportion of 
the time does it occur?
1 = <25%
2 = 26-50%
3 = 51-75%
4 = >75%
(f) If present have you had 
marked benefit from sleep 
within the first 3 years of 
onset?
1 = no
2 = yes
Cardiff
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ID: Clinic Date:
(1) Drug name Dose (4) Times (11) Start
(2)
Number
(3)
Units
Freq (5) (6) (7) (8) (9) (10) Date
(a)
(b)
(c)
(d)
(e)
(f)
(g)
*
l=micrograms/mcg, 2=milligrams/mg, 3=grams/g
1 = Poor 3 = Good
2 = Moderate 4 = Excellent
21.08.07 9
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P R I F Y S C O LCaeRDY(§> ID: Clinic Date:
11. Dyskinesias
(a) Are dyskinesias present i =y D
2=n D
If present, when are they 
present?
(b) immediately after you’ve woken
(c) mid morning
(d) lunchtime
(e) mid afternoon
(f) tea time
(g) evening______________________
1=Y □  2=N □  
1=Y □  2=N □  
1=Y □  2=N □  
1=Y □  2=N □  
1=Y □  2=N □  
1=Y □  2=N □
(h) If present, when are they 
worse?
1 = just after you’ve woken
2 = mid morning
3 = lunchtime
4 = mid afternoon
5 = tea time
6 = evening______________
When did they start? (i) M onth ..................... (j)Year.
(k) What proportion of the 
waking day are dyskinesias 
present
not present
1-25%
26-50%
51-75%
76-100%
32
(1) How disabling are they? not disabling
mildly
moderately
severely
completely
33
(m) How painful are they? not painful
slightly
moderately
severely
markedly
34
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ID: Clinic Date:
12. Early m orning/ off period dystonia
(a) Are off period dystonias 
present
35
0 = no 1 = yes
When did these start (b) M onth ............................  (c)Year
(a) Are motor fluctuations 
present
0 = no 1 = yes
When did off periods start (b) M onth..........................  (c)Year...............................
(d) Are off periods 
predictable
0 = no 1 = yes
36
(e) Are off periods 
unpredictable
0 = no 1 = yes
37
(f) Do off periods come on 
suddenly within a few 
seconds
0 = no 1 = yes
38
(g) What proportion of the 
waking day is spent in an 
off state
0 = none
1 = 1-25%
2 = 26-50%
3 = 51-75%
4 =76-100%
39
(a) Any anorexia, nausea or 
vomiting related to 
medication
0 = no 1 = yes
40
(b) Any sleep disturbance 0 = no 1 = yes
41
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ID: Clinic Date:
17. Freehand Family Tree
C a r d if f
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ID: Clinic Date:
Clinical Examination
1. G eneral
(a) Weight
(4) Chair height to seat(3) standing(1) seated (2) supine
(b) Height
(c) Pulse
2. Eyes
(1) Right (2) Left
1 = normal 2 ^abnormal 1= normal 2 = abnormal
(a) Fundal Examination
□□ □□
Pupils (b) appearance
□□ □□
(c) light 
reaction
□□ □□
(d) Visual fields (draw if
“ OO
□□ □□
(e) Visual acuity (PH)
Eye
movements
(f) Pursuit (1) Horizontal 
l=Normal 2= Abnormal
(2) Vertical
l=Normal 2=Abnormal
(g) Saccades (1) Horizontal (2) Upgaze (3) Downgaze
(i) Size
(ii) Speed
l=Normal 2= Abnormal 
l=Normal 2= Abnormal
l=Normal 
2= Abnormal 
l=Normal 
2 -  Abnormal
l=Normal 
2= Abnormal 
l=Normal 
2= Abnormal
(h) Supranuc ear gaze palsy 1 = present 2 = absent
(i) Nystagmus 0 = absent 1 = horizontal 2 = gaze evoked 3 = 
downbeat 4 = rotational
Eye opening/ closing (j) Apraxia
1 = present 2 = absent
(k) Blepharospasm 
1 = present 2 = absent
21.08.07 13
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ID: Clinic Date:
(a) Facial power CD 1 = normal 1_1 2 = UMN facial
□  3 = LMN facial CD 4 = bifacial weakness
(b) Ptosis □  1 = absent CD 2 = present
(c) Tongue movements CD 1 = normal CD 2 = spastic CD 3 = weak
(d) Tongue appearance 
(wasting/ fasc)
CD 1 = normal CD 2 = wasted CD 3 = fasciculation
(e) Jaw jerk CD 1 = absent/ normal CD 2 = brisk
(f) Facial jerks 
CDl=absent CD2=present
(g) Palmomental 
CDl=absent CD2=present
(h) Pout 
CDl=absent CD2=present
(i) Neck Flexion CD 1 = normal CD 2 = weak
(j) Speech 0 = Normal
1 = Slight loss of expression/diction +/- 
volume
2 = Monotone, slurred but understandable. 
Mod impaired
3 = Marked impairment. Difficult to 
understand
4 = Unintelligible
18
(k) Facial expression 0 = Normal
1 = Minimal hypomimia,
2 = Slight but definite diminuation
3 = Moderate hypomimia, lips parted 
sometimes
4 = Masked/ fixed facies, complete loss of 
facial expression, lips parted lA  inch or more
19
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CafRDY[9 ID: Clinic Date:
(a) Tremor at rest 0 = Absent
1 = Slight and infrequent
2 = Mild + persistent/ moderate + infrequent
3 = Moderate and present most of the time
4 = Marked and present most of the time
20
(1) Head/  face/lips
(2) R UL
(3) L UL
(4) R LL
(5) L LL
(b) Action/ Postural Tremor 0 = Absent
1 = Slight; present with action
2 = Moderate; present wit action
3 = Moderate ; posture holding and action
4 = Marked ; interferes with feeding
21
(1) R
(2) L
Limb rigidity 0 = Absent
1 = Slight or only on reactivation
2 = Mild to moderate
3 = Marked but with full ROM
4 = Severe, difficulty with full ROM
22
(1) Neck
(2) R UL
(3) L UL
(4) R LL
(5) L LL
(a) Finger Taps 0 = Normal
1 = Mild slowing +/or reduction in amplitude
2 = Mod imp. Def early fatiguing . Occ arrests 
in movement
3 = Severely imp. Hesitation in initiation or 
frequent arrests
4 = Can barely perform the task
23
( l)  R
(2) L
(b) Hand Movements Open and close hands in rapid succession 
(score as above)
24
( l)  R
(2) L
(c) Pronation - supination Both hands simultaneously (score as above) 25
(1) R
(2) L
(d) Leg agility Heel taps, picking up entire leg (score as 
above)
26
(l) R
(2) L
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ID: Clinic Date:
(a) Arising from chair 0 = Normal
1 = Slow, may need more than one attempt
2 = Pushes self up from arms of seat
3 = Tends to fall back and may need more 
attempts
4 = Unable to rise without help
27
(b) Posture 0 = Normal erect
1 = Slightly stooped
2 = Moderately stooped
3 = Severely stooped with kyphosis
4 = Marked flexion with extreme abnormality 
of posture
28
(c) Gait 0 = Normal
1 = Slow, may shuffle, no festination/ 
propulsion
2 = With difficulty but requires no/ little 
assistance
3 = Severe gait disturbance requiring 
assistance
4 = Cannot walk at all even with assistance
29
(d) Postural stability 0 = Normal
1 = Retropulsion but recovers unaided
2 = Absence of postural response,would fall if 
not caught
3 = Very unstable, loses balance 
spontaneously
4 = Unable to stand without assistance
30
(e) Body Bradykinesia/ 
hypokinesia
0 = None
1 = Minimal slowness, deliberate
2 = Mild slowness + poverty of movement, 
maybe j  amp
3 = Moderate slowness, poverty or small 
amplitude
4 = Marked slowness, poverty or small 
amplitude
31
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ID: Clinic Date:
(1) Right (2) Left
Upper limb (a) Shoulder abduction
(b) Elbow extension
(c) Finger extension
(d) Finger abduction
Lower limb (e) Hip flexion
(f) Knee extension
(g) Ankle dorsiflexion
(h) Toe extension
(1) Right (2) Left
Upper limb (a) Triceps
(b) Biceps
(c) Supinator
Lower limb (d) Knees
(e) Ankles
(f) Plantars (l=normal, 2=upgoing, 3=mute)
0 )  Right (2) Left
a) Joint position sense
b) Vibration sense
c) Light touch
d) Graphaesthesia
(1) Right (2) Left
a) Finger nose ataxia
b) Intention tremor
c) Dysdiodochokinesia
d) Heel shin ataxia
e) Ataxic gait
Q Unable to tandem walk
10. Sensation (1 =no rm a l, 2 = abnormal)
11. Cerebellar signs ( l= n o , 2=yes)
9. Reflexes ( 1 = normal, 2 ^absent, 3 =reduced, 4 = pathologically brisk)
C a r d if f
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a) Queens Square Brain Bank Criteria □  1 = Yes □  2 = No
b) MMW Final Diagnosis
1) 1= P S P
2 = MSA
3 = CBD
4 = Vascular Parkinsonism
5 = BET
6 = DIP
7 = Other
2) Other
C a r d if f
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ID: Clinic Date:
Video Protocol V27/05/05
Video consent form
1. Face / trunk / hands -  count backwards from 10 to 1.
2. Hands close up -  count backwards from 10 to 1.
3. Face close up -  count backwards from 10 to 1.
4. Eyes close up : open and close eyes x 5,
: look up, down, left then right keeping head still.
5. Hands outstretched in front of face -  10 seconds.
6. Finger nose te s t : right x 3
: left x 3
7. Finger taps, then each finger in turn : right -  10 seconds
: left -  10 seconds.
8. Repeated hand grips, outstretched arms -  10 seconds.
9. Repeated pronation-supination, outstretched arms -  10 seconds.
10. Leg agility/ heel taps, lift heel 3 inches off the ground : right -  10 seconds
: left -  10 seconds.
11. Full body view, arise from chair with arms folded across chest.
12. Walk in corridor : face on > 10 yards turn x 2.
13. Pull test, twice: first gentle tug on shoulders, second more forceful.
14. Reflexes.
15. Handwriting
C a r d if f
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DIAGNOSTIC CHECKLIST
ID: Clinic Date:
Diagnostic criteria Yes No
Mandatory Bradykinesia
+ 1 o f : Tremor
Rigidity
Postural instability
Supportive :
3 or more o f :
Unilateral onset
Rest tremor
Progressive
Persistent asymmetry ( side of onset worse)
Excellent response to L-dopa
Severe L-dopa induced chorea
l-dopa responsive for > 5 yrs
Clinical course of >10 yrs
Exclusion criteria Yes No
Repeated strokes and stepwise progression of PD symptoms
Repeated head injury
Encephalitis
Oculogyric crisis
Neuroleptic at onset
Sustained remission
Cerebellar signs
Tumour/ hydrocephalus on CT head
Negative response to large doses of L dopa
MPTP exposure
Relative exclusion criteria:
Strictly unilateral features >3yrs
Supranuclear gaze palsy
Early severe autonomic involvement
Early severe dementia
Definite pyramidal signs
Parkinson’s Disease based on criteria Yes No
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ID: Clinic Date:
Handwriting for Video :
Copy this sentence in your normal handwriting “Mary had a little lamb” :
Copy Spiral : R ig h t:
L eft:
Copy Spring :
Right
Left
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ID: Clinic Date:
Clinic 
Research 
Administrator 
Interview
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ID: Clinic Date:
(A) Mini Mental State Examination
Score
(1 or 0)
1. What day of the week is it ? 1
2. What is the date today ? 2
3. What is the month ? 3
4. What is the season? 4
5. What is the year ? 5
6. Where are we now? 6
7. What floor are we on? 7
8. In which town are we? 8
9. In which county/ district are we? 9
10. In which country are we? 10
11-13 Repeat the following words : Lemon, Key, Ball
(The examiner should pronounce the words at a rate of one per second.
In case of difficulties, repeat up to 5 times.)
11
12
13
14-18 Subtract 7 from 100 and make 5 subtractions 14
15
16
17
18
19-21 Can you remember the 3 words from before? 19
20
21
22. W hat is this? (show a pencil) 22
23. W hat is this? (show a watch) 23
24. Repeat the following “ no ifs, and or buts” 24
25-
27.
Follow a three-stage command : Take a piece of paper, fold it in half and 
put it on the floor”
25
26
27
28. Read and obey what is written on this piece of paper (“Close your eyes”) 28
29. Write a sentence of your choice on this piece of paper. 29
30. Copy this drawing on a piece of paper on
Total
30
31
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ID: Clinic Date:
Close Your Eyes
W rite  a sentence :
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ID: Clinic Date:
(B) Lang and Fahn Activities of 
Daily Living Dyskinesia Scale
SUBJECT SCORE DESCRIPTION
1. Handwriting 
or drawing
0 No dyskinesias are evident when you write, which is accomplished as well as 
your Parkinson’s disease (PD) allows at the best of times (this may be small or 
partly legible).
l When dyskinesias are at their current maximum, writing is no different from the 
best performance without dyskinesias (writing may be small or illegible at the 
best of times but dyskinesias do not interfere with writing
2 When dyskinesias are at their current maximum, they interfere with writing but 
allow you to complete the writing task successfully with only a slight increase 
in the time or effort required and no further increase in legibility compared with 
the best writing performance without dyskinesias
3 When dyskinesias are at their current maximum, they cause substantial 
impairment in writing or drawing compared with the best performance without 
dyskinesias; result from the dyskinesias is more illegible than without 
dyskinesias and drawing shows more errors.
4 When dyskinesias are at their current maximum, they make writing and 
drawing impossible. Because of dyskinesias, it is impossible to maintain contact 
between pen and paper long enough to write or draw ( ie, it is impossible to 
produce even small, illegible script).
2. Cutting 
Food and 
Handling 
Utensils
0 No dyskinesias are evident when you feed yourself which is accomplished as 
well as your PD allows at the best times.
1 When dyskinesias are at their current maximum, they do not interfere at all with 
cutting food and feeding yourself. The ability to feed yourself is no different 
from the best performance without dyskinesias (this includes slowness and 
clumsiness, possibly even requiring help at the best o f times as a result of 
persistent problems with parkinsonism).
2 When dyskinesias are at their current maximum, they definitely interfere with 
feeding but allow you to complete the necessary feeding task with only a slight 
increase in time or effort compared to the best performance without dyskinesias 
(any assistance required in cutting food or feeding relates mainly to the 
underlying parkinsonism and persists at the best o f times without dyskinesias).
3 When dyskinesias are at their current maximum, they cause substantial 
impairment in feeding compared with the best performance without 
dyskinesias; as a result o f the dyskinesias, more help is required to cut food or 
feed yourself than at the best of times without dyskinesias
i
4 When dyskinesias are at their current maximum, they make feeding impossible 
and even with full assistance from someone else, feeding is exceedingly 
difficult or impossible because of the presence of dyskinesias.
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SUBJECT SCORE DESCRIPTION
3.
Dressing
0 No dyskinesias are evident when you get dressed or undressed including outerwear to go 
outdoors that are as accomplished as well as your PD allows at the best of times.
l When dyskinesias are at their current maximum, they do not interfere at all with the 
performance of dressing tasks. These are completed no differently from the best 
performance without dyskinesias (this includes slowness and clumsiness possibly even 
requiring help at the best o f times as a result o f persistent problems with parkinsonism).
2 When dyskinesias are at their current maximum, they definitely interfere with the 
performance of dressing tasks but allow you to complete them with only a slight increase 
in time or effort compared to the best performance without dyskinesias (any assistance 
required in getting dressed, including doing up buttons or getting arms into sleeves, 
related to the underlying parkinsonism and persists at the best of times without 
dyskinesias).
3 When dyskinesias are at their current maximum, they cause substantial impairment in the 
performance of dressing tasks compared with the best performance without dyskinesias; 
as a result of the dyskinesias, more help is required for dressing than the best o f times 
without dyskinesias.
4 When dyskinesias are at their current maximum, they make performance of dressing tasks 
impossible and even with full assistance from someone else, dressing is exceedingly 
difficult or impossible because of the presence of dyskinesias.
4. Hygiene
0 No dyskinesias are evident when you wash, shower, bathe, shave, brush your teeth, and so 
on, that are accomplished as well as your PD allows at the best of times.
1 When dyskinesias are at their current maximum, they do not interfere with the 
performance of hygiene tasks. These are completed no differently from the best 
performance without dyskinesias (this includes slowness and clumsiness possibly even 
requiring help at the best of times as a result o f persistent problems with parkinsonism).
2 When dyskinesias are at their current maximum, they definitely interfere with the 
performance of hygiene tasks but allow you to complete them with only a slight increase 
in time or effort compared to the best performance without dyskinesias (any assistance 
required in getting dressed, including doing up buttons or getting arms into sleeves, 
related to the underlying parkinsonism and persists at the best of times without 
dyskinesias).
3 When dyskinesias are at their current maximum, they cause substantial impairment in the 
performance of hygiene tasks compared with the best performance without dyskinesias; as 
a result of the dyskinesias, more help is required for washing, grooming, and going to the 
bathroom than the best o f times without dyskinesias.
4 When dyskinesias are at their current maximum, they make performance of hygiene tasks 
impossible and even with full assistance from someone else, washing, grooming, and 
going to the bathroom are exceedingly difficult or impossible because of the presence of 
dyskinesias.
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SUBJECT SCORE DESCRIPTION
5. Walking
0 No dyskinesias are evident when you walk which is accomplished as well as your 
PSD allows at the best o f times.
l When dyskinesias are at their current maximum, they do not interfere at all with 
walking. The ability to walk is no different from your best walking without 
dyskinesias (this includes slowness, unsteadiness, freezing, and even the need for 
assistance at the best o f times as a result of persistent problems with 
parkinsonism).
2 When dyskinesias are at their current maximum, they definitely interfere with 
walking but still allow you to walk with only a slight increase in caution, time, or 
effort compared to the best performance without dyskinesias possibly as a result 
of more unsteadiness or more frequent stumbling (any assistance required for 
walking relates mainly to the underlying parkinsonism and persists at the best of 
times without dyskinesias).
3 When dyskinesias are at their current maximum, they cause substantial 
impairment in walking compared with your best walking without dyskinesias; 
more help is required to walk than at the best o f times without dyskinesias.
4 W hen dyskinesias are at their current maximum, they make walking impossible 
and even with full assistance from someone else, ambulation is exceedingly 
difficult or impossible because of the presence of dyskinesias.
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Clinic 
Assessment: 
Self 
Administered
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BECK DEPRESSION INVENTORY
This questionnaire consists of 21 groups of statements. After reading each group of 
statements carefully, circle the number (0, 1 ,2 or 3) next to the one statement in 
each group which best describes the way you have been feeling the past week, 
including today. If several such statements within a group seem to apply equally 
well, circle each one. Be sure to read all the statements in each group before 
making your choice.
1 I do not feel sad. 0
I feel sad. 1
I am sad all the time and I can't snap out of it. 2
I am so sad and unhappy that I can't stand it. 3
2 I am not particularly discouraged about the future. 0
I feel discouraged about the future. 1
I feel I have nothing to look forward to. 2
I feel the future is hopeless and that things cannot improve. 3
3 I do not feel like a failure. 0
I feel I have failed more than the average person. 1
As I look back on my life, all I can see is a lot of failures. 2
I feel I am a complete failure as a person. 3
4 I get as much satisfaction out of things as I used to. 0
I don't enjoy things the way I used to. 1
I don't get real satisfaction out of anything anymore. 2
I am dissatisfied or bored with everything. 3
5 I don't feel particularly guilty. 0
I feel guilty a good part of the time. 1
I feel quite guilty most of the time. 2
I feel guilty all of the time. 3
P R I  F Y S G O LCa1RDy,§>
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6 I don't feel I am being punished. 0
I feel I may be punished. 1
I expect to be punished. 2
I feel I am being punished. 3
7 I don't feel disappointed in myself. 0
I am disappointed in myself. 1
I am disgusted with myself. 2
I hate myself. 3
8 I don't feel I am any worse than anybody else. 0
I am critical of myself for my weaknesses or mistakes. 1
I blame myself all the time for my faults. 2
I blame myself for everything bad that happens. 3
9 I don't have any thoughts of killing myself. 0
I have thoughts of killing myself, but I would not carry them out. 1
I would like to kill myself. 2
I would kill myself if I had the chance. 3
10 I don't cry any more than usual. 0
I cry more now than I used to. 1
I cry all the time now. 2
I used to be able to cry, but now I can't cry even though I want to. 3
11 I am no more irritated by things than I ever was. 0
I am slightly more irritated now than usual. 1
I am quite annoyed or irritated a good deal of the time. 2
I feel irritated all the time. 3
C a r d i f f
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12 I have not lost interest in other people. 0
I am less interested in other people than I used to be. 1
I have lost most of my interest in other people. 2
I have lost all of my interest in other people. 3
13 I make decisions about as well as I ever could. 0
I put off making decisions more than I used to. 1
I have greater difficulty in making decisions more than I used to. 2
I can't make decisions at all anymore. 3
14 I don't feel that I look any worse than I used to. 0
I am worried that I am looking old or unattractive. 1
I feel that there are permanent changes in my appearance that make me look 
unattractive.
2
I believe that I look ugly. 3
15 I can work about as well as before. 0
It takes an extra effort to get started at doing something. 1
I have to push myself very hard to do anything. 2
I can't do any work at all. 3
16 I can sleep as well as usual. 0
I don't sleep as well as I used to. 1
I wake up 1-2 hours earlier than usual and find it hard to get back to sleep. 2
I wake up several hours earlier than I used to and cannot get back to sleep. 3
17 I don't get more tired than usual. 0
I get tired more easily than I used to. 1
I get tired from doing almost anything. 2
I am too tired to do anything. 3
C a r d i f f
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18 My appetite is no worse than usual. 0
My appetite is not as good as it used to be. 1
My appetite is much worse now. 2
I have no appetite at all anymore. 3
19 I haven't lost much weight, if any, lately. 0
I have lost more than five pounds. 1
I have lost more than ten pounds. 2
I have lost more than fifteen pounds. 3
20 I am no more worried about my health than usual. 0
I am worried about physical problems such as aches and pains, or upset 
stomach, or constipation.
1
I am very worried about physical problems and it's hard to think of much else. 2
I am so worried about my physical problems that I cannot think about 
anything else.
3
21 I have not noticed any recent change in my interest in sex. 0
I am less interested in sex than I used to be. 1
I have almost no interest in sex. 2
I have lost interest in sex completely. 3
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Please tick one box for each question
Due to having Parkinson’s disease, 
how often during the last month 
have you....
1. Had difficulty doing the leisure activities which 
you would like to do?
2. Had difficulty looking after your hom e, e .g . DIY, 
housework, cooking?
3. Had difficulty carrying b a g s  of sh opping?
4. Had problem s walking half a  m ile?
5. Had problem s walking 100  yards?
6. Had problem s getting around the h o u se  a s  
easily  a s  you would like?
7. Had difficulty getting around in public?
8. N eed ed  so m e o n e  e ls e  to accom p an y  you w hen  
you went out?
9. Felt frightened or worried about falling over in 
public?
10. B een  confined to the h o u se  m ore than you  
would like?
11. Had difficulty w ashing yourself?
12. Had difficulty dressing yourself?
13. Had problem s doing up your s h o e  la c es?
ID: Clinic Date:
PDQ-39 QUESTIONNAIRE
Never Occasionally Sometimes Often Always
or cannot
o a D D
do at all□ 3
o a □. D □ 3
D a D □ 3
D o D □ 3 □3
D a Q □ 3
D a □. □ 3 □ 3
D o □ 3
D a O □ 3 □3
O a □ 3
D o □3□3
D a □ 3 □3□ 3
D a D □3□ 3
D D □ 3
Please check that you have ticked one box for each question before going on to the next page.
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Please tick one box for each question
Due to having Parkinson’s disease, 
how often during the last month 
have you....
14. Had problems writing clearly?
15. Had difficulty cutting up your food?
16. Had difficulty holding a drink without 
spilling it?
17. Felt depressed?
18. Felt isolated and lonely?
19. Felt weepy or tearful?
20. Felt angry or bitter?
21. Felt anxious?
22. Felt worried about your future?
23. Felt you had to conceal your 
Parkinson's from
people?
24. Avoided situations which involve eating 
or drinking in public?
25. Felt embarrassed in public due to 
having Parkinson's disease?
26. Felt worried by other people's reaction 
to you?
27. Had problems with your close personal 
relationships?
28. Lacked support in the ways you need 
from your spouse or partner?
If you do not have a spouse or partner tick here
29.Lacked support in the ways you need 
from your family or close friends?
Never Occasionally Sometimes Often Always
or cannot 
do at all
D D a QD
D Q D D D
D Q o D O
D Q o QD
D Q n D D
D QQ
D Q o D D
D Q Ll3 D □3
O O □3 Q □3
D O D D □3
O □3 QD
D O □3 D □3
D O □3 D □3
D □3 Q □3
D Q D O□3
D □. □3 D D
Please check that you have ticked one box for each question before going on to the next page. 
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Please tick one box for each question
Due to having Parkinson's disease, 
how often during the last month 
have you....
Never Occasionally Sometimes Often Always
3 0 . U n e x p e c ted ly  fallen  a s le e p  
during th e d ay? D Q Q Q
31 . H ad p ro b lem s with your  
con cen tra tion , e .g . w h en  reading or 
w atch ing  TV?
D Q D D
32 . Felt your m em ory  w a s  bad? a Q
33 . Had d is tress in g  d rea m s or 
h allu cin ations? D Q Q □3
3 4 . H ad difficulty with your s p e e c h ? D D Q Q□3
3 5 . Felt u n a b le  to co m m u n ica te  with 
p e o p le  properly? D Q D □3
36 . Felt ignored  by p eo p le? D Q □3 Q□3
3 7 . H ad painful m u sc le  cram p s or 
s p a s m s ? D O □3 Q□3
38 . H ad a c h e s  an d  p ains in your 
joints or b od y? D D □3 Q□3
39 . Felt u n p lea sa n tly  hot or co ld? D O □3 Q□3
Please check that you have ticked one box for each question.
Thank you for completing the PDQ 39 questionnaire
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PATIENT DIARY
Please put an X in the correct box for every half-hour period, using the term that best 
describes your condition during the last few minutes of that half-hour. Only one X should be 
in each half-hour period. Please fill in every day for three days.
DAY 1
Date completed:
le (m orning) 6.00 6.30 7.00 7.30 8.00 8.30 9.00 9.30 10.00 10.30 11.00 11.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
:ial off
off
sep
ie  (afternoon) 12.00 12.30 13.00 13.30 14.00 14.30 15.00 15.30 16.00 16.30 17.00 17.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
:ial off
off
sep
ie (evening) 18.00 18.30 19.00 19.30 20.00 20.30 21.00 21.30 22.00 22.30 23.00 23.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
:ial off
off
eep
le (night) 24.00 24.30 01.00 01.30 02.00 02.30 03.00 03.30 04.00 04.30 05.00 05.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
:ial off
off
eep
Cardiff
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PATIENT DIARY
Please put an X in the correct box for every half-hour period, using the term that best 
describes your condition during the last few minutes of that half-hour. Only one X should be 
in each half-hour period. Please fill in every day for three days.
DAY 2
Date completed:
ne (morning) 6.00 6.30 7.00 7.30 8.00 8.30 9.00 9.30 10.00 10.30 11.00 11.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
rial off
off
eep
ne (afternoon) 12.00 12.30 13.00 13.30 14.00 14.30 15.00 15.30 16.00 16.30 17.00 17.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
lial off
loff
eep
ne (evening) 18.00 18.30 19.00 19.30 20.00 20.30 21.00 21.30 22.00 22.30 23.00 23.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
:ial off
off
eep
ne (night) 24.00 24.30 01.00 01.30 02.00 02.30 03.00 03.30 04.00 04.30 05.00 05.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
ial off
off
nep
C a r d if f
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PATIENT DIARY
Please put an X in the correct box for every half-hour period, using the term that best 
describes your condition during the last few minutes of that half-hour. Only one X  should be 
in each half-hour period. Please fill in every day for three days.
DAY 3
Date completed:
ie (morning) 6.00 6.30 7.00 7.30 8.00 8.30 9.00 9.30 10.00 10.30 11.00 11.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
ial off
off
jep
ie (afternoon) 12.00 12.30 13.00 13.30 14.00 14.30 15.00 15.30 16.00 16.30 17.00 17.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
ial off
off
iep
ie (evening) 18.00 18.30 19.00 19.30 20.00 20.30 21.00 21.30 22.00 22.30 23.00 23.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
ial off
off
>ep
>e (night) 24.00 24.30 01.00 01.30 02.00 02.30 03.00 03.30 04.00 04.30 05.00 05.30
with severe dyskinesia
with mild dyskinesia
without dyskinesia
ial off
off
ep
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QUESTIONNAIRE
UNIVERSITY OF BRISTOL
General Instructions
Thank you for agreeing to help us in our research. We assume that you have no further 
questions about the study. If you do, then please contact us (see contact details at the 
back). Your participation is entirely voluntary and you are free to withdraw at any time 
without giving any reason. If you complete and return this questionnaire, we assume that 
you have consented to us using this information for the purpose of research. If you do not 
wish to take part then please return the unanswered questionnaire.
All the information that you give us will be COMPLETELY CONFIDENTIAL and will not be 
seen by your doctor. Please answer ALL the questions to the best of your ability.
For most questions you simply need to tick a box or put a circle around a number.
Here are some questions which have already been filled in as an example:
Some questions will start with a statement and you will be asked to tick the appropriate box
For example, if you would probably visit your general practitioner by car then you would 
answer the following question like this:
Do you use your car to visit your general practitioner?
Definitely Probably Probably Definitely 
Yes Yes No No
□ 0  □ □
Some questions will require you to put a circle around the most appropriate number 
For example, if you find the appointment system at your general practice works well then 
you may answer the following question like this:
Do you find it relatively easy to arrange an appointment to see your general practitioner? 
Agree strongly 1 (2^) 3 4 5 6 7 Disagree strongly
Some questions will require you to write a response on a line
For example, if your age is 73 years then you would complete the following question as 
follows:
How old are you? 73 (years)
L H Q  S F 3 6  E p w o r th  v 4  2 0 .0 7 .0 7 2
Section A: Early life
We would like to start by asking you some questions about your early life. If you can’t 
remember the answer then don’t worry and simply put a X in the don’t know box.
1. When you were a baby
(a) Where were you born?
(b) How much did you weight when 
you were born? (if you don’t know 
leave this blank)
Home
□ .
lbs
(c) If you cannot recall your weight Below average 
were you told that you were □
Hospital
oz
Average
□.
Don’t know□
Above average
We would like you to think about where you lived for the first 20 years of your life in five 
year time periods (between birth until 5 years, between 6 to 10 years of age, between 11 to 
15 years of age, between 16 to 20 years of age). For each time period, we would like to 
know some characteristics of your home.
2. Was your main home from birth until 5 years
(If you lived in more than one home during this period then answer the question for the 
home that you stayed in for the majority of that time.)
(a) located in a City Town Village rural area□, □. a. □ «
(b) supplied with Mains Public Pump Well/ own pump Stream/River
water from □, □. a. □ 4
(c) was the toilet indoors outside (d) number of
bedrooms
in house
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3. Was your main home from 6 until 10 years
(If you lived in more than one home during this period then answer the question for the 
home that you stayed in for the majority of that time.)
(a) located in a
(b) supplied with 
water from
City□
Mains□
Town Village rural area
□, □, □.
Public Pump Well/ own pump Stream/River□ □ □.
(c) was the toilet indoors outside (d) number of 
bedrooms 
in house
4. Was your main home from 11 until 15 years
(If you lived in more than one home during this period then answer the question for the 
home that you stayed in for the majority of that time.)
(a) located in a
(b) supplied with 
water from
Cityn,
Mains
□,
rural area□Town Village□, □,
Public Pump Well/ own pump Stream/River
EL EL EL
(c) was the toilet indoors outside (d) number of 
bedrooms 
in house
5. Was your main home from 16 until 20 years
(If you lived in more than one home during this period then answer the question for the 
home that you stayed in for the majority of that time.)
(a) located in a City Town Village
□, □. □.
(b) supplied with Mains Public Pump Well/ own pump
water from □, □. □,
rural area□
eam/F□
(c) was the toilet indoors outside (d) number of
□ I-------1 bedroomsI | , in h o u se
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6. As a child (until the age of 15 years) did the home you lived in longest have:
Yes No
(a) bathroom?
Yes No
(b) hot water? ■ I 1 ■ I 2
Yes No
(c) your own bedroom? □ ,  □
7. (a) Did you live on a farm for the first twenty years of your life?
Yes No
□, □,
(b) If YES, how many years did you live on the farm years
8. (a) Did your father have a manual or non-manual job when you were a child?
□  1 ManualNon-manual
(b) Did your household have use of a car 
when you were a child?
Yes No Don’t Know□ □ □
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9. As a child did you play or have contact with any of the following animals 
(please tick one box for each row)
(a) Dog
never or rarely 
□ ,
monthly
□ .
weekly
□ ,
daily
□
(b) Cat
□ , □
(c) Bird (pigeon, budgie etc)
□ , a . □
(d) Rabbit/Hamster
□ , □ , □ 3
□
(e) Horse
□ , □ . □ 3 □
(f) Sheep
□ , □ , □ ,
□
(g) Chickens
□ , □ . □ , □
10 (a) Did you go to a nursery before starting school?
Yes No Don’t Know
10 (b) Did you go to day-school or boarding school for your primary school 
education?
Day-School Boarding school
□, □,
10 (c) Did you go to day-school or boarding school for your secondary school 
education?
Day-School Boarding school
□, □.
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Section B: Life style habits
12. (a) Have you ever smoked a cigarette, a cigar or a pipe?
Yes Non i—l
IF NO, PLEASE GO TO QUESTION 14 (a) AT THE TOP OF THE NEXT PAGE
(b) Do you smoke cigarettes at all nowadays?
(ONLY ANSWER THIS IF YOU HAVE TICKED THE YES BOX ABOVE)
Yes No
EL EL
IF NO, PLEASE GO TO QUESTION 13 (a) --------------------------------------
(c) About how many cigarettes a day do you usually smoke?
(ONLY ANSWER THIS IF CURRENT SMOKER)
cigarettes
(d) How old where you when you started smoking regularly?
years old
PLEASE GO TO QUESTION 14 (a) AT THE TOP OF THE NEXT PAGE
13. (a) How often did you smoke cigarettes in the past? * -------------------
(ONLY ANSWER THIS IF FORMER SMOKER) (Please tick one box only)
Regularly, at least Only Never really smoked, just
once a day occasionally tried them once or twice
□, □. □,
IF ONLY OCCASIONALLY OR NEVER REALLY SMOKED SKIP TO QUESTION 14 (a)
(b) About how many cigarettes a day did you regularly smoke?
Cigarettes
(c) How old where you when you started smoking regularly?
years old
(d) How old where you when you stopped smoking?
years old
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14. (a) Did your parents smoke when you were a child?
No one smoked Father Mother Both parents smoked
□, □, □. □.
(b) When you were at school did your best friends smoke?
Yes No
(c) Did your best friends smoke at the time you took up your first job or soon after 
you left school?
Yes No
(d) Did your first long term partner or spouse smoke?
Yes No
We would like to know how much alcohol you used to drink when you 
were between 20 to 29 years of age. If your drinking habit changed during 
this ten year period, please answer the questions for the pattern that was 
the most common over this period.
15. (a) How often would you drink BEER, LAGER, STOUT or CIDER when 
you were in your twenties? (Please tick one box only)
Every day | | 1 5 or 6 days a week | |
3 or 4 days a week Once or twice a week □ .
Once or twice a 
month □ ,
Once every couple of 
months
Once or twice a year □ , Not at all CO
□
15. (b) When you did have a drink of BEER, LAGER, STOUT, CIDER in your 
twenties, how many pints would you usually drink at one sitting?
(Please place a number in the box) |
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16. (a) How often would you drink SPIRITS or LIQUERS when you were in 
your twenties? (Please tick one box only)
Every day 
3 or 4 days a week
Once or twice a 
month
Once or twice a year
□□
□
□
5 or 6 days a week 
Once or twice a week
Once every couple of 
months
Not at all
□□
□
□
16. (b) When you did have a drink of SPIRITS or LIQUERS how many pub 
measures would you usually drink at one sitting?
(Please place a number in the box)
17. (a) How often have you had a drink of SHERRY, MARTINI, PORT, or 
VERMOUTH when you were in your twenties? (Please tick one box only)
Every day 
3 or 4 days a week
Once or twice a 
month
Once or twice a year
□□
□
□
5 or 6 days a week 
Once or twice a week
Once every couple of 
months
Not at all
□□
□
□
17. (b) When you did have a drink of SHERRY, MARTINI, PORT, or VERMOUTH in 
your twenties, how many small glasses would you usually drink at one sitting?
(Please place a number in the box)
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18. (a) How often have you had a drink of WINE or CHAMPAGNE when you were 
in your twenties? (Please tick one box only)
Every day 
3 or 4 days a week
Once or twice a 
month
Once or twice a year
□
n
□
□
5 or 6 days a week 
Once or twice a week
Once every couple of 
months
Not at all
□□
□
□
18. (b) When you did have a drink of WINE or CHAMPAGNE in your twenties, how 
many glasses would you usually drink at one sitting:
(Please place a number in the box)
PHYSICAL ACTIVITY
19. (a) When you were at school were you in any school sports teams
Yes No
□, □.
If YES, which of the following sports did you do?
(b) Swimming
Yes
□,
No
□. (c) Football
Yes
□,
No
□
(d) Rugby □, □. (e) Cricket □, □
(f) Rowing □, □. (g) Boxing □, □
(h) Athletics □, □. (i) Tennis □, □
(j) Other □, □.
(k) IF OTHER, PLEASE SPECIFY SPORT
20. (a) After you left school did you participate in any sports club
Yes No
□, □.
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20. (b) At the age of 20, which of the following best described your level of 
phsyical activity? Please also consider the amount of physical activity your job 
involved at that time. (Please tick one box only)
Very physically active Fairly physically active
Not very physically active I------1 Not at all physically----------- |---- 1
I___ I ,  active I I 4
Section C: For women only
21. The following questions are for women only so if you are a man please leave 
these questions blank and go to Section D below
(a) At what age did you start your periods?
(b) Have your periods stopped?
(c) If they have stopped, at what age did they 
stop (If not stopped then leave blank)
(d) Did your periods stop naturally or because 
of an operation?
(e) Have you ever taken the oral 
contraceptive pill?
(f) For how long have you taken it 
(whether you have stopped or are still 
taking it)
(g) Have you ever taken hormone 
replacement therapy?
(h) For how long have you taken it?
(whether you have stopped or are still 
taking it)
(i) How many pregnancies, including 
stillbirths and miscarriages have you had?
years
Yes□
years
Naturally
□,
Yes
□,
years
Yes□
years
No□
Operation
□.
No□.
not applicable□
No□.
not applicable□
give number
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Section D: Occupational history
The following section covers your employment history 
22 (a) Are you currently:
Employed
Retired
Full-time student 
Doing voluntary work
□□
□□
At home doing housework / caring 
for family
Unemployed seeking work
Unemployed through 
sickness/disability
□□
□
23. (a) What is/was your main job? If retired or unemployed please describe your 
main previous employment:
Job title:____________________________________________________________________
23. (b) Please describe the main things you do/did in this job:
23. (c) Which one of the following best describes your position in your current or last
job (tick ONE box only)
Self employed (25 or more I I Manager (less than I I
employees) I__ 11 25 employees) I___15
Self employ 
employees)
ed (less than 25 [ ~ ] 2 Supervjsor Q
Self employed (no employees) □  3 Employee □
Manager (more than 25 employees)
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23. (d) Would you describe this job as non-manual or manual?
Non-manual I------1 Manual□, Ma“ai □,
24. Over your career, have you ever worked on a regular basis (once a week or more) 
with any of the following:
(a) Lead
Yes
□,
No
□.
If YES for how many years?
years
(b) Copper □, □. years
(c) Manganese □, a years
(d) Iron □, □. years
(e) Wood □, □. years
(f) Chemical Solvents □, □. years
(g) Paint strippers □, □. years
(h) Fertilizers □, □. years
(i) Pesticides □, □. years
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Section E: Past medical history and general well being
25. Have vou ever been told bv a doctor that vou have, or have had. anv of the 
following?
Yes No
(a) Angina □ □.
(b) Heart Failure (shortness of breath due to 
heart problems) □ □.
(c) Stroke / or mini-stroke (TIA -  transient 
ischaemic attack) □ □.
(d) Heart attack (coronary thrombosis, 
myocardial infarction) □ □.
(e) Diabetes □ □.
(f) High cholesterol level □ □.
(g) High blood pressure □ □.
(h) Lung Cancer □ □.
(i) Bowel / Colon Cancer □ □.
(j) Prostate Cancer □ □.
(k) Breast Cancer □ □.
(I) Depression □ □.
(m) Asthma □ □.
(n) Chronic Bronchitis □ □.
(o) Emphysema □ □.
(p) Other Illness -please specify: □ □.
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26. Have you ever had an injury to the head that resulted in any of the following 
(If more than one episode than enter the age the first time it occurred)
(a) Seizure or fit
(c) Dizziness
(e) Loss of consciousness
(g) Attendance at the Accident 
and Emergency Dept
(i) Admission to hospital
Yes
□ ,
No
□ , (b)
Age at event
years
□ , □ . (d) years
□ , □ . (f) years
□ , □ . (h) years
□ , □ . (i) years
The following questions ask for your views about your health and how you feel about 
life in general. If you are unsure about how to answer any question, try and think 
about your overall health and give the best answer you can. Do not spend too much 
time answering, as your immediate response is likely to be the most accurate.
27. (a) In general, would you say your health is: (Please tick one box)
Excellent
Good
Poor
□□
□
Very good □  
□Fair
(b) Compared to 3 months ago, how would you rate your health in general now?
(Please tick one box)
Much better than 3 months ago 
Somewhat better than 3 months ago
About the same 
Somewhat worse now than 3 months ago 
Much worse now than 3 months ago
□
□□
□
□
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28. The following questions are about activities you might do during a typical day. 
Does your health limit you in these activities? If so, how much?
(Please tick one box on each line)
a) Vigorous activities, such as running, lifting
heavy objects, participating in strenuous
sports
b) Moderate activities, such as moving a table,
pushing a vacuum, bowling or playing golf
c)
d)
e)
f)
9)
h)
i) 
i)
Lifting or carrying groceries 
Climbing several flights of stairs 
Climbing one flight of stairs 
Bending kneeling or stooping 
Walking more than a mile 
Walking half a mile 
Walking 100 yards 
Bathing and dressing yourself
Yes, 
limited a
Yes, 
limited a
No, not 
limited at
lotD littleQ allQ
D □ 2 Q
D D DD □ 2
D □ 2 Q
D D D
D □ 2 QD □>
D □»D □ 2
29. (a) During the past 2 weeks, how much time have you had any of the following 
problems with your work or other regular daily activities as a result of your physical 
health?
(Please tick one box) on each line
a) Cut down on the amount of time you 
spent on work or other activities
b) Accomplished less than you would 
like
c) Were limited in the kind of work or 
other activities
d) Had difficulty performing the work or 
other activities (eg it took more effort)
All of Most Some A little None
the of the of the of the of the
time time time time timeD EH2 O D D
D Q D D O
D Q O D D
EH2 □» EH* EH"
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29. (b) During the past 2 weeks, how much time have you had any of the following 
problems with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)?
(Please tick one box) on each line
a) Cut down on the amount of time 
you spent on work or other activities
b) Accomplished less than you would 
like
c) Didn't do work or other activities as 
carefully as usual
All of 
the
Most 
of the
Some 
of the
A little 
of the
None 
of the
time time time time timeDa DDQ
Da QOQ
Da QOQ
29 (c) During the past 2 weeks, to what extent have your physical health or emotional 
problems interfered with your normal social activities with family, neighbours or 
groups?
(Please tick one box)
Not at all D
Slightly Q
Moderately D
Quite a bit O
Extremely
29. (d) How much bodily pain have you had during the past 2 weeks ?
(Please tick one box)
None D
Very mild D
Mild O
Moderate D
Severe D
Very severe O
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29 (e) During the past 2 weeks, how much did pain interfere with your normal work 
(including both outside the home and housework)?
(Please tick one box)
Not at all
Slightly o
Moderately o
Quite a bit Q
Extremely Q
30. These questions are about how you feel and how things have been with you 
during the past 2 weeks. For each question please give one answer that comes 
closest to the way you have been feeling.
(Please tick one box) on each line
How much time during the All of 
last 2 weeks:
a) Did you feel full of life?
b) Have you been a very 
nervous person?
c) Have you felt so down in the 
dumps that nothing would 
cheer you up?
d) Have you felt calm and 
peaceful?
e) Did you have a lot of 
energy?
f) Have you felt downhearted 
and low?
g) Did you feel worn out?
h) Have you been a happy 
person?
i) Did you feel tired?
the
Most 
of the
A good 
bit of
Some 
of the
A little 
of the
None 
of the
time
D
time
o
the time
o
time
o
time
o
time
D
Do Qo o
QQ
DQQd o
DQO qQ
DOOo o
DDO o
Da Qo
o o
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31. During the past 2 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting friends, 
relatives etc.).
(Please tick one box)
All of the time D
Most of the time O
Some of the time Q
A little of the time Q
None of the time D
32. How TRUE or FALSE is each of the following statements for you?
(Please tick one box on each line)
Definitely Mostly Not Mostly Definitely
true true sure false false
a) I seem to get ill more 
easily than other 
people D a Do
b) I am as healthy as 
anybody I know D o OD
c) I expect my health to 
get worse D a OD
d) My health is excellent Q Q
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33. Please use the scoring system below to rate how likely you are in each of the 
following situations to fall off to sleep. This should refer to how you have usually felt 
recently.
SITUATION CHANCE OF DOZING OFF
NO
chance
SLIGHT
chance
MODERATE
chance
HIGH
chance
(a) Sitting and reading D o CO□ Q
(b) Watching TV D D Q
(c) Sitting inactive in a public place 
e.g. theatre, meeting D C\J□ Q O
(d) As a passenger in a car for an 
hour without a break D C\l□ D
(e) Lying down to rest in the 
afternoon D CM□ □»
(f) Sitting and talking to someone D o CO□ O
(g) Sitting quietly after lunch (when 
you’ve had no alcohol) D Q CO□ Q
(h) In a car, whilst stopped for a few 
minutes in traffic Q
Section F: Family History
Yes No
34. (a) Are your parents related in I--- 1 I---- 1
anyway? |__| |__ |
34 (b) If YES in what way e.g. first cousin
35 Where was your father born?
(a) Town:________________________ (b) County:.
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36 Where was your mother born?
(a) Town:. (b) County:.
37. The following questions help us to determine your family size
(a) How many brothers were there in 
your family (include half-brothers if 
appropriate)
no. of brothers
(b) How many sisters were there in 
your family (include half-sisters if 
appropriate)
no. of sisters
(c) How many of your brothers and 
sisters were older than you? (If you are 
the first born then please enter
the number 0)
(d) How many brothers did your 
mother have in her family (include 
half-brothers if appropriate)
no. of older siblings
no. of maternal brothers
(e) How many sisters did your mother 
have in her family (include half-sisters 
if appropriate)
no. of maternal sisters
(f) How many brothers did your father 
have in his family (include half-brothers 
if appropriate)
no. of paternal brothers
(g) How many sisters did your father 
have in his family (include half-sisters if 
appropriate)
no. of paternal sisters
L H Q  S F 3 6  E p w o r th  v 4  2 0 .0 7 .0 7 21
38. Did any member of your family (parents, brothers, sisters, uncles or aunts) 
ever have a tremor of their hands which was present when their hands were 
resting? (Record the number of any such relative(s) in the relevant box below, 
for example if 1 maternal uncle had a tremor you should enter the number 1 in 
that box; if none of your maternal uncles had a tremor, please enter 0.)
(a) Father □ (b) Mother □
(c) Brothers □ (d) Sisters □
(e) Maternal Uncles □ (f) Maternal Aunts □
(g) Paternal Uncles □ (h) Paternal Aunts □
39. Did any member of your family (parents, brothers, sisters, uncles or aunts) 
have a diagnosis of Parkinson’s disease? (Record the number of any such 
relative(s) in the relevant box below, for example if 1 maternal uncle had 
Parkinson’s disease you should enter the number 1 in that box; if none of your 
maternal uncles had Parkinson’s disease, please enter 0.)
(a) Father □ (b) Mother □
(c) Brothers □ (d) Sisters □
(e) Maternal Uncles □ (f) Maternal Aunts □
(g) Paternal Uncles □ (h) Paternal Aunts □
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Section G: Further background information
40. Are you? Male □ Female □
41. Date of birth : _____ (day) / (month) / (year)
42. Where were you born?
Wales D South Africa
England □ 3 Middle East I I10
Scotland □ 3 India □ «
N. Ireland D Pakistan I I12
Republic of 
Ireland □ 3 Bangladesh I I13
Caribbean □ 3 Far East I I14
East Africa o Other I I15
West Africa
43. (b) If other please specify:
44. (a) What is your religion, if any? (please tick the most appropriate answer) 
Christian (Church of England,
Catholic, Protestant, and 
other denominations)
Buddhist
Hindu
Muslim
Q
Q
n.
D
Sikh
Jewish
None (atheist/agnostic)
Other
□
□
□
□
44. (b) If other please specify:.
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45. Please tick the box that most accurately describes your ethnic origin 
(A) White (B) Black or Black British
British
Welsh
Irish
Any other White 
background
□*
Caribbean
African
Any other Black background
please state.
□
□
□
please state.
(C) Mixed
White and Black 
Caribbean
White and Asian
White and Black 
African
Other mixed 
background
D
□
(D) Asian or Asian British
Indian
Bangladeshi
Pakistani
10 Other Asian background
□
□
□
12
13
14
please state. please state.
(E) Chinese or other ethnic group
Chinese □  '3
□Other 16
Please state
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46. (a) How old were you when you left school? ________________ years
46. (b) Have you had any full or part time further or higher education since you left 
school?
□  1 NO EDYES
If there are any other comments you would like to make please write them here:
Name of the participant 
Address ____________
Postcode__________________________________________________
Thank you for filling in this questionnaire
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Many clinicians view age at onset as an im portant determinant of clinical phenotype in 
Parkinson’s disease (PD) and this has been reinforced by the identification of Men- 
delian genes that account for some cases of younger onset PD. A systematic review of 
OVID Medline for articles relevant to the relationship between clinical features and 
age at onset in PD published in English between 1950-2007 was performed. There are 
very few prospective community based studies which focus on the relationship 
between age at onset and the features o f PD and a variety of case definitions are used 
in the literature. Most studies o f young onset PD are based on specialist clinic referral 
series. The available evidence suggests that PD  patients with a younger age at onset 
have: (i) a slower disease progression, (ii) an increased rate of dystonia at onset and 
during treatment, (iii) a lower rate of dementia and (iv) an increased rate of dyski­
nesias in response to l-DOPA  treatment. The majority of the available studies do not 
report patient genotype data, but it is probably that the clinical heterogeneity of PD 
will be further refined with detailed clinico-genetic studies.
Introduction
Historically, Parkinson’s disease (PD) has been defined 
by the clinical features of pathologically diagnosed 
Lewy body disease with loss of nigro-striatal neurones 
and the presence of alpha-synuclein containing Lewy 
bodies [1]. The risk of developing PD is age dependant, 
and affects 1-2%  o f the population over 65 years [2,3]. 
The relationship between PD and age suggests that 
cumulative exposure to an environmental factor, and/or 
an age dependant biological factor, determines its 
development. The Kaiser Permanente study identified 
an incidence of 1.5/100 000 person years in the under- 
50s, com pared with 13.4 per 100 000 overall, and in a 
prevalent PD population 0.9% of patients developed 
PD before the age of 40, and 5.4% before the age of 50 
[2,4,5], The identification of Mendelian genes which can 
cause typical parkinsonism with young onset and 
reports of pathological heterogeneity raise the possibil­
ity that young onset PD (YOPD) may be different to late 
onset PD (LOPD) [6-8]. If this is the case then the advice 
and treatm ent given to patients, in particular future 
disease modifying therapies may need to be tailored 
according to the age of onset and related parkinsonism/ 
PD sub-type. The disease entity of PD has been defined 
by the presence of Lewy bodies, but only a minority of 
patients go on to have post-mortem analysis. Lewy body 
pathology is rare in patients with parkin m utations
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having been reported in 2/6 cases [9-14], A brain bank 
series of 12 YOPD patients (onset before 40 years) and 
24 LOPD patients (onset after 70 years) showed no 
difference in the occurrence of Lewy body pathology 
[15], and it is not known whether YOPD patients as a 
whole frequently have non-Lewy body pathology.
Here, we review the evidence for the separation of PD 
and parkinsonism based on age at onset specifically 
looking at the following clinical questions: (i) do YOPD 
patients have slower or faster disease progression than 
LOPD patients, (ii) do YOPD patients have a different 
rate of trem or at presentation or during the disease 
course, (iii) do YOPD patients have an increase in 
dystonia, (iv) do YOPD patients have an increase in 
susceptibility to dyskinesias and (v) do YO PD  patients 
have a lower or higher rate of dementia. We review the 
evidence relating to these issues and identify some o f the 
problems in interpreting the available data.
Methods
Search strategy
This review is based on a literature search of the English 
language Ovid Medline databases spanning 1950-2007 
using: PD, parkinsonian syndrome, parkinsonism, 
paralysis agitans, and akinetic-rigid syndrome, com ­
bined with young onset, early onset, age at onset and 
juvenile onset. We have also used the authors’ personal 
databases and hand searching of references. We used 
the search terms ‘Parkinson’s disease’, ‘parkinsonian 
syndrome’, ‘parkinsonism ’, ‘paralysis agitans’, and
© 2009 The Author(s)
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‘akinetic-rigid syndrome’, limited articles to the English 
language and combined with the search terms ‘young 
onset’, ‘early onset’, ‘age at onset’ and ‘juvenile onset’. 
This yielded 1526 articles. The abstracts of these were 
reviewed for relevance to the questions set in this 
review. Including both review articles and original data 
papers led to 376 articles, potentially relevant to this 
review. Papers including data relevant to the selected 
research questions were analysed including analysis of 
confidence intervals and significance of reported dif­
ferences between groups.
Case definition
The initial difficulty in reviewing YOPD is case defini­
tion. The terms juvenile, young and early onset have all 
been used to describe YOPD with inconsistent defini­
tions. [16-21]. In 1987, Quinn and colleagues suggested 
that ‘juvenile onset parkinsonism’ should be reserved 
for cases with onset before the age of 21, and ‘young 
onset’ for patients with onset between 21 and 40 years 
[22,23]. More recent papers, including those reviewing 
genetic factors, have used the term early onset to 
describe PD occurring before the age of 45. Other have 
used cut-offs of up to 70 years to define clinical differ­
ences. Since many different ages of onset have been used 
to define YOPD, in this review we use YOPD to indi­
cate the younger onset comparative group and define 
the age at onset where possible.
Results
Disease progression and quality of life
Variations in measures of disease progression make 
direct comparison between studies difficult (Tables SI 
and S2). The majority of studies are retrospective 
[24,25]. Two methods have been used -  comparing 
progression in two groups defined by age at onset 
[24,26,27], or comparing mean age at onset in groups 
defined by rate of progression [24,26,28-30]. The Syd­
ney Multi-Centre Study group concluded that age at 
onset was the best predictor of deterioration in PD over 
5 years (younger onset, slower progression) [24,25]. In 
the DATATOP study, a retrospective estimate of pro­
gression showed more rapid progression in LOPD 
(onset at or above age 70) than YOPD (onset at or 
before age 40) [26], Three further studies have con­
firmed that YOPD has a slower disease progression 
(Tables SI and S2) [27-29]. Conflicting views have been 
reported, using different methods. In a study of 60 
YOPD (onset <40 years) and 60 LOPD (onset 42- 
68 years) patients estimating disease progression as the 
interval from first symptom onset to the development of
a bilateral clinical picture, 60% of the YOPD group 
developed bilateral involvement within 12 months of 
onset compared with 5% of the LOPD group [16]. This 
may reflect earlier bilateral involvement in YOPD but 
the relatively short follow-up period in this study means 
that it is difficult to generalize this finding. The majority 
of studies of YOPD are based on specialist clinic case 
ascertainment; therefore a further possible confounding 
factor is case referral bias. Elderly patients with indo­
lent disease may be treated by their non-specialist 
family practitioners, rather than being referred to 
specialist clinics, although this will vary in different 
health care systems. On balance, the majority of the 
evidence from retrospective clinic based series supports 
a slower disease progression in YOPD as compared 
with LOPD.
Whilst slower disease progression may be a source of 
some reassurance for younger onset patients, the rela­
tive effect o f PD on mortality and absolute effect on life 
expectancy is more marked in YOPD. A previous 
population-based cohort study of patients with par­
kinsonism noted that the standardized mortality ratio 
for cases aged 40-50 years at onset was 3.9 (almost four 
times that o f the general population) compared with 2.0 
for cases aged between 75 and 84 years [31]. The 
interpretation of this figure requires caution however, 
as it may include patients with multiple system atrophy 
and progressive supranuclear palsy [32]. A recent liter­
ature review [33] estimated that the life expectancy of 
patients with onset between 25 and 39 years was 
38 years compared with 49 years in the general popu­
lation resulting in a relative loss of 22% but in absolute 
terms 11 years of life. The equivalent figures for cases 
with onset older than 64 years was 5 compared with 
9 years in the general population, which is 44% in rel­
ative terms but a 4-year loss of survival in absolute 
terms. There may also be a differential impact on 
quality of life in YOPD. A survey of YOPD and LOPD 
patients indicates that despite similar disease severity, 
YOPD patients have poorer quality of life and are 
much more probably to retire early [34], Thus, young 
onset disease is associated with more years of worsened 
quality of life and late onset disease, in contrast, shows 
a relative ‘compression of morbidity’. Evidence from 
preference studies suggest that the general public 
rate past years of ill-health and young age at onset 
as more im portant in terms of allocating treatments 
[35].
Parkinsonian symptoms at presentation and dominant 
motor phenotype
Parkinson’s disease can be tremor-dominant or pos­
tural instability with gait disorder dom inant [26].
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Several studies have associated m otor phenotype with 
rate of progression. Trem or dominance both at pre­
sentation and after 2-7 years from onset are associ­
ated with slower progression [26,36-41]. It has been 
suggested that ‘benign tremulous parkinsonism’ is a 
separate clinical entity with prominent tremor not 
responding well to L-dopa, and minimal progression 
of other aspects o f parkinsonism [42]. There is no 
consensus on trem or frequency in YOPD having been 
reported less, more and equally as frequently as 
LOPD (Table 1) [15,16,24,37,43-46], YOPD patients 
are less probably to have gait disturbance as an early 
symptom (Table S3) [15,44,46]. This may reflect the 
confounding effects of age and co-morbidity. Obser­
vations may also be biased due to referral and diag­
nosis -  the presence of trem or is probably to have a 
significant effect on management by non-specialists. A 
community based study in the UK showed that 16% 
of patients who developed tremor after the age of 55, 
diagnosed in the community with non-parkinsonian 
trem or, met the criteria for probable PD [47]. Y oun­
ger onset patients are more probably to be referred to 
specialists, so tremulous PD may be underrepresented 
in the later onset group because of misdiagnosis in 
prim ary care, although this will depend on local 
health care systems. The available data suggest that 
patients with YOPD have less gait difficulty early in 
the disease course than LOPD patients but there is no 
clear conclusion regarding the frequency of trem or 
dominant disease.
Dystonia
Dystonia can occur either pre-treatment, or on treat­
ment as peak-dose or off-period m otor features [48]. 
Limb dystonia related to exercise can be a striking 
feature of YOPD and has been reported to be frequent 
in Japanese and other patients with autosomal recessive 
juvenile parkinsonism subsequently found to have 
parkin mutations [49-52], Dystonia at onset is pre­
sumably an alternative manifestation of dopamine 
deficiency in YOPD and occurs with a frequency of 
between 14% and 57% (Table 2). Painful off period 
dystonia, particularly affecting the feet and ankles is 
also more common in patients with YOPD occurring at 
a rate of 30-59% during treatment [15,23].
Dementia and neuropsychiatric features
Cognitive impairment and neuro-psychiatric side effects 
to medication are less frequent in YOPD. A large body 
of evidence suggests LOPD patients are at a higher risk 
of dementia [26,37,39,53-56], and that the incidence of 
dementia in YOPD aged under 65 years is negligible
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[23,24,26,55,57-63]. However, there may be evidence of 
subtle cognitive involvement in YOPD [55,57]. In the 
CA M PA IG N  study of patients defined by the UK 
Brain Bank criteria, older age at onset is a risk factor 
for developing cognitive impairment, although in this 
study only one patient had disease onset before 40 years 
[64]. Studies comparing the rates of dementia in PD 
patients with age matched non-PD controls suggest that 
patients with PD have significantly higher risk of 
developing dementia, and age at onset of PD was 
reported as a determinant of developing dementia in 
these patients [65-68], In a population based study of 
PD the percentage o f patients with dementia increased 
with age but the prevalent PD cases with and without 
dementia did not differ in disease duration suggesting 
that age rather than disease duration influences the 
prevalence o f dementia [60].
Treatment response and related complications
It has been widely reported that YOPD patients have 
an excellent response to l-DOPA  treatment, marred 
by the early development of treatment related 
dyskinesias and m otor complications (Table 3) 
[15,16,18,23,24,44,53,54,69]. Studies comparing differ­
ences in treatm ent response are confounded by delay 
in l-DOPA  treatm ent in YOPD patients, differences 
in total l-DOPA  dosage and the use of concurrent 
dopamine agonists. In an attempt to overcome this 
Kostic and colleagues carried out a carefully designed 
study of YOPD (onset between 21 and 40 years) and 
LOPD (onset > 40 years); matched for gender, dura­
tion of disease, mode of onset, Hoehn and Yahr stage, 
duration of treatm ent and dose of l-DOPA  [44], 
Twenty-five patients were identified in each group. 
This small study showed a significantly higher fre­
quency of both dyskinesias and response fluctuations 
in the YOPD group. A further population based study 
showed a higher 5-year dyskinesia incidence with 
younger age at onset (50% in those with onset 
<60 years, and 16% in those with onset >70 years) 
but did not include any patients with onset before age 
40 years [70]. Clinical series data suggest that patients 
with YOPD develop dyskinesias earlier than LOPD 
patients but the impact on quality of life, and age 
thresholds are not clearly defined.
Discussion
M ost PD studies report current age rather than age at 
onset, involve small numbers of patients, include 
highly selected specialty clinic based populations and 
are subject to variation in methodology which causes 
difficulty in comparison across studies and introduces
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Table 3 Dyskinesia and motor fluctuations
n (YOPD/ YOPD Source of Dyskinesia Dyskinesia Fluctuations Fluctuations
Study LOPD) age (years) patients YOPD LOPD YOPD LOPD
Yokoshi [20] 32/— <40 32%
Quinn [23] 56/- <40 Clinic 55% at 1 year 
100% at 6 years
Perderzoli [54] Increased
Tanner [75] 91%
Gibb [15] 46/52 <45 Clinic 91%
Gershanik [18] 75%
Kostic [44] 25/25 72% at 3 years* 28% at 3 years 64% at 3 years** 28% at 3 years
Hely [24] 90/33 < 70 Sydney 
Multicentre 
trial (referral)
No differences
Barbeau [76] 32 <40 42% at 2 years 35% at 2 years
Kumar [70] 5 / - <50 Population 40% at 5 years 28% at 5 years
YOPD, young onset Parkinson’s disease; LOPD, later onset Parkinson’s disease. 
*P-value for difference = 0.002.
**P-value for difference = 0.01.
potential biases. Variation in methodology include 
inclusion/diagnostic criteria, age definitions and dis­
ability measures. The available evidence suggests that 
patients with YOPD have (i) a slower disease pro­
gression, (ii) more frequent dystonia at onset, (iii) 
more frequent early dyskinesias in response to 
l-DOPA  treatment, (iv) less frequent gait disturbance 
and (v) less frequent dementia. Amongst these differ­
ences the dystonia at onset is often seen in YOPD 
(4-57%  of cases) and is uncommon in LOPD. 
Dyskinesias as an early complication of l-DOPA  
therapy are appreciably more common in YOPD with 
an approximate doubling of the risk of dyskinesias at 
between 3 and 5 years. YOPD is probably to comprise 
a heterogeneous patient group, related to genetic 
aetiology. Approximately 9-20% of early onset PD 
patients have mutations in the parkin gene with a 
further 1% of cases related to mutations in the 
PINK1 and DJ-1 genes. M utation frequencies vary 
with population ascertainment and age at onset 
[8,50,71-74] . Some YOPD patients may have a dif­
ferent disease based on genetic aetiology and specific 
pathology but this has not been established in a 
community based, pathologically confirmed sample. 
There is currently little direct evidence to support 
patho-physiological difference between ‘non-genetic’ 
YOPD and LOPD. It is probably that the definition 
of further genetic risk factors and biomarkers will lead 
to a fuller definition of the heterogeneity of PD. 
Ultimately this should lead to a more directly patient- 
centred approach to PD management, with specific 
advice on familial risk, prognosis, likelihood of disease 
related complications and appropriate disease modi­
fying therapies based on genetic background and age 
at onset.
Supporting Information
Additional Supporting Information may be found in 
the online version of this article:
Table SI. Disease Progression YOPD versus LOPD. 
Table S2. Disease progression -  Other analysis 
methods.
Please note: Wiley-Blackwell are not responsible for the 
content or functionality of any supporting materials 
supplied by the authors. Any queries (other than 
missing material) should be directed to the corre­
sponding author for the article.
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Shor t  report
Prevalence and age of onset of Parkinson's disease in 
Cardiff: a community based cross sectional study 
and meta-analysis
M M W ickremaratchi,1 D Perera,1 C O'Loghlen,1 D Sastry,2 E M organ,2 A J o n e s ,2 
P Edwards,3 N P Robertson,1 C Butler,4 H R Morris,1 Y Ben-Shlom o5
ABSTRACT
Background: Previous prevalence stud ies of Parkinson's 
d ise a se  (PD) in the  UK have spanned a 40 year period and 
have predom inantly been in the  North of the  country. 
T hese have p resen ted  ra te s  by current ag e  but have not 
exam ined this by age  a t d isease  onset.
Methods: A com m unity based  prevalence study w as  
undertaken w hich a ttem p ted  to  identify all clinically 
diagnosed c a se s  of PD from primary and secondary  care  
for th e  city of Cardiff, W ales, UK. A m eta-analysis of all 
p as t stud ies in the  UK, including our own, w as  also 
undertaken.
Results: Overall, 380 c a se s  of PD w ere  identified from  a 
population of 292 637 residents, giving a crude pre­
valence rate  of 130 per 100 000 (95% Cl 117 to 144) and 
an ag e  standard ised  rate of 142 per 100 000 (95% Cl 
128 156), standard ised  to  the 1997 England and W ales 
population. Our prevalence ra tes  w ere  very similar to the  
w eighted  average  of previous UK stu d ies although there  
w a s  evidence of b e tw een  study heterogeneity  
(p =  0 .0006). 5.4% and 31.2%  of prevalent PD patien ts 
had their d isease  onset below  th e  ag e  of 50 or 65 years, 
respectively.
Conclusions: The data  su g g est th a t th e re  are  no major 
geographical variations in th e  prevalence of PD in th e  UK 
and th a t th e  ag e  ad justed  prevalence rate  has rem ained 
relatively stab le  over the  p as t 40 years. Although PD risk 
is far g rea ter in older sub jects, patien ts w ith young onse t 
are not th a t uncom m on in the  com m unity, and health and 
social care provision should reflect their needs.
Previous epidemiological studies in the UK reported 
the crude prevalence of Parkinson's disease (PD) as 
113-164 per 100 000 persons.1-8 PD prevalence 
studies usually present data by current age and 
ignore age at disease onset. While young onset PD 
(YOPD) is rare, with an incidence of approximately 
7 per million per year under the age of 50 years,9 
YOPD cases may be more common among all 
prevalent cases because of increased survival. We 
have completed a community based prevalence 
study of PD in Cardiff, South Wales, UK. The aim 
of this study was to specifically examine what 
proportion of prevalent cases had young onset 
disease, to study how age at onset influences source 
of health care and undertake a meta-analysis of all 
published UK prevalence studies to examine if there 
are geographical and temporal variations.
METHODS
We identified potential PD cases from primary care 
by undertaking two standardised searches using
diagnostic Read Code F12 and sub-codes and any 
of the dopaminergic group of drugs used in PD (see 
appendix 1 online), excluding bromocriptine and 
amantadine because of their frequent use in 
conditions other than PD. After removing dupli­
cates, a unique list of general practitioner case 
records were screened (MMW). Cases were defined 
as prevalent if they (a) were alive and symptomatic 
during the period January to December 2006, (b) 
were registered with a participating practice, (c) 
had been diagnosed as having PD and (d) met the 
Queen Square Brain Bank criteria10 at clinic 
assessment or if the information held in the clinical 
notes were consistent with a diagnosis of PD and 
without recognised exclusion criteria. Patients 
were invited by the general practitioners after 
excluding any miscoded patients and those felt 
unsuitable for contact (eg, patients with a terminal 
illness). Participating patients completed question­
naires and attended a clinical assessment. 
Anonymised patient information was used to 
monitor recruitment and calculate prevalence 
rates. Notes were cross checked for each patient 
registered with the participating Cardiff general 
practices and attending the main secondary care 
PD Clinic in Cardiff over a 6 month period and 
where available from consultant neurologists in 
Cardiff using pseudo-identifiers. In addition, neur­
ology consultants in Cardiff were asked to recruit 
patients who resided in Cardiff and whom had not 
yet been approached.
Crude prevalence rates and 95% confidence 
intervals (Cl) were calculated using the Poisson 
distribution and standardised to the 1997 England 
and Wales population. Previous studies were 
reanalysed using the same standard population. 
We calculated the between study variation from a 
mixed effects Poisson model.
RESULTS
Forty-five out of 54 (88%) of the eligible primary 
care practices participated, providing a population 
denominator of 292 637 (96% of the Cardiff 
population). The diagnostic search yielded 731 
unique potential cases (see web fig 1 online). A 
total of 378 cases were excluded (210 were 
prescribed dopaminergic agents for an alternative 
diagnosis, 96 cases had secondary parkinsonism, 72 
patients did not have PD as either miscoded (26), 
essential tremor (35) or did not have their diagnosis 
revised after specialist review (11)).
We identified an additional 49 cases (20 from 
general neurology clinics, 27 from PD clinic, one
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Table 1 Age, sex specific and standardised prevalence rates of Parkinson's disease
Age (years)
Total Men Women
PD cases
Population
size
Age 
specific 
rates per 
100 000
PD
cases
Population
size
Age 
specific 
rates per 
100 000
PD
cases
Population
size
Age
specific  
rates per 
100 000
0 -2 9 0 122 571 0 0 61 661 0 0 60 910 0
30 -39 1 44 399 2.3 0 23 397 0 1 21 002 4.8
40 -49 4 40 523 9.9 4 21 429 19 0 19 094 0
50 -59 24 32 249 74 14 16 901 83 10 15 348 65
60 -69 63 23 155 272 38 11 616 327 25 11 539 217
70 -79 129 17 481 738 68 893 830 61 9288 657
> 8 0 159 12 259 1297 74 413 1677 85 7846 1083
Crude rate per 100 000 380 292 637 130 198 147 610 134 182 145 027 126
Age standardised rates per 100 000* 142 (128, 156) 171 (147, 195) 120 (103, 138)
* Rates were d irectly standardised to  the England and W ales 1997 population. 
PD, Parkinson's disease.
self-referral, one other), resulting in 402 potential cases. Fifteen 
cases were excluded before examination as not being PD. A total 
of 132 of the 387 potential prevalent cases were examined (35%) 
and seven additional cases (5%) were excluded as not PD. Only 
one diagnosis revised case had not seen a secondary care 
specialist. This resulted in 380 prevalent cases (182 females, 198 
male).
Prevalence rates increased with age (see table 1) although 
males rates were greater at all ages. The age adjusted rates were 
142 per 100 000 (95% Cl 128 to 156 per 100 000) overall, and 
male and female rates were 171 (95% Cl 147 to 195) and 120 
(95% Cl 103 to 138), respectively. The male to female 
prevalence rate ratio was 1.43 (95% Cl 1.17 to 1.76; p = 0.001).
Age at symptom onset was obtained for 336 of the 380 (88%) 
prevalent patients (see web table 1 online). For men, mean age 
at onset was 67.7 years (95% Cl 66.0 to 69.3 years) and for 
women mean age at onset was 69.7 years (95% Cl 68.1 to 
71.4 years). There was a bimodal distribution of age at onset
with peaks at 40-44 years and 75-79 years. PD had begun in 
3.6% of patients before the age of 45 years. The average disease 
duration for the prevalent group was 6.2 years. The YOPD 
group (onset <45 years) had longer disease duration (11.1 years, 
95% Cl 7.9 to 14.4 years) than the later onset (onset ^45 years) 
PD group (6.0 years, 95% Cl 5.4 to 6.5) with a significant 
difference of 5.1 years (95% Cl 2.2 to 8.0; p = 0.0006). Cases 
who did not attend the clinic had an older age at onset but had 
the same duration of disease as those who did (see web table 2 
online). In total, 85% of PD patients identified in primary care 
had been seen by a neurologist or PD specialist. Neurologists 
were most likely to have made the diagnosis of PD (44%). For 
YOPD, a neurologist made the diagnosis in 90% of cases 
(p<0.001) although in a substantial number of cases (31%) 
there was no information available. Overall follow-up care was 
mainly provided by the geriatrician led PD clinic (63%) and 
neurologists (17%) although, again, details were not available on 
follow-up care in 31%. Of those patients assessed in the research
Study (year) Cases Denominator
prevalence
Crude
Brewis8 (1966) 80 71 101 113
Sutcliffe7 (1985) 226 193 047 117
Mutch8 (1986) 249 151 644 164
Sutcliffe5 (1992) 384 316 930 121
Schrag3 (2000) 156 121 608 128
Hobson2 (2005) 112 76 158 147 -
Porter1 (2006) 161 108 597 148
Wickremaratchi
(2009)
380 292 637 130
Age standardised 
prevalence per 
100 000 (95% Cl)
129 (99,159) 
134(116, 151) 
178(155, 201) 
140 (126, 154) 
169 (142, 195) 
105 (85, 124) 
135(115, 156) 
142 (128, 156)
! , ! , ! ,
80  100 120 140 160 180
Figure 1 Forest plot of age standardised Parkinson's disease (PD) prevalence rates in the UK (1966-2008).
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clinic, 45.5% were under follow-up by the movement disorder 
geriatrician, 22.7% by neurologists, 4.5% by general practi­
tioners and 2.3% by other consultants.
Our prevalence rate (142 per 100 000) was very close to the 
global average for all previous UK prevalence studies (fig 1) but 
there was evidence of statistical heterogeneity (p 
value = 0.0006). Prevalence rates showed no systematic tem­
poral change over the past 42 years.
DISCUSSION
We found that the prevalence of PD in Cardiff is similar to other 
studies in the UK (at approximately 140 per 100 000). Although 
the prevalence of young PD cases is much lower than that for 
older cases, 5.4% and 31.2% of the total prevalent PD 
population have their disease onset before 50 years or 65 years 
of age, respectively. Approximately 1 in 20 PD patients develop 
disease before the age of 45 years, normally considered to be a 
cut-off at which genetic autosomal recessive PD should be 
considered. While the crude rate of PD in those under 50 years 
in Cardiff is 2.4 per 100 000, the prevalence of those whose 
disease started before the age of 50 years is greater at 6.2 per 
100 000. These figures equate to approximately 3700 people in 
the UK currently alive with YOPD and means that YOPD, 
defined by an age of onset below 50 years, is at least as common 
as motor neuron disease, Huntington disease and progressive 
supranuclear palsy.
Our meta-analysis of all UK studies suggests that the 
prevalence of PD in the UK is fairly uniform and has been 
relatively stable over the past 40 years. This is somewhat 
surprising given the increase in overall life expectancy, increased 
awareness and better management of PD, which would if 
anything increase prevalence. It is possible that incidence has 
declined but the incidence trends from 1976 to 1990 from 
Rochester, Minnesota, were relatively stable.11 More recent 
studies are likely to have excluded other parkinsonian condi­
tions, such as multiple system atrophy (approximately 10% of 
cases),12 which may have been misdiagnosed as PD in the past.
We believe that the heterogeneity between studies can be 
explained by methodological differences. The study from 
Aberdeen actively searched for cases in nursing homes, which 
would have an over-representation of PD cases.6 In contrast, the 
study from rural Wales5 did not use diagnostic databases but 
relied on prescription records and referrals. In addition, it is not 
known whether PD survival is worse in rural compared with 
urban areas.
Almost all of the YOPD patients were diagnosed by a 
neurologist but only one-third of the later onset patients. 
Recent national guidelines13 suggest that the diagnosis of PD 
should always be made by a specialist but this was not always 
the case at the time of our study.
Neurologists only looked after about half of the YOPD 
patients, and few (9%) of those whose disease started after the 
age of 65 years. A substantial minority (15%) of PD patients 
were followed-up solely by their general practitioners.
Short  report
Limitations
Although we obtained a very high rate of participation from our 
primary care practices in Cardiff, we only clinically examined 
about one-third of all the cases, and older cases were less likely 
to be seen. We also did not invite cases with a diagnosis of 
essential tremor although the previous London study3 identified 
patients with unrecognised tremor dominant PD. In that study, 
11 of the 56 patients with non-parkinsonian tremor had 
probable or possible PD and their inclusion increased the 
number of PD cases by 7.9%.14
In conclusion, our prevalence estimate suggests that rates 
have remained relatively constant over the past 40 years. 
Although PD is a disease of the elderly, YOPD is far more 
common than appreciated, and the provision of health and 
social care for these patients should be an important considera­
tion.
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